>>WELCOME
TO THE BOARD MEETING FOR THE
16TH OF JUNE OF 2023.
I'D LIKE TO FIRST THANK YOU ALL
FOR ACCOMMODATING OUR DELAYED
START TIME FOR THIS MEETING TO
ALLOW FOR THE TOUR OF THE
CLINICAL CENTER, AND FOR OUR
MEMBERS WHO HAVE NOT DONE SO
PREVIOUSLY, I'VE HEARD FROM THE
PARTICIPANTS THAT THE TOUR WAS A
BIG SUCCESS.
SPECIAL THANKS TO THE CC ACTING
DEPUTY EXECUTIVE OFFICER WHO
CONDUCTED THE TOUR ON BEHALF OF
DR. GILMAN, AND JIM, IF YOU WANT
TO MAKE A QUICK COMMENT, I'LL
TURN IT OVER TO YOU.
>>WELCOME, EVERYBODY.
I APOLOGIZE FOR NOT BEING THERE
WITH YOU.
I CAME BACK FROM TWO WEEKS OF
ANNUAL LEAVE WITH THE NEXT ROUND
OF CORONAVIRUS, AND SO I'M DOING
THIS REMOTELY.
I ACTUALLY, PER CDC GUIDELINES,
I COULD HAVE ENTERED THE PUBLIC,
I COULD HAVE LEFT QUARANTINE
THIS MORNING.
I CONSULTED WITH TWO PEOPLE AND
IT TURNS OUT THAT I CONSULTED
WITH THE TWO PEOPLE I WOULD
PROBABLY BE SITTING NEXT TO
DURING THE MEETING.
THEY GENERALLY ADVISED THAT THEY
WERE VERY HAPPY TO HAVE ME TO
PARTICIPATE REMOTELY TODAY.
AND SO I AM -- I DO NOT FEEL TOO
BADLY.
THIS IS MY SECOND ROUND.
THE FIRST ONE WAS LAST MAY.
I DID HAVE A GREAT TIME WHEN I
WAS AWAY WITH FAMILY, AND BEGAN
FEELING A LITTLE ILL ON MY WAY
BACK.
SO NOW THE BIG -- MY BIG ANXIETY
IS ABOUT WHETHER I'LL BE A
VICTIM OF PAXLOVID REBOUND, IN
WHICH CASE IT WILL KEEP ME OUT
OF THE OFFICE A LITTLE LONGER,
BUT IF NOT, I'LL BE BACK NEXT
WEEK.
BUT THREE WEEKS OUT OF THE
OFFICE IS A VERY LONG TIME FOR
ME, AND SO -- BUT THANK YOU ALL
FOR BEING THERE AND I'M SURE
THAT DR. FREISCHLAG AND
ANTOINETTE GOT A GREAT TOUR FROM
THE TOAST MASTER OF THE CLINICAL
CENTER, DAVID SAGER.
THANKS.
>>THANKS SO MUCH, JIM.
REALLY APPRECIATE THAT.
GET WELL SOON, CERTAINLY.
SO WE ARE ALL AWARE OF THE
COMPLEXITIES OF THE ONBOARDING
PROCESS TO BECOME OFFICIAL
MEMBERS OF THE CCRHB, AND SO I'M
PLEASED TO REPORT THAT BOTH
MR. JACK LESLIE AND DR. SHERIN
DEVASKAR ARE NOW FULL BOARD
MEMBERS.
SO THIS BRINGS OUR MEMBERSHIP TO
11, WHICH IS OUR USUAL MEMBER
NUMBER, AND PER OUR CHARTER, WE
HAVE UP TO 14 MEMBERS ON OUR
ROSTER.
SO WE WELCOME BOARD MEMBERS
TODAY ATTENDING IN PERSON FOR
OUR FIRST POST-PANDEMIC MEETING.
JOINING IN PERSON ARE MR. DAVID
BAUM, DR. DAVID CHIN, DR. JULIAN
FREISCHLAG, MS. ANTOINETTE
ROYSTER AND ALSO JOINING US IN
PERSON HERE IN THE ROOM IS PIUS,
THE CLINICAL CENTER CHIEF
OPERATING OFFICER.
PARTICIPATING VIA ZOOM ARE
MS. STEPHANIE REEL, DR. REGINA
CUNNINGHAM, DR. SHERIN DEVASKAR,
MR. STEVEN GOLDSTEIN, DR. CRAIG
SAMITT, AND MR. JACK LESLIE.
AND I'D ALSO LIKE TO WELCOME ALL
OF OUR NIH LEADERS, ALSO JOINING
US ON ZOOM AND TO THE MEMBERS OF
THE PUBLIC AND THE NIH COMMUNITY
WHO ARE JOINING US LIVE IN THE
VIDEOCAST SESSION.
SO ON BEHALF OF THE BOARD, I
SENT A LETTER AND A COPY OF THE
CCRHB PEDIATRIC WORKING GROUP
REPORT TO DRS. TABAK AND
SCHWETZ, FOLLOWING THE MEETING
THAT WE HAD BACK IN FEBRUARY.
THE LETTER INCLUDED THE
DELIBERATIONS RELATED TO THE
REPORT FINDINGS AND THE
NOTIFICATION THAT THE BOARD
VOTED UNANIMOUSLY TO ACCEPT THE
FINDINGS AND RECOMMENDATIONS AS
DESCRAIBED IN DESCRIBED IN THEI.
WE ALL APPRECIATE THE EFFORTS OF
THE PEDIATRICS WORKING GROUP AND
WE LOOK FORWARD TO HEARING FROM
DR. GILMAN IN CONSIDERING THE
WORKING GROUP REPORT'S
RECOMMENDATIONS.
I'D LIKE TO JUMP INTO THE
MEETING.
FIRST UP WILL BE DR. TABAK.
WELCOME, DR. TABAK, AND THANK
YOU FOR BEING WITH US ONCE
AGAIN.
WE'LL BEGIN WITH YOUR SLIDES AS
WE LOOK FORWARD TO YOUR NIH
UPDATES.
>>THANK YOU SO MUCH AND GOOD
MORNING, EVERYBODY.
IT'S REALLY A PLEASURE TO BE
HERE AND SEE SOME OF YOU IN
PERSON, UP CLOSE.
THAT'S WONDERFUL.
AND AGAIN, THAT CAN THOSE OF YOU
TO ZOOM, FOR JOINING US BY ZOOM.
IF I CAN HAVE THE NEXT SLIDE,
PLEASE.
SO I'D WHRIEK TO COVER THESE
TOPICS, AND THEY'RE BRIEF SO I
WON'T BE SPENDING TOO MUCH TIME
ON THIS, BUT I WANT TO TALK
ABOUT LEADERSHIP CHANGES, GIVE
YOU SOME UPDATES ABOUT THE
BUDGET AS FAR AS WE TELL,
BRAG A LITTLE BIT ABOUT SOME OF
OUR NIH STAFF WHO ARE UP FOR
SOME PRESTIGIOUS AWARDS, JUST
TOUCH UPON THE VISIT THAT THE
DEPUTY SECRETARY OF HEALTH AND
HUMAN SERVICES PLAYED TO THE
CLINICAL CENTER, MENTIONED THE
70TH ANNIVERSARY OF THE CLINICAL
CENTER WHICH IS COMING UP, AND
FINALLY END WITH SOME UPDATES
ABOUT COVID.
SOMEBODY SAID, YOU KNOW, WE'RE
DONE WITH COVID BUT COVID MAY
NOT BE DONE WITH US, SO APROPOS,
WE'LL GIVE YOU A FEW ADDITIONAL
UPDATES.
SO IF I CAN HAVE THE NEXT SLIDE,
PLEASE.
SO I WANT TO BEGIN WITH
LEADERSHIP CHANGES.
OR AT LEAST IN SOME INSTANCES
PROPOSED LEADERSHIP CHANGES.
SO WE HAVE THE NEXT SLIDE.
SO AS I'M SURE YOU ALL KNOW, THE
PRESIDENT HAS NOMINATED
DR. MONICA BERTAGNOLLI, WHO IS
THE DIRECTOR OF THE NATIONAL
CANCER INSTITUTE, AND I BELIEVE
MONICA IS ON THE CALL IN HER
CAPACITY AS THE CHAIR OF THE
CCRHB.
AND SO WELCOME, MONICA.
SO FOR THOSE OF YOU NOT FAMILIAR
WITH THE INSIDE THE BELTWAY
RULES, THE PRESIDENT MAKES THE
NOMINATION, THE SENATE MUST
CONFIRM THE NOMINATION BEFORE
DR. BERTAGNOLLI CAN ASSUME
LEADERSHIP OF THE NIH.
PRECEDING THE CONFIRMATION ARE A
SERIES OF MEETINGS
DR. BERTAGNOLLI WILL HAVE TO
HAVE WITH MEMBERS OF THE SENATE,
THERE'S A CO CONFIRMATION HEARIG
BY THE SENATE HEALTH COMMITTEE
WHICH AUTHORIZES NIH AND IS
OVERSEEING THESE TYPES OF
PROCEEDINGS, AND THEN FINALLY A
FULL SENATE VOTE.
AND OF COURSE, WE ARE ALL
ANXIOUSLY AWAITING THAT, AND
LOOK FORWARD TO THE TIME WHEN
SHE ASSUMES LEADERSHIP OF THE
AGENCY.
UNTIL THEN, DR. BERTAGNOLLI IS
DIRECTOR OF THE NCI AND I WILL
CONTINUE IN MY CURRENT ACTING
ROLE.
IF I CAN HAVE THE NEXT SLIDE,
PLEASE.
WE HAVE AN ACTING ASSOCIATE
DIRECTOR FOR LEGISLATIVE POLICY
AND ANALYSIS.
MS. LAUREN HIGGINS.
LAUREN IS A LONG-TIME MEMBER OF
OPA.
SHE STEPPED IN WHEN THE FORMER
DIRECTOR, ADRIENNE HALLETT,
DEPARTED GOVERNMENT SERVICE FOR
AN OPPORTUNITY IN BIOTECH.
AND WE ARE REALLY GRATEFUL TO
LAUREN FOR STEPPING IN,
PARTICULARLY AT A TIME WHEN
THERE'S QUITE A BIT OF ACTIVITY
ON THE HILL, WHICH I'LL SHARE A
LITTLE BIT WITH YOU, AND AN
ACTIVE SEARCH IS ONGOING FOR THE
PERMANENT DIRECTOR OF THAT
CRUCIAL OFFICE.
ALSO WE HAVE AN ACTING ASSOCIATE
DIRECTOR FOR AIDS RESEARCH,
DR. KA POGIANNIS.
BILL STEPPED IN LATE MARCH WHEN
DR. MAUREEN GOODENOW STEPPED
DOWN AS THE DIRECTOR OF OAR.
SHE HAD DONE THAT FOR ALMOST
SEVEN YEARS AND WE'RE VERY
GRATEFUL TO HER FOR THAT
SERVICE.
AND AGAIN, WE ARE IN THE MIDST
OF A NATIONWIDE SEARCH TO FIND
THE PERMANENT DIRECTOR OF THIS
VERY IMPORTANT OFFICE.
LEST YOU THINK THAT EVERYBODY AT
NIH IS IN AN ACTING CAPACITY,
I'M PLEASED TO SHARE WITH YOU
DR. STEFAN PASIAKOS WHO IS NOW
THE NEW DIRECTOR OF THE OFFICE
OF DIETARY SUPPLEMENTS.
HE'LL BEGIN IN MID JULY.
HE IS CURRENTLY A PHYSIOLOGIST
AT THE ARMY RESEARCH INSTITUTE
OF ENVIRONMENTAL MEDICINE, WHERE
HE LEADS A RESEARCH PROGRAM TO
DEVELOP EVIDENCE-BASED SOLUTIONS
TO LIMIT MUSCULOSKELETAL
INJURIES, AND ACCELERATE RETURN
TO DUTY AND TO OPTIMIZE PHYSICAL
AND BEHAVIORAL PERFORMANCE IN
MILITARY TRAINING AND OTHER
OPERATIONAL ENVIRONMENTS.
I WANT TO THANK DR. DAVID
MURRAY, WHO SERVED AS THE ACTING
DIRECTOR DURING THE PERIOD OF
THE SEARCH.
WE ARE DELIGHTED TO HAVE
DR. PASIAKOS JOIN US SHORTLY.
DR. WENDY SMITH IS CURRENTLY THE
ACTING ASSOCIATE DIRECTOR FOR
THE BEHAVIORAL AND SOCIAL
SCIENCES RESEARCH.
SHE FOLLOWS DR. CHRISTINE HUNTER
IN THAT ACTING ROLE.
WE ARE GRATEFUL FOR HER TO TAKE
ON THIS ROLE.
WE ARE IN THE END MOMENTS OF THE
SEARCH TO BRING A PERMANENT
DIRECTOR ON BOARD AND SHOULD BE
ABLE TO MAKE AN ANNOUNCEMENT
SHORTLY.
SO AGAIN WE'RE VERY GRATEFUL TO
DR. SMITH, WHO'S ACTUALLY BEEN
AT OBSSR SINCE 2013, AND SHE HAS
HELD SEVERAL LEADERSHIP
APPOINTMENTS PRIOR TO ASSUMING
THIS IMPORTANT ROLE.
SO THANK YOU TO HER.
THEN FINALLY, IF I CAN HAVE THE
NEXT SLIDE, PLEASE.
WE ARE REALLY PLEASED TO
ANNOUNCE THE APPOINTMENT OF
DR. KARINA WALTERS AS THE
DIRECTOR OF THE NIH TRIBAL
HEALTH RESEARCH OFFICE.
DR. WALTERS IS AN ENROLLED
MEMBER OF THE CHOCTAW NATION OF
OKLAHOMA AND SHE BRINGS A WEALTH
OF EXPERIENCE AND A VERY DEEP
COMMITMENT TO ENGAGING TRIBAL
LEADERSHIP IN HEALTH RESEARCH
EFFORTS.
AS YOU KNOW, WHEN YOU'RE DEALING
WITH AMERICAN INDIAN AND ALASKA
NATIVE COMMUNITIES, YOU ARE
DEALING WITH SOVEREIGN NATIONS,
AND SO IT IS A VERY, VERY
COMPLEX AND IMPORTANT
RELATIONSHIP THAT YOU HAVE TO DO
CORRECTLY, AND YOU NEED
EXPERTISE TO NAVIGATE THAT AND
DR. WALTERS CERTAINLY FILLS THAT
BILL.
SHE'S PREVIOUSLY A TENURED
PROFESSOR AT THE UNIVERSITY OF
WASHINGTON SCHOOL OF SOCIAL
WORK, WHERE SHE SUSTAINED
COLLABORATIONS WITH A NUMBER OF
NATIVE COMMUNITIES AND ACTUALLY
CONDUCTED SUCCESSFUL CLINICAL
TRIALS, AMONG AND WITH TRIBAL
COMMUNITIES.
AND SO WE ARE DELIGHTED TO HAVE
DR. WALTERS HERE WITH US.
SO LET'S TALK A BIT ABOUT THE
BUDGET, WHICH AS YOU KNOW IS IN
A VERY FLUID STATE.
BUT LET ME SHARE WITH YOU WHAT I
CAN.
SO THE 23 APPROPRIATION ACTION
BECAME LAW ON DECEMBER 29TH,
AFTER THREE CONTINUING
RESOLUTIONS.
IT DID PROVIDE NIH WITH A FULL
YEAR DISCRETIONARY
APPROPRIATION.
IT ALSO AUTHORIZED THE ADVANCED
RESEARCH AGENCY FOR HEALTH,
ARPA-H, AS AN INDEPENDENT ENTITY
WITHIN THE NIH, AND I BELIEVE
YOU'RE HAVING A PRESENTATION
LATER IN THE DAY FROM
DR. ROBERTS FROM ARPA-H AND WE
WILL LEARN MORE ABOUT THAT
ORGANIZATION AT THAT TIME.
UNFORTUNATELY CONGRESS DID NOT
PASS THE ADMINISTRATION'S
PANDEMIC PREPAREDNESS PROPOSAL
WITH MANDATORY FUNDING NOR DID
THEY PROVIDE ADDITIONAL COVID
SUPPLEMENTAL FUNDS, SO WE
OBVIOUSLY HAVE TO PRIORITIZE TO
ENSURE THAT THE MOST IMPORTANT
WORK PROCEEDS, BUT INDEED, THAT
IS WHAT WE ARE DOING.
SO THE NUMBERS FOR '23 ARE
SUMMARIZED IN THIS TABLE.
THE CHANGE FROM FISCAL YEAR
'22 TO '23 IS $3 BILLION, WHICH
REPRESENTS A 6.5% CHANGE.
OF THAT, $1.5 BILLION GOES TO
ARPA -- $.5 BILLION GOES TO
ARPA-H, WHICH REPRESENTS A 50%
INCREASE IN THEIR BUDGET.
AND SO IT REFLECTS THE
ADMINISTRATION PRIORITY IN
BUILDING OUT ARPA-H TO ITS FULL
DEPLOYMENT.
JUST SOME HIGHLIGHTS OF THE
'23 BUDGET.
THE LARGEST TARGETED INCREASES
ARE LISTED HERE BY SIZE.
ALZHEIMER'S DISEASE RESEARCH
RECEIVED THE LARGEST INCREMENT,
A SUPPLEMENT TO THE NATIONAL
CANCER INSTITUTE TO HELP ENHANCE
THEIR SUCCESS RATE WAS THE
SECOND LARGEST.
AIDS RESEARCH, BUILDING &
FACILITIES ARE NEXT, THE COMMON
FUND, WHICH IS LOCATED IN THE
OFFICE OF THE DIRECTOR, WHERE WE
SUPPORT, IN MY MIND, AT LEAST,
YOU KNOW, SOME OF OUR CUTTING
EDGE RESEARCH IN THE AGENCY.
THE BRAIN INITIATIVE, ALSO VERY,
VERY CREATIVE EFFORT.
IMPORTANTLY, ADDITIONAL
RESOURCES FOR HEALTH DISPARITIES
RESEARCH.
SPREAD TO SOME OF THE INSTITUTES
AND CENTERS THAT HERETOFORE DID
NOT HAVE SPECIFIC APPROPRIATIONS
FOR THAT.
SO WE ARE EXPANDING THE
FOOTPRINT OF HEALTH DISPARITIES
RESEARCH AT THE AGENCY, WHICH IS
INCREDIBLY IMPORTANT.
AND A PROGRAM FOR ALS, SO CALLED
LOU GEHRIG'S DISEASE AND FINALLY
ADDITIONAL SUPPORT FOR OPIOID
USE DISORDER AND PAIN RESEARCH.
ALL OF THESE ARE, OF COURSE, IN
IMPORTANT AREAS OF SCIENCE, AND
WE ARE VERY GRATEFUL TO THE
CONGRESS FOR PROVIDING US THAT
ADDITIONAL SET OF RESOURCES.
SO WE CONTINUE CRITICAL COVID
RESEARCH, AND WE HAVE USED SOME
REMAINING RESOURCES FROM
SUPPLEMENTAL APPROPRIATIONS.
AS WELL AS AMOUNTS THAT WERE
PROVIDED BY HHS THAT ARE
ADMINISTERED UNDER DELEGATED
AUTHORITY.
IMPORTANTLY, THIS INCLUDES THE
SO CALLED PROJECT NEXTGEN, WHICH
IS A COLLABORATION BETWEEN THE
BIOMEDICAL ADVANCED RESEARCH AND
DEVELOPMENT AUTHORITY OR BARDA,
WHICH IS LOCATED WITHIN THE
DEPARTMENT, AND NIH, PRINCIPALLY
NIAID, THAT WILL ACCELERATE AND
STREAMLINE DEVELOPMENT OF THE
NEXT GENERATION OF COVID-19
VACCINES AND TREATMENTS.
IF I COULD HAVE THE NEXT SLIDE,
PLEASE.
NOW, IF ALL OF THAT WAS NOT
DIZZYING ENOUGH, WE OF COURSE
HAD THE PRESIDENT'S BUDGET
RELEASE FOR '24 BUT THEN
SUBSEQUENTLY THE FISCAL
RESPONSIBILITY ACT OF '23 WAS
PASSED.
SO WHAT THIS ENCOMPASSES IS,
FIRST, A DEBT LIMIT SUSPENSION
FOR TWO YEARS, AND CONCOMITANT
WITH THAT IS A TWO-YEAR BUDGET
HOLD, WHICH WOULD RESULT IN
HOLDING NON-DEFENSE SPENDING,
WHICH OBVIOUSLY IS WHERE NIH
SITS IN THE BUDGET PICTURE IN
'24, AND THEN THEY ARE ABLE TO
INCREASE THE BUDGET BY 1%, THAT
IS, OF COURSE, THE ENTIRE BUDGET
IN '25.
AN ADDITIONAL ELEMENT TO THIS IS
THAT IF ALL 12 APPROPRIATION
BILLS ARE NOT ENACTED INTO LAW
BY THE END OF THE CALENDAR YEAR
OF '23, THE STATUTORY CAPS WOULD
RESET 1% BELOW '23 LEVELS.
SO WHAT THIS IS IS AN INCENTIVE
FOR THE MEMBERS TO GET THE BILLS
PASSED IN A MANNER JUST BEFORE
THE END OF THE CALENDAR YEAR,
AND IF THEY DON'T, THEN THEY
WILL LOSE SOME OF THEIR DEGREES
OF FREEDOM.
SO THEY PUT A DELIMITER ON
THEMSELVES, IF YOU WILL.
THERE WAS RESCISSION OF CERTAIN
COVID SUPPLEMENTAL
APPROPRIATIONS THAT WERE NOT YET
OBLIGATED.
THERE WERE SOME EXEMPTIONS FOR
SPECIFIC AMOUNTS BY STATUTORY
SOURCES.
I WILL TELL YOU THAT NIH STAFF
WORKED EXTREMELY HARD TO WORK
THROUGH THIS SO THAT WE SPENT
RESOURCES THAT COULD BE SPENT IN
THE MOST APPROPRIATE AND, YOU
KNOW, IMPORTANT WAY, BUT THERE
WERE OTHER THINGS THAT WE WERE
NOT ABLE TO DO THAT FOR, SO THE
MONEYS WERE RESCINDED.
SO THE PRESIDENT'S BUDGET OF '2O
COMPORT WITH THIS FISCAL
RESPONSIBILITY ACT OF '23, SO
YOU KNOW, WE'LL PROBABLY BE
ROUGHLY FLAT UNLESS THE
APPROPRIATION BILLS AREN'T
ENACTED BY THE END OF '23, IN
WHICH CASE WE'LL BE ROUGHLY 1%
LOWER, AND AGAIN, THESE ARE
GUESSES BECAUSE THE NUMBERS
REPRESENT THE OVERALL AVERAGE
ACROSS THE ENTIRE GOVERNMENT,
AND NO DOUBT, THERE WILL BE SOME
THINGS THAT WILL DO A LITTLE BIT
BETTER AND SOME THINGS THAT DO A
LITTLE WORSE, AND IT REMAINS TO
BE SEEN WHERE NIH FALLS.
OBVIOUSLY WE ARE WORKING VERY,
VERY HARD TO MAKE THE CASE FOR
WHY BIOMEDICAL RESEARCH
CONTINUES TO BE SO CRITICALLY
IMPORTANT FOR SO MANY, MANY
PEOPLE, BOTH IN THIS NATION AND
AROUND THE WORLD.
OKAY.
SO THIS IS BRAGGING TIME.
IF I CAN HAVE THE NEXT SLIDE,
PLEASE.
WE HAVE TWO GROUPS, IF YOU WILL,
OR ONE INDIVIDUAL, ONE GROUP,
THAT MADE TO THE FINALIST ROUND
OF THE SERVICE TO AMERICA AWA
AWARDS.
THIS GROUP FROM THE GENOME
INSTITUTE WERE THE LEADS IN THE
TELOMERE-TO-TELOMERE EFFORT,
WHICH BASICALLY COMPLETED THE
SEQUENCING OF THE HUMAN GENOME.
NOW YOU'RE THINKING WELL, WAIT A
MINUTE, DIDN'T THAT HAPPEN OVER
20 YEARS AGO?
WELL, IT DID, BUT IT WAS SORT OF
A REALLY GOOD DRAFT.
AND WHAT WAS REMAINING WAS THE
SORT OF ENDS OF THE CHROMOSOMES,
THE TELOMERES, WHICH TEND TO BE
INTRACTABLE FOR A NUMBER OF
TECHNICAL REASONS.
WHAT'S FASCINATING ABOUT THIS
TEAM IS THEY ARE SORT OF CODERS
FIRST AND BIOMEDICAL RESEARCHERS
SECOND.
IN OTHER WORDS, A LOT OF
COMPUTATIONAL POWER WAS REQUIRED
TO PULL THIS OFF.
AND WE NOW HAVE TRULY A COMPLETE
GENOME AS A RESULT OF THEIR
EFFORTS, AND MANY, MANY, MANY
COLLEAGUES ALL AROUND THE WORLD.
AND SO THEY ARE IN THE FINALIST
CATEGORY FOR THE SO-CALLED
SAMIs.
AND THEN DR. FEUER FROM THE
NATIONAL CANCER INSTITUTE WAS A
FINALIST FOR THE PAUL A. VOLCKER
ACHIEVEMENT AWARD.
HE HAS USED DATA AND STATISTICAL
ANALYSIS OVER THE COURSE OF HIS
CAREER TO REALLY HELP ALL
STAKEHOLDERS UNDERSTAND THE
IMPACT OF CANCER TO THE
POPULATION.
HE'S USED THESE DATA TO
DEMONSTRATE HOW NEW PREVENTION,
SCREENING AND TREATMENT OPTIONS
MIGHT REDUCE CANCER RATES, AND
IN THE CONTEXT OF THE CANCER
MOONSHOT, THESE TYPES OF
ANALYSES ARE PARTICULARLY
IMPORTANT, AS DR. BERTAGNOLLI
AND HER TEAM ACROSS THE AGENCY,
NOT JUST LIMITED TO THE NCI, ARE
TRYING TO FIGURE OUT THE BEST
WAYS OF ACHIEVING THE GOALS THAT
THE PRESIDENT HAS SET.
FOR THE
CANCER MOONSHOT.
JUST A VERY BRIEF MENTION, WE
WERE REALLY HONORED TO HAVE THE
DEPUTY SECRETARY FOR HEALTH AND
HUMAN SERVICES, ANDREA PALM, WHO
IS IN THE MIDDLE ON YOUR LEFT,
DIRECTLY OPPOSITE ME, AND SHE
WAS HERE BOTH TO ATTEND THE
GROUND BREAKING CEREMONY FOR THE
SURGERY, RADIOLOGY AND LAB
MEDICINE WING, WHICH I KNOW JIM
WILL TALK ABOUT DURING HIS
COMMENTS, BUT SHE WAS ALSO HERE
TO LEARN MORE ABOUT SOME OF OUR
EFFORTS IN MENTAL HEALTH, AND
MET WITH A MEMBER OF NIMH WHO
PRESENTED A PATIENT TO HER, AND
I THINK THAT WAS A VERY
MEANINGFUL PART OF HER VISIT.
AN INDIVIDUAL WHO HAD SUFFERED
THEIR ENTIRE LIVES FROM
DEPRESSION, WHO, THROUGH NEW
TREATMENTS, SEEMS TO BE DOING
FAR, FAR BETTER.
AND SHE ALSO HAD THE OPPORTUNITY
TO SPEAK WITH DR. SCHWETZ, WHO'S
TO MY RIGHT IN THE FIGURE,
DR. VOLKOW, WHO IS ON THE FAR
RIGHT, AND I BELIEVE THAT'S
DR. BIANCHI WHO IS TO MY LEFT.
I DON'T REMEMBER WHO WAS TO THE
LEFT OF DR. BIANCHI.
BUT ANYWAY, WE HAD A REALLY
GOOD -- SORRY?
OH, DR. RODGERS.
OKAY.
THANK YOU.
DR. GRIFF RODGERS FROM NIDDK.
AND SO WE REALLY HAD A GREAT
MEETING WITH HER AND IT'S ALWAYS
WONDERFUL TO HOST LEADERSHIP
HERE AT NIH.
I GUESS THIS IS THE
ADVERTISEMENT PART OF MY
COMMENTS.
TO JUST TELL YOU ABOUT THE 70TH
ANNIVERSARY OF THE COMPLIN CLINL
CENTER.
SO IN JULY, THERE WILL BE A
CELEBRATION IN LIPSETT.
THERE ARE A SERIES OF OTHER
EVENTS IN THE SUMMER.
LATER THIS MONTH, THERE WILL BE
AN ANNIVERSARY GRAND ROUNDS
LECTURE BY FRANCIS, AND
APPARENTLY ADDITIONAL
EXHIBITIONS THROUGHOUT THE
SUMMER AND AGAIN, I SUSPECT JIM
WILL SPEAK TO THIS IN A LITTLE
MORE DETAIL.
BUT I DID WANT TO CALL THIS TO
YOUR ATTENTION.
SO JUST TO SOME COVID UPDATES.
SO MUCH OF OUR ATTENTION AT THE
AGENCY HAS TURNED TOWARDS
SO-CALLED LONG COVID, AND WHILST
WE ARE DOING A NUMBER OF THINGS,
A SORT OF CENTRAL PLATFORM FOR
THIS IS THE RECOVER INITIATIVE.
AND THIS JUST TRIES TO CAPTURE
THE APPROACH THAT WE ARE TAKING
WITH WHAT IS AN UNPRECEDENTED
INITIATIVE TO UNDERSTAND WHAT IS
THE POST SEQUELAE OF A VIRUS
INFECTION, AND AS SOME OF YOU
KNOW, THERE ARE MANY EXAMPLES OF
VIRAL INFECTIONS THAT BEGET, YOU
KNOW, SEQUELAE AFTER THE FACT.
WE HAVE ONE ADVANTAGE HERE AS WE
KNOW EXACTLY WHICH VIRUS IT WAS,
BUT THE VIRUS HAS BEEN, AS YOU
KNOW, TRICKY AND CONTINUES TO
EVOLVE, AND THE ANCESTRAL STRAIN
OF SARS-COV-2 IS DECIDEDLY
DIFFERENT FROM THE OMICRON
VARIANTS THAT WE HAVE NOW.
AND SO PART OF THE CHALLENGE OF
THIS EFFORT IS WE'RE DEALING NOT
WITH ONE VIRUS BUT MANY VIRUSES.
AND SO FAR, THE AVAILABLE
INFORMATION SUGGESTS THAT THE
ANCESTRAL STRAIN IS MOST LIKELY
TO YIELD THE MOST COMPLICATED
POST SEQUELAE WITH THE MORE
RECENT VARIANTS LESS SO, BUT
THERE IS STILL MORE TO BE
LEARNED ABOUT THIS.
SO THIS IS ONGOING WORK.
THE FIGURE ON YOUR LEFT, I HOPE
CAPTURES FOR YOU OUR GOAL IN
THIS PATIENT-CENTERED EFFORT
THAT THIS IS AN INTEGRATED
APPROACH.
WE WANT TO PREDICT, WE WANT TO
TREAT AND WE WANT TO PREVENT
LONG COVID.
AND TO DO THIS, THE AIMS ARE
ARTICULATED ON THE RIGHT OF THE
SLIDE.
FIRST TO UNDERSTAND THE RANGE OF
RECOVERY AND CHANGES IN OUR
BODIES OVER TIME.
REMARKABLY, JUST ABOUT EVERY
ORGAN SYSTEM IN THE BODY IS
AFFECTED IN ONE PERSON OR
ANOTHER.
IT'S UNPRECEDENTED.
IT REALLY IS.
WE WANTED TO FIND RISK FACTORS,
NUMBER OF PEOPLE GETTING LONG
COVID, AND IF, INDEED, IF THERE
ARE SPECIFIC DIFFERENT TYPES OF
LONG COVID, AND AGAIN, AVAILABLE
EVIDENCE SUGGESTS THERE MIGHT
BE.
SOME WHERE THERE'S MORE
NEUROLOGICAL SEQUELAE, OTHERS
WHERE THERE ARE MORE
NEUROMUSCULAR, OTHERS WHERE
CARDIAC IMPACT IS SEEN.
WE NEED TO KNOW HOW LONG COVID
PROGRESSES OVER TIME, AND DOES
IT RELATE TO OTHER ILLNESSES.
FOR EXAMPLE, MSCFS, PERHAPS
OTHERS KNOW IT AS CHRONIC
FATIGUE.
THERE ARE SOME SIMILARITIES.
WHAT INSIGHTS WILL WE GET FROM
STUDYING COVID, LONG COVID, INTO
THAT DISEASE AND CONDITION?
AND THEN FINALLY, YOU KNOW, TO
IDENTIFY TREATMENTS, WHICH, OF
COURSE, EVERYBODY IS WAITING F
FOR.
THERE'S BEEN A LOT OF WORK AT
THIS.
THIS JUST SUMMARIZES SOME OF
WHAT HAS BEEN DONE SO FAR.
FIRST AND VERY, VERY
IMPORTANTLY, WE HAVE ASSEMBLED
THE LARGEST MOST DIVERSE DEEPLY
CHARACTERIZED CLINICAL COHORT OF
PASC PATIENTS IN THE WORLD.
UNFORTUNATELY, AND NOT
SURPRISINGLY, THERE ARE
SIGNIFICANT DISPARITIES AMONG
DIFFERENT POPULATIONS IN TERMS
OF LONG COVID.
AND SO OUR COHORT THAT WE'RE
GOING TO USE TO STUDY THIS HAS
TO REFLECT THE BURDEN OF THE
DISEASE.
SO FOR EXAMPLE, HISPANIC
INDIVIDUALS ARE, RELATIVE TO
THEIR CENSUS IN THE POPULATION,
ARE OVERREPRESENTED IN THIS
COHORT BECAUSE OF THE
UNFORTUNATE PREDILECTION IN THIS
GROUP FOR THIS DISEASE.
SIMILARLY, BLACK AND AFRICAN
AMERICANS HAVE A SEVERE
OVERREPRESENTATION, AND SO WE'RE
TRYING TO BALANCE THAT COHORT IN
A MANNER THAT REALLY REFLECTS
THE DISEASE ITSELF.
WE HAVE ALSO TAKEN ADVANTAGE OF
EXISTING COHORTS WHERE PEOPLE
HAVE BEEN FOLLOWED FOR MANY,
MANY YEARS, IN SOME CASES
DECADES, SO THAT WE CAN TAKE
ADVANTAGE OF THAT VERY RICH AND
COMPLETE ANTECEDENT WORK TO HELP
US CHARACTERIZE THOSE PEOPLE IN
THOSE COHORTS THAT TURNED OUT TO
SUFFER FROM LONG COVID.
THERE HAVE BEEN OVER 40
PATHOBIOLOGY STUDIES THAT ARE
LOOKING AT THE PATHOPHYSICIANPHY
OF THIS.
WE ARE STARTING THIS NEXT
QUARTER, STARTING IN JULY, A
SERIES OF MASTER PROTOCOLS OR
PLATFORM CLINICAL TRIALS.
THREE OR FOUR WILL BEGIN,
BEGINNING IN JULY, WITH ONE OR
TWO, DEPENDING UPON HOW THE
THIRD OF THAT GROUP -- FOURTH IN
THAT GROUP PANS OUT BY THE
FOURTH QUARTER.
AGAIN, WE'VE USED ELECTRONIC
HEALTH RECORDS TO LOOK AT
PREVALENCE RISK FACTORS IMPACT
AND THE DISPARITIES.
TO DO THAT, WE'VE ANALYZED OVER
60 MILLION RECORDS THAT INCLUDE
OVER 7 MILLION COVID TESTS,
CASES, BIOMARKER RESULTS ARE
UNDERWAY.
WE'RE USING ALL SORTS OF MOBILE
HEALTH PLATFORMS, LOTS OF
COMMUNITY ENGAGEMENT.
CAN'T DO THIS UNLESS YOU GO TO
WHERE THE PEOPLE ARE.
SO THERE'S A TREMENDOUS AMOUNT
OF COMMUNITY ENGAGEMENT.
FINALLY, AND I ALLUDED TO THIS,
WE'RE TRYING TO CHARACTERIZE THE
IMPACT OF THE DIFFERENT VARIANTS
ON VAITI -- ON VACCINATION AND E
VARIANTS ON THE COURSE OF THIS
DISEASE.
BUT THERE ARE STILL ELEMENTS TO
THE THERAPEUTIC INTERVENTIONS
FOR THE ACUTE INFECTION THAT ARE
ONGOING.
THEY'RE LISTED HERE.
AND SO WE EXPECT READOUTS
THROUGHOUT THIS YEAR AND NEXT.
A NUMBER OF REPURPOSED DRUGS,
FOR EXAMPLE, ORAL MONTELUKAST,
AND INDEED THERE IS SOME
ADDITIONAL THOUGHT BEING GIVEN
TO USING ADDITIONAL REPURPOSED
DRUGS, FOR EXAMPLE, METFORMIN IS
ONE THAT HAS COME UP, AND WE
WILL SEE IF WE ARE ABLE TO
LAUNCH THAT ONE IN THE NOT TOO
DISTANT FUTURE.
SO MANY SUCCESSES FROM THE
ACTIVE PARTNERSHIP BETWEEN
INDUSTRY, NIH AND OTHER
GOVERNMENT AGENCIES, NOT FOR
PROFITS, WE ENROLLED OVER 23,000
PATIENTS, OVER 300 SITES, DID
THE ENROLLING.
AS YOU MIGHT IMAGINE, MANY
PUBLICATIONS THAT WERE READ
WIDELY.
WE REVIEWED OVER 800 AGENTS.
OF THE 800 THAT WERE REVIEWED,
34 WERE TESTED, AND SIX
INITIALLY PROVED EFFICACIOUS.
NOT ALL REMAINED EFFICACIOUS
BECAUSE THE VIRUS EVOLVED, AND
SOME WERE NO LONGER USEFUL.
NOW, PEOPLE LOOK AT THAT AND
SAY, WOW, YOU ONLY CAME UP WITH
SIX AGENTS THAT ARE EFFICACIOUS.
I REMIND YOU THAT WE ALSO RULED
OUT THE 794 THAT WERE NOT
USEFUL.
AND THAT WAS EQUALLY IMPORTANT
TO DETERMINING WHAT WAS USEFUL.
NEVERTHELESS, A NUMBER OF
ACHIEVEMENTS.
AND SO WITH THAT, AND I
APOLOGIZE FOR BEING TWO MINUTES
OVER, I'LL STOP AND I WILL TURN
IT BACK TO THE CHAIR.
>>THANKS SO VERY MUCH,
DR. TABAK.
ARE THERE ANY QUESTIONS OR
COMMENTS IN REFERENCE TO THE
PRESENTATION?
I'D LIKE TO THANK YOU VERY MUCH
FOR THAT.
YOU KNOW, AND I'M ALWAYS GLAD TO
SEE THE RESEARCH THAT'S GOING ON
THAT CONTINUES DOWN THE COVID
LINES, PARTICULARLY WITH THE
LONG COVID, AND SO THIS IS NOW A
BODY OF EVIDENCE THAT CONFIRMS
KIND OF ANECDOTALLY WHAT WE SAW
IN OUR OWN STAFF, THAT THOSE WHO
HAD COVID IN WAVE ONE,
ESPECIALLY BEFORE WE HAD
VACCINES, ARE STILL SUFFERING
FROM LONG COVID, CHRONIC
RECURRENT RASHES, THINGS LIKE
THAT, BUT IN SUBSEQUENT WAVES
AND ESPECIALLY OMICRON -- THANK
YOU, THIS IS GREAT.
THANK YOU SO MEC MUCH, DR. TABA.
NEXT WE'VE GOT THE CEO UPDATE BY
DR. GILMAN.
I THINK, JIM, YOU'VE ALSO GOT
BACK TO BACK PRESENTATIONS ON
STRATEGIC THOUGHTS IN
PREPARATION FOR THE NEXT
STRATEGIC PLAN FOR THE CLINICAL
CENTER.
SO I'LL GO AHEAD AND TURN IT
OVER TO YOU.
>>THANKS.
THERE'S BEEN A LOT OF STUFF
GOING ON IN THE LAST FEW MONTHS,
AS DR. TABAK SORT OF INDICATED.
OKAY.
SO GO AHEAD TO THE NEXT SLIDE,
CARLY.
SO AS DR. TABAK INDICATED, THIS
IS THE 70TH ANNIVERSARY OF THE
CLINICAL CENTER, AND WE HAVE A
NUMBER OF ACTIVITIES THAT ARE IN
PLACE AND ONGOING AND PLANNED
AND THIS IS THE LOGO FOR THE
70TH ANNIVERSARY THAT WAS PUT
TOGETHER BY -- OR DEVELOPED BY
THE OFFICE OF COMMUNICATIONS AND
MEDIA RELATIONS, AND THEY'VE
BEEN THE PIVOT POINT FOR MOST OF
THE ACTIVITIES RELATED TO THE
70TH ANNIVERSARY.
WE DO HAVE DR. COLLINS FOR
CLINICAL CENTER GRAND ROUNDS ON
JUNE 28TH, AND HE'S PROMISED NOT
ONLY TO TALK ABOUT THE 70 YEARS
OF HISTORY OF THE CLINICAL
CENTER BUT ALSO OF THE -- OF
WHAT HE SEES WITH RESPECT TO THE
FUTURE OF THE CLINICAL CENTER,
AND THAT'S SOMETHING THAT WE'RE
LOOKING FORWARD TO VERY MUCH.
THE 70 YEARS OF FIRSTS EVENT MAY
ACTUALLY GET PUSHED BACK A
LITTLE BIT.
WHEN I LOOKED AT THIS EVENT
PLANNING SOME TIME BACK, I
THOUGHT THAT IT NEEDED A LITTLE
MORE WORK, BUT SOMETIME DURING
THIS YEAR, WE HOPE TO HAVE THIS
70 YEARS OF FIRSTS EVENT.
WE HAVE DEVELOPED THE
BACKGROUND, THE VIRTUAL
BACKGROUND FOR THE ZOOM AND MS
TEAMS CONFERENCE CALLS AND WE
ACTUALLY -- DR. COOTS WILL
APPRECIATE THE FACT THAT WE HAVE
A 70TH ANNIVERSARY CHALLENGE
COIN THAT HAS ACTUALLY BEEN
COMPLETED AND IS DOWN IN OUR
BOOKSTORE.
WHEN I CAN LEAVE QUARANTINE,
I'LL GO DOWN AND PICK THEM UP
AND I LOOK FORWARD TO ACTUALLY
SEEING HOW THE COIN TURNED OUT.
YOU CAN SEE THE ARTIST RENDITION
THERE.
DR. FREISCHLAG GOT A CHANCE, I
THINK, TO SEE OUR ORANGE STATUES
IN THE CLINICAL CENTER.
THIS IS PART OF OUR 70TH
ANNIVERSARY AND PART OF OUR
FOCUS ON DIVERSITY, EQUITY,
INCLUSION AND ACCESSIBILITY.
AND IF OTHERS ARE FAMILIAR WITH
THIS EXHIBIT, THEN I WON'T
BELABOR IT A LOT.
BUT I WOULD -- IT IS A VERY,
VERY INTERESTING EXHIBIT.
120 STATUES OF WOMEN CONNECTED
WITH STEM FIELDS.
NOT ALL ARE CONNECTED TO
MEDICINE OR BIOLOGICAL SCIENCE.
MANY, MANY FIELDS OF SCIENCE,
TECHNOLOGY, ENGINEERING AND MATH
ARE REPRESENTED.
THERE'S A LONG BACKGROUND HERE
THAT I THINK THE PRINCIPAL
COLLABORATION WAS WITH THE LYDA
HILL FOUNDATION AND THE AMERICAN
ACADEMY FOR THE ADVANCEMENT OF
SCIENCE.
120 WOMEN CHOSEN TO BE
AMBASSADORS AND ROLE MODELS IN
STEM FIELDS.
WE HAVE ON DISPLAY ABOUT 10 OF
THE STATUES.
EACH ONE OF THE STATUES CONTAIN
THE -- THE DISPLAY INCLUDES A QR
CODE SO YOU CAN FIND OUT A
LITTLE BIT MORE ABOUT THEM, AND
THEN YOU SEE AT THE BOTTOM OF
THE SLIDE, THE PICTURE OF THE
SCIENTIFIC REVIEW OFFICER,
DR. JONES, FROM THE NATIONAL
INSTITUTE FOR NEUROLOGIC
DISEASES AND STROKE TO LOOK AT
HER STATUE WITH SOME OF HER OUT
OF TOWN FRIENDS.
IF YOU DON'T KNOW VERY MUCH
ABOUT THIS, WE CAN SEND YOU
INFORMATION OR YOU SEE THE WEB
LINK AT THE BOTTOM, BUT IT BEARS
LEARNING ABOUT -- THE GROUP
BEGAN WITH A SURVEY OF
AMERICA'S -- OR THE UNITED
STATES' LARGEST CITIES TO FIND
STATUES OF WOMEN, AND THEY'VE
BASICALLY FOUND ONLY ENOUGH
STATUES OF WOMEN THAT YOU COULD
COUNT THEM ALL ON TWO HANDS, AND
SO THAT'S SORT OF LED THEM DOWN
THIS PATH.
THE HILL FOUNDATION IS DEDICATED
TO TECHNOLOGY AND -- SCIENCE AND
TECHNOLOGY ENHANCEMENT AND HAS
MADE A NUMBER OF LARGE GRANTS TO
ORGANIZATIONS THROUGHOUT THE
U.S., BUT WE'RE VERY GRATEFUL
FOR THE DISPLAY AND THE LOAN OF
10 OF THE STATUES FOR A PERIOD
OF TIME.
THANKS.
SO WE HAD A GROUNDBREAKING EVENT
ON TUESDAY, MAY 16TH FOR THE
SURGERY, RADIOLOGY AND
LABORATORY MEDICINE WING.
WE DO HAVE A PICTURE FROM THIS
EVENT THAT WE WILL GET TO ALL OF
THE BOARD MEMBERS AND ALL OF THE
PAST BOARD MEMBERS AS WELL.
IT IS -- YOU CAN SEE WHAT THE
BUILDING WILL HOUSE.
IT WILL NOT BE COMPLETED FOR
SEVERAL YEARS AND WE WILL DEAL
WITH THE DUST, THE NOISE AND THE
TRAFFIC INTERRUPTIONS ASSOCIATED
WITH THIS CONSTRUCTION, BUT YOU
CAN SEE HOW IMPORTANT IT IS AND
IF IN SOME PAST TOURS THE
CLINICAL CENTER, I WOULD SPEND A
LOT OF TIME TALKING ABOUT THE
VAGARIES OF A PORTION OF THE
BUILDING THAT CAUSED SO MUCH
DIFFICULTY WITH THEIR
OPERATIONS, AND THIS BUILDING,
SURGERY, RADIOLOGY AND
LABORATORY MEDICINE WING, IS AT
LEAST A BIG STEP TOWARDS SOLVING
ALL THOSE ISSUES.
THESE ARE PICTURES OF THE
SPEAKERS AT THE GROUND BREAKING.
SPEECHES WERE SHORT SINCE THERE
WERE A NUMBER OF THEM.
DR. TABAK AND ANDREA PALM, THE
DEPUTY SECRETARY OF HHS THAT DR,
WERE THE KEY NOTES AND THEN THE
DEPUTY DIRECTOR FOR MANAGEMENT,
DR. JOHNSON.
THE CHIEF -- THE ASSOCIATE
DIRECTOR FOR RESEARCH
FACILITIES, DAN WHELAN, AND THEN
DR. SCHOR WHO'S ON THIS ZOOM
CALL.
I HAD A FEW THINGS TO SAY AND
THEN STEVE ROSENBERG REPRESENTED
THE INVESTIGATORS OF THE NIH AND
GAVE ROW MARKS AS WELL.
THIS IS THE PICTURE THAT YOU ALL
SHOULD RECEIVE, AND WE
APPRECIATE THE HELP OF BOTH
CURRENT AND PAST BOARD MEMBERS
IN HELPING US GET TO THIS POINT.
AND WE WANT TO MAKE SURE YOU
HAVE SOME MOMENTO RELATED TO IT.
ALONG WITH STARTING THE PROJECT,
WE BROUGHT ON BOARD SOMEBODY
THAT WE HAVE SOME BACKGROUND
WITH AS SORT OF THE CLINICAL
CENTER'S PROJECT LEAD TO
CONSOLIDATE ALL CLINICAL CENTER
ISSUES RELATED TO CONSTRUCTION
AND OTHER ASPECTS OF THIS
UNDERTAKING.
RICK BOND RAN THE HEALTH
FACILITIES PLANNING AGENCY FOR
THE UNITED STATES ARMY FOR A
NUMBER OF YEARS AND THEN
PROVIDED A SIMILAR FUNCTION AT
THE V.A.
RICK WILL SPLIT HIS DUTIES
BETWEEN US AND THE UNIFORMED
SERVICES UNIVERSITY ACROSS THE
STREET, BUT HE HAS FORMAL
TRAINING IN ARCHITECTURE AND
CONSTRUCTION MANAGEMENT, AS WELL
AS A MASTER'S IN BUSINESS
ADMINISTRATION FROM WHARTON, AND
IT IS GREAT TO HAVE SOMEBODY
WITH HIS EXPERIENCE AND
BACKGROUND WHO WILL SERVE AS THE
INTEGRATOR FOR ALL OF THE ISSUES
THAT CROP UP WITHIN THE CLINICAL
CENTER TO WORK WITH THE OFFICE
OF RESEARCH FACILITIES, THE
CONTRACTORS, AND THE ARCHITECTS.
WE HAVE MADE SOME PROGRESS IN
FILLING SOME OF OUR KEY
VACANCIES.
I THINK DR. TABAK'S PRESENTATION
HIGHLIGHTED SOME OF THE -- SOME
OF THE OPENINGS AND SOME OF THE
ACTIVITY AT THE NIH LEVEL.
AND THIS IS ALWAYS PART OF OUR
UPDATE.
ON THE RIGHT-HAND SIDE, WE DO
HAVE A CHIEF HOSPITAL E
EPIDEMIOLOGIST NOW, AND THE
CHIEF OF THE HOSPITAL
EPIDEMIOLOGY SERVICE, DR. ALISON
HAN CAME OVER FROM THE NATIONAL
INSTITUTE FOR ALLERGY AND
INFECTIOUS DISEASES, AND HAS
BEEN DOING A REALLY GREAT JOB OF
WORKING WITH OUR HOSPITAL
EPIDEMIOLOGY SERVICE AND STAFF,
AND HAS HELPED US TRANSITION
FROM MASKS EVERYWHERE TO MASKS
WHERE THEY'RE NEEDED MOST WITH
MASK OPTIONAL IN OTHER AREAS.
TOM BURKLOW HAS BEEN WITH US FOR
A LITTLE OVER THE LAST FIVE
YEARS, AND HAS BEEN THE LEAD FOR
THE MEDICAL RESEARCH SCHOLARS
PROGRAM.
TOM WAS ELEVATED TO THE CHIEF OF
THE OFFICE OF CLINICAL RESEARCH
TRAINING AND MEDICAL EDUCATION.
AND DAN RY REINHOLTZ RETIRED FRM
THE NIH A YEAR AND A HALF AGO
AND HIS REPLACEMENT IS THE CHIEF
OF THE OFFICE OF FINANCIAL -- AD
RESOURCE MANAGEMENT, JURIS
MOHSENI IS ON BOARD.
JURIS IS A VERY INTERESTING
FELLOW AND HAS BEEN VERY
IMPRESSIVE IN HIS EARLY EFFORTS
IN FILLING A BIG JOB.
WE ARE VERY CLOSE TO BEING ABLE
TO ADVERTISE THE NAME OF OUR
NEXT CHIEF NURSE.
WE'RE GETTING PRETTY CLOSE,
MAYBE BY OCTOBER WE'LL BE ABLE
TO TALK ABOUT THE PERMANENT
CHIEF OF THE PHARMACY, BUT WE DO
HAVE TWO IMPORTANT SEARCHES THAT
ARE JUST GETTING UNDERWAY.
ONE IS FOR THE CHIEF OF THE
DEPARTMENT OF TRANSFUSION
MEDICINE, AND THE EXECUTIVE
OFFICER SEARCH MAY NOT START
RIGHT AWAY FOR REASONS THAT WE
DON'T NEED TO GO INTO, BUT IT
HAS TO DO WITH PERHAPS CHANGING
THAT POSITION.
WE'VE ACTUALLY REQUESTED TO HAVE
THAT POSITION ELEVATED TO SES
STATUS, AND THERE'S A PROCESS
AND IT'S NOT A SHORT ONE THAT
ONE GOES THROUGH.
WE HAVE NO IDEA HOW THAT'S GOING
TO TURN OUT YET, BUT IT WOULD
NOT BE FAIR TO SELECT SOMEBODY
FOR THAT POSITION PERMANENTLY,
AND THEN HAVE THEM HAVE TO TURN
AROUND AND COMPETE FOR THE
POSITION A SECOND TIME.
SO WE MAY HOLD OFF ON THAT A
LITTLE BIT.
FORTUNATELY WE HAVE SOME
TALENTED ADMINISTRATIVE OFFICERS
THAT WILL BE ABLE TO FILL IN FOR
THE NEXT FEW MONTHS.
SO THIS IS OUR DEPARTURE OF DAN
LONNERDAL.
HE IS REMAINING IN THE
DEPARTMENT OF HEALTH AND HUMAN
SERVICES, BUT IS LEAVING -- HAS
LEFT US TO MOVE OVER TO THE
AGENCY FOR SUBSTANCE ABUSE AND
MENTAL HEALTH SERVICES, SAMHSA.
HE'S NOT VERY FAR AWAY.
HE WAS SELECTED FOR THE SENIOR
EXECUTIVE SERVICE POSITION
THERE.
IT IS A PROMOTION FOR DAN.
DAN, I THINK, HAS AN
EXTRAORDINARY REPUTATION WITH
OUR ADMINISTRATIVE STAFF FOR
BEING A GREAT SUPPORTIVE LEADER
AND ALSO ONE WHO FOCUSES ON
PERSONNEL DEVELOPMENT, AND
SUPPORT FOR EFFORTS OF OUR STAFF
TO GROW AND TO BE BETTER.
SO WE WILL MISS DAN'S LEADERSHIP
VERY MUCH.
BUT BECAUSE WE'VE HAD HIM IN THE
CLINICAL CENTER FOR A WHILE, I
THINK THE YOUNGER LEADERS OR THE
NEWER LEADERS THAT HE'S BEEN
IMPORTANT IN THEIR DEVELOPMENT
WILL SERVICE IN GOOD STEAD.
ILA FLANN IGA N IS THE DEPUTY
WHO HAS BEEN DAN'S DEPUTY FOR A
WHILE, WILL BE ACTING AS THE
EXECUTIVE OFFICER, AND HER
DEPUTY WILL BE DR. -- NOT
DR. BUT DAVID SAEGER WHO HAS
BEEN CHIEF OF THE OFFICE OF
HOSPITAL ADMINISTRATIVE SUPPORT.
WE DID FILL ONE OF OUR OTHER KEY
LEADERSHIP POSITIONS.
ACTUALLY SUNIL VASUDEVAN WILL
BEGIN NEXT WEEK AS THE CHIEF
FINANCIAL OFFICER.
THIS IS ABOUT AN 18-MONTH-LONG
PROCESS TO FILL THE VACANCY LEFT
BY MARIA JOYCE WHEN SHE RETIRED.
HE'S COMING ACROSS THE STREET AS
THE SENIOR DIRECTOR, WHERE HE
WAS THE SENIOR DIRECTOR OF
FINANCE AT SUBURBAN HOSPITAL,
AND HAD THESE OTHER ROLES, MAYBE
WELL-KNOWN TO STEPHANIE REEL,
WHO'S ON THIS CALL AS WELL.
>>VERY -- LOVELY, LOVELY MAN.
>>THANK YOU, STEPHANIE.
I HAD A CHANCE TO INTERVIEW
SUNIL, AND WE'RE VERY EXCITED
ABOUT HAVING HIM ON BOARD.
HE WILL BE COMMISSIONED AS A
MEMBER OF THE SENIOR EXECUTIVE
SERVICE ON THE 27TH OF JUNE BY
ALFRED JOHNSON, THE NIH'S
DIRECTOR -- DEPUTY DIRECTOR FOR
MANAGEMENT.
IN FEBRUARY, WE TALKED ABOUT OUR
EFFORTS TO HONOR DR. GALLIN, AS
HE RETIRED FROM THE NIH, AND WE
DID THAT WITH A VERY NICE
PROGRAM AND RECEPTION IN APRIL
THAT DR. GALLIN'S FAMILY, ALL
EXCEPT FOR ONE GRANDSON, WERE
EITHER PRESENT IN THE ROOM OR
PRESENT VIRTUALLY, AND
DR. LEIGHTON CHAN, WHO HAS BEEN
THE CHIEF OF REHAB MEDICINE FOR
THE CLINICAL CENTER, FOR A
NUMBER OF YEARS, HAS BEEN
ELEVATED TO AN ACTING CHIEF
SCIENTIFIC OFFICER.
I'VE WORKED -- THIS OFFICE HAS
RESPONSIBILITIES TO BOTH THE
CLINICAL CENTER BUT ALSO TO THE
DEPUTY DIRECTOR FOR INTRAMURAL
RESEARCH.
DR. SCHOR AND I HAVE GONE BACK
AND FORTH A COUPLE OF TIMES TO
MAKE SURE THAT WE HAVE A
POSITION DESCRIPTION THAT WILL
FULFILL ALL OF THE IMPORTANT
ROLES, AND I THINK WE'RE
SATISFIED WITH THAT.
WE ALREADY HAVE THE MEMBERSHIP
FOR A VERY GOOD SEARCH
COMMITTEE, AND THAT SEARCH WILL
GET KICKED OFF VERY SOON.
WE ANNOUNCED THE CEO AWARDS IN A
VIRTUAL CEREMONY LAST DECEMBER,
AND THEN WE SCHEDULED SORT OF AN
IN-PERSON EVENT BECAUSE I HADN'T
HAD MY PICTURE TAKEN ENOUGH
LATELY, AND WE DID THAT ON THE
SECOND OF MAY, AND PRESENTED THE
AWARDS TO A NUMBER OF THE
AWARDEES.
WE HAD LIGHT REFRESHMENTS, LOTS
OF PHOTOS, MUSIC, AND IT PROVED
TO BE A SUCCESS, AND MANY
THANKS.
ONE OF THE REASONS WHY WE HAD TO
WAIT SO LONG WAS BECAUSE WE HAD
TO HAVE ALL OF THE MEDALLIONS
REPRINTED THIS YEAR.
THE CONTRACTOR DIDN'T DO A VERY
GOOD JOB THE FIRST TIME, AND SO
WE GAVE THEM THE TIME NEEDED IN
ORDER TO DO IT ACCORDING TO THE
WAY THAT WE TOLD THEM TO DO IT
FIRST TIME, AND WE FINALLY HAVE
THOSE DISTRIBUTED.
THANKS TO PAT PIERINGER, NATASHA
POINTER AND LOTS AND LOTS OF
OTHER PEOPLE FOR THEIR HELP.
WE'RE VERY PROUD, DR. YUKIKO
ASADA WAS ACCEPTED INTO A TENURE
TRACK POSITION IN THE DEPARTMENT
OF BIOETHICS, PROBABLY ABOUT A
YEAR AGO.
AND THIS TENURE TRACK POSITION
IS FOCUSED ON THE BIOETHICAL
ISSUES IN RESEARCH INTO HEALTH
DISPARITIES.
THEN RECENTLY, WE FOUND OUT THAT
DR. ASADA HAS BEEN ACCEPTED IN
TO THE NIH'S DISTINGUISHED
SCHOLARS PROGRAM.
AND THAT'S A GREAT THING FOR HER
IN TERMS OF GREATER, MORE
RESOURCES TO FOCUS ON HER
RESEARCH, AND IT'S A GREAT
FEATHER IN THE CAP OF THE
CLINICAL CENTER, AND
PARTICULARLY TO THE BIOETHICS
DEPARTMENT.
THAT DEPARTMENT IS LED BY
DR. CHRISTINE GRADY.
THE DISTINGUISHED SCHOLARS
PROGRAM FOCUSES ON -- IT
PRIORITIZES OR PROVIDES THOSE
SCHOLARS SEEKING RESOURCES WHO
HAVE DEMONSTRATED ACTIVITIES IN
TERMS OF DIVERSITY, EQUITY,
INCLUSION, HEALTH DISPARITIES,
ET CETERA.
AND SO THIS IS A GREAT FEATHER
IN THE CAP OF THE CLINICAL
CENTER AS I INDICATED.
WE DO WANT TO -- WE'RE RAPIDLY
APPROACHING COMBINED FEDERAL
CAMPAIGN SEASON AGAIN, AND WE
DID WIN ACROSS THE NATIONAL
CAPITAL REGION FOR THE BEST
DIGITAL MEDIA CATEGORY FOR LAST
YEAR'S CAMPAIGN, AND IT'S THE
CLINICAL CENTER GINGERBREAD
HOUSE TRADITION.
AND DR. DAVID LANGE, DR. BARBARA
JORDAN AND DAN LONNERDAL WERE
THE PERFORMERS, ALONG WITH
MICHAEL ALEXANDER, WHO WAS A
FIXTURE AT OUR FRONT DESK FOR
MANY YEARS.
AND YOU CAN SEE THE RESULTS OF
OUR CFC CAMPAIGN.
AND MUCH THANKS TO JANICE DURAN
AND DAN SILBER IN THE OFFICE OF
COMMUNICATIONS AND MEDIA
RELATIONS FOR ACCOMPLISHING
THAT.
SO I THINK THIS BRINGS TO
CONCLUSION MY BRAGS FOR THIS
CCRHB.
THIS IS WHAT OUR CENSUS LOOKS
LIKE, AND OTHER THAN AVOIDING
THE JANUARY, 2022 DIP THAT WAS
ASSOCIATED WITH SORT OF THE
OMICRON VARIANT, THINGS LOOK A
LOT LIKE THEY DID LAST YEAR ON
THE INPATIENT SIDE, ON THE
INPATIENT CENSUS.
OUTPATIENTS ARE A LITTLE
DIFFERENT.
THE INPATIENT CENSUS MAY NOT BE
CHANGING MUCH BUT ADMISSIONS
HAVE GONE UP 12%.
PEOPLE AREN'T STAYING QUITE AS
LONG.
OUR INPATIENT DAYS IS THE SAME
AS YOU WOULD EXPECT FROM THE
FACT THAT THE CENSUS IS THE
SAME.
BUT OUR OUTPATIENT VISITS REMAIN
UP AND AT 11% MORE THAN LAST
YEAR, AND OUR NEW PATIENTS ARE
UP 12% AS WELL.
THIS SHOWS OUR TELEHEALTH VIS
VISITS.
THE BEST WAY -- THE WAY I THINK
ABOUT THIS IS THE NUMBER OF
TELEHEALTH VISITS PER MONTH IS
ROUGHLY EQUAL TO ABOUT TWO DAYS
OF OUTPATIENT VISITS IN OUR
CLINICAL CENTER, AND YOU KNOW,
IN AN AVERAGE MONTH, THERE ARE
ABOUT 20 WEEKDAYS IN THE MONTH,
SO TWO DAYS' WORTH OF BUSINESS
IN 20 DAYS IS ABOUT 10%.
SO THAT'S ABOUT WHAT WE'RE
SEEING.
IT'S BEEN FAIRLY STABLE OVER
TIME.
IT ALWAYS LOOKS LIKE IT'S
DROPPING OFF BUT IT USUALLY
COMES BACK BECAUSE TELEHEALTH
VISITS CLOSE OUT MORE SLOWLY
THAN REGULAR VISITS.
WE REMAIN VERY FOCUSED ON
DIVERSITY, EQUITY AND INCLUSION
AND ACCESSIBILITY.
THE NIH RELEASED ITS STRATEGIC
PLAN FOR DEIA 2023-2027 EARLIER.
THE CLINICAL CENTER DIVERSITY,
EQUITY AND INCLUSION
ACCESSIBILITY ADVISORY COMMITTEE
WAS STOOD UP EARLIER THIS YEAR
AND SUBGROUPS WERE ESTABLISHED
IN MARCH.
WE ARE FOCUSED ON RECOGNIZING
THOSE PEOPLE WHO PARTICIPATE IN
PROGRAMS THAT ARE DESIGNED TO
ENHANCE UNDERSTANDING AND TO
LEARN ABOUT GROUPS OTHER THAN
THE GROUP THEY BELONG TO.
WE DID COMPLETE THE FOCUS
ASSESSMENT REVIEW OF OUR RACIAL
AND ETHNIC EQUITY PLAN IN
FEBRUARY OF THIS YEAR, AND WE
LAUNCHED OUR PROGRAMS IN MARCH
CH THIS YEAR.
THE NEXT SLIDE OUTLINES THOSE
PROGRAMS.
SO THESE ARE THE THREE THAT
WE'VE HELD SO FAR.
THE LAST ONE WAS JUST EARLIER
THIS WEEK.
BECAUSE OF THINGS THAT HAPPENED
IN MEMPHIS IN JANUARY, WE DID
THINK THAT TALKING ABOUT
DISPARITIES AND POLICE VIOLENCE
WAS SOMETHING THAT WAS OF
INTEREST TO OUR STAFF.
AS A MATTER OF FACT, THEY TOLD
US IT WAS OF INTEREST TO THEM.
AND SO WE HAD A FACILITATED
DISCUSSION, BUT THEY INCLUDED
THE ACTING CHIEF OF THE NIH
POLICE, AND A NUMBER OF
PARTICIPANTS FROM THE POLICE
DEPARTMENT AS WELL AS THE NIH
OFFICE OF EQUITY, DIVERSITY AND
INCLUSION.
WE RAN OUT OF TIME.
WE DIDN'T HAVE A CHANCE TO TALK
ENOUGH, SO WE CAME BACK IN APRIL
AND WE HAD THE SECOND EVENT
FOCUSED ON THE SAME TOPIC.
THOSE SESSIONS WERE WELL
ATTENDED IN PERSON, AND MANY
PEOPLE WATCHING THEM THROUGH
WEBCAST.
THEN THIS WEEK, WE HAD -- IN
RECOGNITION OF PRIDE MONTH, WE
HAD A PROGRAM ON SEX, GENDER,
PRONOUNS AND MORE.
IT WAS ALSO NIH VIDEOCAST.
BETWEEN THE PEOPLE WHO ATTENDED
IN PERSON, THE ONES WHO WATCHED
IT ON VIDEO, WHEN IT HAPPENED,
AND THOSE THAT HAVE WATCHED THE
RECORDING, I THINK WERE
SOMEPLACE BETWEEN 350 AND 400
PEOPLE PARTICIPATED IN THOSE
EVENTS -- IN THAT EVENT, WHICH I
THINK IS REALLY PRETTY
REMARKABLE.
AND IT'S A CREDIT TO THE AMOUNT
OF WORK THAT C.C. HENRY, OUR
SCIENTIFIC DIVERSITY ADVISOR,
HAS BEEN PUTTING IN TO THAT
EFFORT.
SO THE NEXT THINGS, WE'RE STILL
WORKING ON OPERATIONALIZING OUR
SUBGROUPS.
THE AWARDS AND RECOGNITION
PROGRAM, I'M ACTUALLY GOING TO
HAVE A CHANCE TO TALK TO THE
ADVISORY COMMITTEE IN A WEEK OR
SO, AND WE CONTINUE TO FOCUS ON
THE INITIATIVES OUTLINED IN OUR
RACIAL AND ETHNIC EQUITY PLAN,
AND THERE'S BEEN A SEVENTH
INITIATIVE THAT C.C. HAS
IDENTIFIED THAT WE'LL
INCORPORATE IN THAT PLAN.
YOU CAN SEE THE NATIONAL
COMMEMORATIONS THAT ARE TAKING
PLACE THIS MONTH.
NOW, WE'RE STILL SORT OF FORMING
HOW WE'RE GOING TO ADDRESS
HEALTH DISPARITIES EFFORT IN THE
WAY THAT THE JOINT COMMISSION
HAS ASKED HOSPITALS TO ADDRESS
IT.
IT'S A LITTLE BIT MORE NUANCED
IN OUR SETTING THAN IT IS IN THE
HOSPITAL WHERE THERE'S PUBLIC
ACCESS OR IN A CLINICAL RESEARCH
ENVIRONMENT.
IT GETS A LITTLE MORE
CHALLENGING TO FIGURE OUT
EXACTLY HOW TO MEET THE MARK,
AND WE'VE FRANKLY STRUGGLED WITH
THIS A LITTLE BIT, BUT WE'RE
STILL WORKING ON IT.
AND WE'LL NEED TO HAVE AN
EXECUTIVE GROUP MEETING TO
FINALIZE HOW WE'RE GOING TO
ADDRESS THE JOINT COMMISSION'S
IMPERATIVES VERY SOON.
WE HAVE GRADUALLY RELAXED
COVID-19 RESTRICTIONS, AS LARRY
SAID, WE WANT TO BE DONE WITH
THE VIRUS BUT THE VIRUS IS NOT
DONE WITH US.
WE HAVE STOPPED DOING AT-WILL
TESTING, WHICH MEANS THAT ANY
STAFF MEMBER IN THE CLINICAL
CENTER WHO WANTED TO BE TESTED
COULD BE TESTED JUST BY ASKING.
TESTING NOW REQUIRES GOING
THROUGH EITHER THE OCCUPATIONAL
MEDICINE SERVICE OR THE HOSPITAL
EPIDEMIOLOGY SERVICE, WITH A
STAFF THAT WERE DEDICATED TO AT
WILL TESTING HAVE NOW BEEN SENT
BACK TO DO WHAT THEY WERE DOING
BEFORE.
WE DO HAVE A NEW MASK POLICY,
AND IT BASICALLY SAYS -- IT
REQUIRES US TO MASK IN PATIENT
CARE AREAS AND MAKES MASKS
OPTIONAL IN NON-PATIENT CARE
AREAS.
AS YOU ALL ARE PROBABLY AWARE,
MAKING THOSE TRANSITIONS IS NOT
AN EASY THING, AND PEOPLE GET
IDEAS THAT AREN'T PARTICULARLY
APPLICABLE, AND SO WE'RE STILL
KIND OF WORKING THROUGH THAT,
BUT MUCH OF WORKING THROUGH THAT
TOOK PLACE WHILE I WAS AWAY ON
ANNUAL LEAVE.
I WAS GLAD TO BE GONE DURING
SOME OF THAT.
BUT I THINK IT'S WORKING OUT
PRETTY WELL.
BUT WE DO UNDERSTAND OUR MASK
REQUIREMENTS MAY CHANGE,
DEPENDING ON WHAT THE VIRUS
DOES.
WE STILL HAVE VARIOUS ENTRY
POINTS TO THE CLINICAL CENTER,
IN TERMS OF SORT OF STAFF
SATISFACTION, WE MUST CONTINUE
TO LOOK AT WHEN WE CAN OPEN UP A
LITTLE BIT MORE.
THIS IS PART OF OUR JOINT
COMMISSION SURVEY PREPARATION.
WE HAD TWO MOCK SURVEYS, WE HAD
ONE SORT OF MORE OF THE
TRADITIONAL CLINICAL SERVICES BY
A CONSULTANT ORGANIZATION IN
JANUARY, AND THEN WE HAD OUR
ENVIRONMENT OF CARE SAFETY --
COME THROUGH A MONTH OR SO
LATER, AND THAT'S THE WAY OUR
LEADERSHIP ROUNDS ARE FOCUSED.
IN THE PAST, WE MADE REGULAR
PATIENT SAFETY OR LEADERSHIP
ROUNDS FOCUSED ON PATIENT
SAFETY, BUT THEY WERE RELATIVELY
UNFOCUSED.
WE'RE DOING A LITTLE BIT BETTER
JOB OF FOCUSING IN ON THOSE
THINGS THAT WE HAD A PROBLEM
WITH DURING THE LAST SURVEY,
THINGS THAT WERE IDENTIFIED BY
THE MOCK SURVEYOR, AND OTHER
PERENNIAL PROBLEM AREAS THAT YOU
MIGHT -- MANY OF YOU ARE
PROBABLY AWARE.
WE ALSO HAVE MOCK TRACERS DONE
EVERY COUPLE OF WEEKS THAT
INVOLVE THE OFFICE OF PATIENT
SAFETY AND CLINICAL QUALITY IN
THE CLINICAL CENTER NURSING
DEPARTMENT, AND THERE'S ONE
TOPIC OR AREA FOCUSED TRACER
THAT INCORPORATES CLINICAL AREAS
AND CLINICAL CENTER DEPARTMENTS.
AND IT FOCUSES ON THE SPECIFIC
ISSUES IDENTIFIED IN THE JOINT
COMMISSION RESOURCES DOCUMENTS,
AND IT GETS VERY DETAILED INTO
THE JOINT COMMISSION ELEMENTS OF
PERFORMANCE.
WE'LL BE WORKING WITH THE
LEADERSHIP ROUNDS AND THE MOCK
TRACERS AS WE EXPECT THE NEXT
VISIT FROM THE JOINT COMMISSION
IN ABOUT A YEAR.
YOU ALL HAVE RECEIVED THE
PATIENT SAFETY QUARTERLY METRICS
FROM DR. LANG, AND IF THERE ARE
ANY QUESTIONS ABOUT THOSE, THEY
ARE ALSO POSTED ON THE CLINICAL
CENTER WEBSITE FOR PUBLIC
VIEWING.
IF YOU HAVE ANY QUESTIONS, I'LL
TRY TO ANSWER THEM, ALTHOUGH I'M
PROBABLY BEHIND TIME ALREADY.
THIS IS THE AGENDA FOR TODAY.
YOU'VE ALREADY HEARD DR. TABAK
AND THE FIRST OF MY TWO TALKS.
AFTER I FINISH THE SECOND TALK,
DR. WALLEN, WHO WAS THE CHIEF
NURSE IN THE CLINICAL CENTER FOR
A NUMBER OF YEARS, AND NOW HEADS
THE TRANSFORMATIONAL
BIOBEHAVIORAL AND HEALTH
DISPARITIES BRANCH AT THE
CLINICAL CENTER IS GOING TO TALK
ABOUT THEIR RESEARCH PORTFOLIO.
AFTER A SMALL BREAK, A SHORT
BREAK, PROBABLY SHORTER THAN YOU
WOULD WANT, WE'LL HAVE -- I
THINK DR. CUNNINGHAM AT THE LAST
CLINICAL CENTER RESEARCH
HOSPITAL BOARD ASKED ABOUT SOME
OF OUR IN-HOUSE TRAINING AND
DEVELOPMENT PROGRAMS, AND THE
CHIEF OF THE OFFICE OF WORKFORCE
MANAGEMENT AND DEVELOPMENT,
CHARLOTTE PAK, WILL GIVE THAT
PRESENTATION.
AND FOLLOWING CHARLOTTE'S
PRESENTATION, THEN, THERE WERE A
FEW QUESTIONS AT THE LAST
CLINICAL CENTER RESEARCH
HOSPITAL BOARD THAT HAD TO DO
WITH ARPA-H, AND SO JENNIFER
ROBERTS, THE DIRECTOR OF
RESILIENT SYSTEMS AT ARPA-H,
WILL GIVE A -- HAS 45 MINUTES
FOR PRESENTATION.
SO I THINK WE CAN GO TO THE --
WE CAN GET OUT OF THOSE SLIDES
AND DR. CUNNINGHAM, I SAW YOUR
QUESTION WHEN IT POPPED UP.
I'LL GET YOU AN ANSWER FOR THAT.
I BELIEVE THAT THAT CAN BE
VIEWED OUTSIDE OF THE NIH, BUT
I'M NOT 100% SURE, AND SO I'LL
TRY TO GET YOU AN ANSWER.
>>OKAY.
THANK YOU VERY MUCH.
>>ARE THERE ANY OTHER QUESTIONS
BEFORE I GO ON TO THE NEXT TOP
TOPIC?
>>DR. GILMAN, JUST FOR MY
KNOWLEDGE, HOW DO YOU PLAN TO
SET UP THE HEALTH DISPARITIES
WORK?
>>SO WHAT I'M FIRST -- WHAT WE
FIRST HAVE TO DO IS FIGURE OUT
WHO'S GOING TO BE THE PERSON
RESPONSIBLE.
WHEN THE JOINT COMMISSION ASKED
ME.
AND FRANKLY, WE'RE STILL -- I'M
STILL STRUGGLING WITH THAT JUST
A LITTLE BIT.
AND WE HAVE DONE -- AND I THINK
WE MAY EVEN HAVE PRESENTED TO
THIS GROUP.
IF NOT, WE'VE PRESENTED AT THE
NIH.
FOR INSTANCE, WE'VE LOOKED AT
OUR PATIENT SATISFACTION SURVEY,
OUR PRESSGRAY KNEE RESULTS, AND
WE HAVE ANALYZED THAT DATA BY
THE LIMITED AMOUNT OF
CATEGORIZATION WE HAVE WITH
RESPECT TO ETHNICITY.
AND RACE.
AND IT GENERALLY DOESN'T SHOW A
CHANGE.
THE PROBLEM, OF COURSE, IS -- I
THINK WHAT PEOPLE HAVE IN MIND,
WHAT THEY'RE TALKING ABOUT IS
HEALTH OUTCOMES, AND THE KIND OF
RESEARCH WE DO, WHICH IS A LOT
OF FAIRLY SMALL TRIALS, IT'S
KIND OF HARD SOMETIMES TO BE
ABLE TO DO COMPARISONS, TO HAVE
ENOUGH DATA TO DO COMPARISONS.
DR. HAD IGA N TURNED ON HER
CAMERA SO SHE MIGHT HAVE
SOMETHING SHE WOULD LIKE TO ADD.
>>I'M HERE TO ADD ANYTHING THAT
PEOPLE MAY HAVE QUESTIONS FOR,
BUT I THINK DR. GILMAN
SUMMARIZED IT WELL.
WE'RE CURRENTLY AT THE STAGE
WHERE WE'RE LOOKING AT WHAT ARE
THE DEMOGRAPHIC CHARACTERISTICS
THAT WE HAVE SYSTEMATICALLY
COLLECTED AND HOW WE MIGHT
DEFINE WHAT IT IS THAT WE'RE
GOING TO LOOK AT.
IN THE PRELIMINARY DISCUSSIONS,
THERE ARE THINGS THAT WE COULD
USE THAT GO ACROSS INSTITUTIONS,
ACROSS DISEASE PROCESS THAT MAY
BE WORTH LOOKING AT, LIKE
RELATED TO ACCESS, LANGUAGE.
WE DON'T HAVE GOOD MARKERS FOR
SOCIOECONOMIC STATUS.
>>OH, I SEE.
>>BUT THAT'S NOT A REQUIREMENT.
WHEN YOU LOOK AT THE JOINT
COMMISSION REQUIREMENTS, WE CAN
DO IT BY AGE, WE CAN DO IT BY
SEX, WE CAN DO IT BY RACE, YOU
KNOW, WE CAN DO IT BY REGION OF
THE COUNTRY.
BUT ONE OF THE AREAS THAT WE
THINK WOULD BE INTERESTING TO
LOOK AT PARTICULARLY AS IT
PERTAINS TO RESEARCH IS LANGUAGE
AND LITERACY.
SO THAT MIGHT BE AN AREA
WHERE -- ONE OF OUR FIRST DEEP
DIVES IN KIND OF PULLING SOME
DATA AND SEE WHAT WE HAVE.
>>THANK YOU.
>>WHEN YOU DON'T DEAL WITH
COVERED LIVES IN POPULATION
HEALTH, IT BECOMES A LITTLE
HARDER TO ACTUALLY DO THE KINDS
OF QUANTITATIVE ANALYSES THAT I
THINK WOULD REALLY BE BENEFI
BENEFICIAL.
OKAY?
>>DR. GILMAN?
>>YEAH.
>>SINCE WE'RE NOT A PUBLIC
HOSPITAL WITH PUBLIC ACCESS, AND
EVERYBODY HAS TO BE INVITED,
WOULDN'T -- WOULD THE JOINT
COMMISSION'S DIRECTIVES OR THE
INFORMATION THEY'RE SEEKING ALSO
HAVE TO INVOLVE THE PROCESS OF
SCREENING PATIENTS FOR ADMISSION
TO PROTOCOLS?
>>WE CAN -- THE ANSWER IS, I
THINK, YES, BUT SCREENING IS
DONE WHERE THE PATIENTS START IN
MANY INSTANCES, AND IT'S DONE
WITH A PHONE CALL, IT NOT DONE
WITH A RECORD.
YOU KNOW, WE HAVE -- WE HAVE
DATA ON WHO -- WE HAVE SOME DATA
ON WHO ACTUALLY CONTACTS OUR
CALL CENTER, WHO ACTUALLY
CONTACTS US, AND WE ACTUALLY --
WE HAVE TAKEN A FAIR -- WE'VE
TAKEN A PRETTY GOOD LOOK AT THAT
AS WELL.
BUT I THINK IN TERMS OF TRYING
TO SAY THAT PATIENTS -- THE
INCLUSION/EXCLUSION CRITERIA
COME FROM THE INVESTIGATORS, AND
MANY OF THEM ARE
DISEASE-FOCUSED.
AND THEY'RE NOT BIG STUDIES FOR
THE MOST PART.
AND THEY'RE UNUSUAL IN RARE
DISEASES OR REFRACTORY DISEASES,
AND SO HOW WE GET SOME REALLY
GOOD COMPARATORS IS GOING TO BE
A STRUGGLE, BUT THE JOINT
COMMISSION MOSTLY WANTS TO MAKE
SURE THAT WE HAVE SOMEBODY WHO'S
TRYING TO DO THIS.
THAT'S WHAT THEY WANT RIGHT NOW.
>>THANK YOU.
>>ONE MORE QUESTION.
>>YEP.
>>DR. GILMAN, THE DEIA FORUM,
IS THAT ACCESSIBLE TO THE PUBLIC
OR THAT'S JUST SOMETHING THAT IS
ONLY FOR NIH EMPLOYEES OR --
>>IT'S FOCUSED ON NIH STAFF
MEMBERS.
I DON'T BELIEVE WE BROADCAST
THOSE OUTSIDE, BUT C.C. IS ON
THE CALL AND SHE CAN TELL ME.
>>HI, EVERYONE.
YES, THAT IS CORRECT.
THE DEIA FORMS ARE FOR NIH STAFF
ONLY, INTERNAL WORKFORCE.
THE FORUMS ARE TARGETED TO WHAT
THEIR ASSESSED NEEDS ARE, SO IT
IS TARGETED TO OUR INTERNAL
WORKFORCE.
>>OKAY.
I THINK WE NEED TO MOVE ON, AND
SO IF WE CAN HAVE THE NEXT SET
OF SLIDES UP, CARLY.
I'LL TRY TO GO THROUGH THIS A
LITTLE MORE QUICKLY, AND SO IT'S
TIME FOR US TO GO TO WORK ON OUR
NEXT STRATEGIC PLAN FOR THE NEXT
THREE TO FIVE YEARS.
JUST BY WAY OF BACKGROUND, I
BELIEVE THE DOCUMENT WE PRODUCED
IN 2019 WAS KIND OF THE FIRST OF
ITS KIND FOR THE CLINICAL
CENTER, AND IT WAS -- IN TRYING
TO PLAN FOR HEALTHCARE
OPERATIONS MORE THAN A FEW YEARS
DOWN THE ROAD IS, I THINK -- IT
IS A FIELD OF DREAMS, IF WE'RE
NOT CAREFUL.
AND SO THIS IS SORT OF THE
PLANNING TIME FRAME THAT WE
FOCUS ON.
I REVIEWED THE PROGRESS ON THIS
PLAN FOR THE CLI A YEAR AGO.
BEFORE THE PANDEMIC HIT, WE WERE
MEETING MOST OF THE MILESTONES.
SO IF YOU LIVE WITH THE
FIVE-YEAR RULE, THEN OUR NEXT
PLAN IS DUE IN 2024, AND IT'S
TIME TO START THE PLANNING
CYCLE.
AS I INDICATED, THE ONE IN 2019,
WE DEVELOPED FROM WHOLE CLOTH.
WE DIDN'T HAVE ANYTHING TO START
OFF WITH.
FORTUNATELY FOR 2024, WE HAVE
THE 2019 PLAN TO BEGIN WITH.
THIS IS EARLY DAYS, BUT TODAY
OFFICIALLY INITIATES THE
LEARNING AND LISTENING PROCESS
AS WE START WORKING ON THE PLAN
FOR 2024.
SO WE'RE PRETTY HAPPY WITH THIS
MISSION STATEMENT.
WE DON'T THINK THAT THAT SHOULD
CHANGE VERY MUCH.
THE DOCUMENT ALSO OUTLINES SEVEN
GUIDING PRINCIPLES, AND I'LL
TALK ABOUT EARLY THOUGHTS THAT I
HAVE ABOUT THREE OF THOSE.
I THINK THE OTHER FOUR PROBABLY
DON'T NEED ANY ADJUSTMENT, BUT I
DO THINK THAT THERE ARE THREE
HERE THAT BEAR SOME ADDITIONAL
THOUGHT.
SO PASSION FOR OUR PATIENTS,
THEIR FAMILIES AND ONE ANOTHER.
I FINISHED A COURSE ON
COMPASSIONATE LEADERSHIP WITH
MHEI, A TWO-DAY COURSE, AND ONE
OF THE ASPECTS OF COMPASSION
THAT I HAD NOT GIVEN MUCH
THOUGHT ABOUT WAS EMPHASIZED
THERE WAS WE NEEDED TO START
BEING A LITTLE EASIER ON
OURSELVES.
AND SO I THINK WE'LL NEED TO
FIGURE OUT A WAY TO INCORPORATE
THAT INTO THAT GUIDING PRINCIPLE
THE NEXT TIME AROUND.
DIVERSITY AND INCLUSION OF
PEOPLE AND IDEAS.
WE DID LIST THAT IN 2019, BEFORE
GEORGE FLOYD, BEFORE ANY OF THE
OTHER THINGS THAT HAVE HAPPENED,
BEFORE BLACK LIVES MATTER,
BEFORE ME TOO, BEFORE LOTS AND
LOTS OF THINGS THAT HAVE
DOMINATED THE ENVIRONMENT IN THE
LAST FEW YEARS.
BUT WE DIDN'T INCLUDE
ACCESSIBILITY, AND I THINK
THAT'S NOW IMPORTANT, AND
ESPECIALLY AS A HEALTHCARE
ORGANIZATION, I THINK WE NEED TO
INCORPORATE THAT SOMEHOW.
AND OBVIOUSLY, THE FOCUS ON
DIVERSITY AND INCLUSION, EQUITY
AND ACCESSIBILITY HAS RECEIVED
MUCH GREATER EMPHASIS AT THE NIH
DURING THE LAST FEW YEARS, AND
IN MANY AREAS OF THE COUNTRY.
I THINK THAT MEANS THAT WE'LL
HAVE TO GO BACK AND TAKE A LOOK
AT THIS GUIDING PRINCIPLE AND
DECIDE HOW WE WANT TO -- WHAT
WE'RE GOING TO DO WITH IT.
YOU'RE GOING TO HEAR MORE ABOUT
OUR COMMITMENT TO PROFESSIONAL
GROWTH AND DEVELOPMENT, AND I
THINK YOU'LL SEE THAT WE'VE MADE
GOOD PROGRESS BUT WE'RE ALWAYS
INTERESTED IN OTHER IDEAS ABOUT
HOW TO DO MORE FOR OUR STAFF IN
THAT AREA.
THE PLAN IN 2019 HAD FOUR BROAD
AIMS LEADING THE WORLD,
CONTINUING TO LEAD THE WORLD AND
CONDUCTING FIRST IN HUMAN
CLINICAL RESEARCH WITH A FOCUS
ON RARE AND REFRACTORY DISEASE.
I THINK THAT THAT'S A KEEPER.
I DON'T THINK WE'LL CHANGE THAT.
INCREASING THE USE OF THE
CLINICAL CENTER BY THE
INTRAMURAL RESEARCH PROGRAM
WHILE ACCELERATING THE CLINICAL
CENTER'S STATUS AS A NATIONAL
RESOURCE FOR THE EXTRAMURAL
COMMUNITY.
THIS WAS THE AIM THAT WE
GRADED -- WE GAVE OURSELVES BA
BARELY ACCEPTABLE MARKS ON A
YEAR AGO.
MUCH OF THAT WAS DUE TO THE
PANDEMIC AND CIRCUMSTANCES
BEYOND OUR CONTROL, BUT WE
ALWAYS HAVE TO BE THINKING ABOUT
THE CHANGES THAT ARE TAKING
PLACE AND THE KINDS OF RESEARCH
THAT NIH INVESTIGATORS WANT TO
DO, AND MAKING SURE THAT WE DO
WHAT WE CAN TO ESTABLISH THE
CAPABILITIES TO SUPPORT THAT
RESEARCH.
I THINK THE THIRD AIM IS
SELF-EVIDENT AND I DON'T SEE
THAT CHANGING VERY MUCH.
AND THEN THE FOURTH ONE, AND WE
RECOGNIZED IT WAS GOING TO BE A
CHALLENGING ENVIRONMENT BASED ON
THE SENIORITY OF MANY OF THE
STAFF AT THE CLINICAL CENTER IN
2019.
BUT THE NEXT SLIDE SORT OF
OUTLINES WHAT THIS IS, HOW I
THINK THIS IS AN EVEN BIGGER
CHALLENGE THAN WE PROBABLY
ANTICIPATED FIVE YEARS AGO.
SO RECRUIT, DEVELOP AND RETAIN
THE NEXT GENERATION OF GREAT NIH
CLINICAL RESEARCHERS.
SO THIS IS EVEN MORE IMPORTANT
TODAY THAN IT WAS IN 2019.
AND IT'S EVEN HARDER TODAY THAN
IT WAS IN 2019.
IT'S ONE THING TO TALK ABOUT
RECRUITING, DEVELOPING AND
RETAINING THE NEXT GENERATION OF
GREAT NIH CLINICAL RESEARCHERS.
THAT'S CHALLENGING ENOUGH.
BUT WHEN YOU'RE TROYING TO DO IT
WHILE ALSO MAKING THE NIH
CLINICAL CENTER MORE REFLECTIVE
OF THE -- OF THE POPULATION THAT
WE SERVE, IT MAKES IT EVEN MORE
DIFFICULT.
AND I THINK MANY OF YOU IN
HEALTHCARE LEADERSHIP ARE TRYING
TO DEAL WITH THIS, BUT IT ADDS A
LAYER OF COMPLEXITY.
WE'RE KIND OF COMFORTABLE WITH
COMPLEXITY AT THE NIH, SO I'M
NOT SAYING THIS PUTS THIS IN THE
TOO HARD TO DO CA CATEGORY, AND
THINK IN OUR RACIAL AND ETHNIC
EQUITY PLAN AND WITH OUR DEIA
ADVISORY COUNCIL AND WITH THE
LEADERSHIP OF CECE HENRY, I
THINK WE'LL BE ABLE TO MAKE
STRIDES.
I THINK WE HAVE MADE STRIDES IN
THE LAST FIVE YEARS.
BUT IT WAS -- IT IS, THERE'S NO
DOUBT ABOUT THE FACT THAT IT'S A
CHALLENGE.
AND WHETHER THE DIVERSITY,
EQUITY AND INCLUSION AND
ACCESSIBILITY FOCUS BECOMES A
SEPARATE STRATEGIC AIM OR
WHETHER IT REMAINS INCORPORATED
WITH THE SORT OF RECRUIT,
DEVELOP AND RETAIN AIM IS
SOMETHING THAT WE'VE STARTED TO
HAVE SOME DISCUSSIONS ABOUT.
NOT SURE WE'VE REACHED AGREEMENT
YET.
SO I DO THINK THAT WE WILL HAVE
A NEW STRATEGIC AIM IN THIS ONE,
AND IT BASICALLY RELATES TO OUR
ABILITY TO ACCESS AND USE
INFORMATION OF ALL TYPES.
EVEN IN THE ADMINISTRATIVE
AREAS, THERE'S TOO MUCH FOR
ANYONE TO REMEMBER OR KNOW, AND
IS IT ALL NECESSARY OR CAN SOME
OF IT BE PUT INTO BACKGROUND.
RIGHT NOW IT'S NOT ALWAYS EASY
FOR ANYONE TO FIND, SO IS IT
ORGANIZED AS WELL AS IT COULD
BE?
OUR CURRENT WEB PRESENCE HAS A
POOR SEARCH FUNCTION, AND I
THINK WE'RE ALREADY COMMITTED,
AT LEAST I'VE ALREADY COMMITTED
AND I THINK WE'VE IDENTIFIED THE
RESOURCES TO CREATE A NEW
WEBSITE FOR THE CLINICAL CENTER.
AND THEN SOMEBODY THAT I'VE
TALKED ABOUT WITH STEPHANIE REEL
OFFLINE, OUTSIDE OF THESE
MEETINGS, IS WE ALSO ARE AT THE
POINT WHERE WE NEED TO PROCURE A
NEW ELECTRONIC HEALTH RECORD.
AND IF WE'RE NOT ABLE TO DO
THAT, THEN WE HAVE TO MAKE A
VERY SIGNIFICANT INVESTMENT IN
OUR CURRENT ELECTRONIC HEALTH
RECORD IN ORDER TO MAKE IT MORE
USEFUL, NOT JUST FOR US BUT FOR
THE NIH AT LARGE COMMUNITY.
WE TALKED ABOUT PEDIATRICS, AND
I'VE COMMUNICATED WITH
DR. DEVASKAR AHEAD OF THIS
MEETING, AND SHE KNOWS WHAT I'M
GOING TO SAY, AND AS INDICATED,
WE HAVE THE RESULTS OF T HER GR,
AND I PROVIDED THAT TO THE
PEDIATRIC PLANNING GROUP, THAT
THEY ARE NOT FANS OF THE
ALTERNATIVE APPROACH.
FRANKLY, IF THEY WERE FANS OF
THE ALTERNATIVE APPROACH OF
DOING MORE OF THE WORK THAT THEY
WANT TO DO IN THE EXTRAMURAL
COMMUNITY, WE PROBABLY WOULDN'T
HAVE LAUNCHED THIS EFFORT TWO
YEARS AGO.
BUT IT'S VERY CLEAR THAT WE HAVE
SOME MAJOR STEPS THAT HAVE TO BE
TAKEN IF WE'RE GOING TO DO MORE
RESEARCH IN SMALLER AND YOUNGER
CHILDREN AT THE NIH CLINICAL
CENTER.
AND WE WON'T GET A LOT MORE OF
THAT DONE THIS YEAR.
SO THESE ARE THE THINGS I THINK
WE CAN CONTINUE TO DO.
WE CONTINUE TO FORMALIZE THE
ORGANIZATION OF A DEPARTMENT OF
PEDIATRICS.
BY THE WAY, DR. TABAK TALKED
ABOUT ROCKY FEUER IS A FINALIST
FOR A SAMMY AWARD.
HER WIFE IS OUR CHIEF OF THE
PEDIATRICS DEPARTMENT, SO IF DRE
GOING TO CLAIM PART OF IT.
SO WE WILL CONTINUE TO ADVANCE
THE MODEL OF CARE FOR PEDIATRIC
PATIENTS SO THAT ALL ARE CARED
FOR BY DOCTORS AND NURSES WITH
AGE-SPECIFIC COMPETENCIES AND
WE'RE VERY CLOSE TO
ACCOMPLISHING THAT ALREADY.
THAT'S BEEN REALLY A MAJOR
ACHIEVEMENT ATTRIBUTABLE TO MANY
STAFF.
RIGHT NOW WE DON'T ADMIT
PATIENTS YOUNGER THAN THE AGE OF
3.
WE ARE CAREFULLY ASSESSING OUR
ABILITY TO CARE FOR PATIENTS
DOWN TO THE AGE OF 2 WITHOUT
ADDING THE PEDIATRIC ICU.
I DON'T THINK IN VIEW OF THE
RESOURCE ENVIRONMENT FOR THE NIH
AND THE NIH CLINICAL CENTER FOR
2024, I DON'T THINK IT'S
REALISTIC TO TACKLE THE
PEDIATRIC ICU FOR 2024 AND THERE
WILL BE NO BUDGET REQUEST FOR
THOSE RESOURCES.
I DO THINK THAT WE CAN FIND THE
RESOURCES TO ADD CHILD LIFE
SPECIALISTS TO THE CARE OF
CHILDREN.
WE'VE HAD A FAIR NUMBER OF
DISCUSSIONS ABOUT THIS, AND WE
MAY NOT HAVE DECIDED EXACTLY HOW
THEY'RE GOING TO BE ALIGNED, BUT
WE HAVE DECIDED -- WE MADE A
COUPLE OF DECISIONS ABOUT WHERE
THEY'RE NOT GOING TO BE ALIGNED.
BUT I DO BELIEVE THAT THIS WILL
ENHANCE OUR ABILITY TO PROVIDE
CARE, GOOD CARE, FOR THE
CHILDREN WE CURRENTLY CARE FOR
GOING FORWARD.
SO PEDIATRICS WILL STILL
CONTINUE TO GET A LOT OF FOCUS.
ALTHOUGH AT ONE POINT, I THINK
WE HAD HOPED TO TAKE THE NEXT
BIG STEP AND I JUST DON'T
BELIEVE THAT THIS IS THE YEAR TO
DO IT.
WE'RE VERY CLOSE TO FINISHING
THE LAST MAJOR PHARMACY
CONSTRUCTION PROJECT, AND THAT
IS FINISHING THE PERMANENT
INTRAVENOUS ADMIXTURE UNIT.
AS SOME OF YOU ARE AWARE, THESE
FACILITIES ARE EXTREMELY
DEMANDING, AND THE DEVIL IS VERY
MUCH IN THE DETAILS, AND THERE'S
ALWAYS A PROBLEM OR TWO THAT
COMES UP NEAR THE FINISH LINE,
AND BECAUSE THE FACILITIES HAVE
TO OPERATE WITH GREAT EXACTNESS,
IT DOESN'T TAKE VERY MUCH OF A
PROBLEM TO PROLONG THE LENGTH OF
TIME.
SO IN THE RED TEAM REPORT AND IN
THE INSPECTION OF THE PHARMACY,
THE PHARMACODEVELOPMENT SERVICE
WAS A SOURCE OF GREAT CONCERN,
AND WAS PERMANENTLY CLOSED.
AND IT'S VERY CLEAR, AND IT'S
BEEN VERY CLEAR SINCE I ARRIVED
OVER SIX YEARS AGO, THAT THE
PHARMACODEVELOPMENT SERVICE THAT
HOUSED A NUMBER OF CAPABILITIES
THAT INVESTIGATORS MISS, AND SO
WE ARE IN THE PROCESS OF LOOKING
AT SOME VERY BASIC FUNCTIONS,
THAT THE PDS PROVIDED, TO SEE
WHETHER IT'S POSSIBLE TO BRING
ANY OF THOSE BACK.
NOW, IF DR. TABAK IS STILL IN
THE MEETING, I KNOW HE'LL BE
VERY CONCERNED ABOUT WHAT I'M
SAYING.
I DO WANT TO MAKE SURE THAT IT'S
VERY CLEAR.
WE ARE NOT TALKING ABOUT --
WE'RE NOT TALKING ABOUT A VERY,
VERY EXPENSIVE CONTRACTING
MANUFACTURING ORGANIZATION.
WE'RE TALKING ABOUT IMPROVING
OUR ABILITY TO DO COMPOUNDING.
AND IT'S NOT JUST OUR ABILITY TO
DO IT.
WE'RE TALKING ABOUT IMPROVING
OUR ABILITY TO OUTSOURCE BATCH
PROCESSING IN TERMS OF
COMPOUNDING.
AND WE'RE NOT GOING TO RESUME
MANUFACTURING THAT WAS DONE IN
THE PDS IN ANY FORESEEABLE
FUTURE OR MY LIFETIME, AND
EVERYTHING WE DO WILL BE DONE
WITH SAFETY AND COMPLIANCE.
THE CLINICAL CENTER GOVERNING
BOARD HAS DEALT WITH THE
PHARMACY AND NON-STERILE
COMPOUNDING ISSUES IN A COUPLE
OF MEETINGS THIS YEAR, THERE
ACTUALLY WAS SUPPOSED TO BE A
CLINICAL CENTER GOVERNING BOARD
MEETING YESTERDAY THAT HAD TO BE
CANCELED, AND THAT MEETING ALSO
WILL HAVE NON-STERILE
COMPOUNDING.
BUT I THINK WE HAVE A WAY AHEAD
THAT WILL BE ACCESSIBLE TO
INVESTIGATORS THAT REALLY NEED
NON-STERILE COMPOUNDING IN
BATCHES BUT WILL MOSTLY INVOLVE
OUTSOURCING THIS EFFORT.
SO WHAT HAPPENS NOW IS I NEED TO
TALK WITH LOTS AND LOTS AND LOTS
OF OTHER PEOPLE, AND I NEED TO
SPEND A LOT OF TIME NOT JUST
TALKING BUT LISTENING.
THOSE INCLUDE THE EXTERNAL
STAKEHOLDERS OF THE NIH CLINICAL
CENTER, AS WELL AS ALL THE
PEOPLE INSIDE THE CLINICAL
CENTER.
AND MY HOPE IS THAT BY THE END
OF THIS YEAR, THAT WE'VE DONE
OUR TALKING AND LISTENING AND
WE'LL BE ABLE TO SIT DOWN AND
ACTUALLY BEGIN WORKING ON A REAL
PLAN, SOMETHING THAT LOOKS LIKE
A REAL PLAN, WHY THE IDEA THAT
IT WOULD BE OUT IN 2024.
I THINK THAT'S MY LAST SLIDE.
IT LOOKS LIKE I DID MAKE UP A
LITTLE BIT OF TIME, AND SO IF
THE SLIDES CAN COME DOWN, I'LL
BE HAPPY TO ANSWER QUESTIONS,
BUT MORE THAN ANYTHING, NOT JUST
NOW, BUT WITH ANY TIME, I HOPE
YOU HAVE THOUGHTS ABOUT THIS
PLAN AND YOU HAVE IDEAS, AND YOU
CAN -- YOU'LL SEND THEM TO US SO
THAT WE HAVE A CHANCE TO TAKE A
LOOK AT THEM AND SEE WHAT YOU
THINK.
>>ARE THERE ANY QUESTIONS FOR
DR. GILMAN OR ANY DISCUSSION?
DAVID.
>>ONLY ONE QUESTION.
I DIDN'T SEE PATIENTS IN THE
EXTERNAL CONSTITUENTS FOR
CONSULTATION.
>>YEAH, THAT'S A GOOD POINT.
WE CAN CERTAINLY TALK ABOUT THIS
AT THE FALL CLINICAL CENTER
PATIENT ADVISORY GROUP.
>>THANK YOU.
DAVID.
>>TWO QUESTIONS.
DOES THE CLINICAL CENTER HOUSE
THE I.T. INFRASTRUCTURE FOR THE
REST OF THE INSTITUTE?
I MEAN, IN TERMS OF THE EHR AND
ALSO AROUND TELEHEALTH?
I MEAN, IT LOOKS LIKE TELEHEALTH
IS GOING TO BE A PERMANENT
FEATURE OF MEDICINE, AND I KNOW
THERE'S A LOT OF VARIATION AMONG
CLINICAL DEPARTMENTS AS TO WHICH
ONES USE MORE TELEHEALTH THAN
OTHERS.
I WAS JUST WONDERING, WHERE IS
THAT IN THE STRATEGIC PLAN?
>>SO THE VARIATION, DAVID, HAS
MORE TO DO WITH THE SIZE OF THE
INSTITUTE AND THE SIZE OF THEIR
CLINICAL PROGRAMS THAN IT DOES
WITH THEIR ACCEPTANCE.
OF
TELEHEALTH.
SO I THINK THAT IT IS -- SO THE
CLINICAL CENTER HOUSES THE
INFRASTRUCTURE OF TELEHEALTH.
IT IS AVAILABLE, EQUALLY
AVAILABLE TO ALL OF THE ICs.
ALL OF THE INSTITUTES AND
CENTERS.
NCI LEADS THE LIST BECAUSE THEY
ARE FAR AND AWAY THE LARGEST
I.C.
THEY HAVE MORE PATIENTS, MORE
PROVIDERS, MORE RESOURCES.
SO I THINK -- BUT THE TELEHEALTH
INFRASTRUCTURE IS ALL PROVIDED
BY THE CLINICAL CENTER, AND IT'S
EQUALLY ACCESSIBLE TO ALL
I.C.s.
DID THAT ANSWER YOUR QUESTION?
>>YES, IT DID.
I THINK THE ONLY COMMENT IS THAT
AMONG THE CLINICAL DEPARTMENTS,
REGARDLESS OF SIZE, THERE'S
DIFFERENT PERCEPTIONS OF
TELEHEALTH VISITS VERSUS
IN-PERSON VISITS.
SO -- ASSOCIATED WITH THAT AS
WELL.
GINA AND STEPHANIE PROBABLY --
AND STEVE PROBABLY KNOW MORE
ABOUT THIS THAN I DO.
>>AND I THINK -- I'M PRE I APPE
YOU POINTING THAT OUT.
WE CAN TAKE A LOOK AT THAT.
FOR THE MOST PART, THE CLINICAL
CENTER IS NOT INVOLVED IN
TELLING THE PROVIDERS AND
INSTITUTES HOW TO TAKE CARE OF
THEIR PATIENTS.
IF WE LOOK AT WHAT WE'VE LEARNED
IN OUR TELEHEALTH JOURNEY AND WE
CAN IDENTIFY CAPABILITIES THAT
AN INSTITUTE SAYS THAT WOULD
ENABLE THEM TO DO MORE BY
TELEHEALTH, WE CAN CERTAINLY
HAVE A LOOK AT THAT.
>>DR. GILMAN, IN REFERENCE TO
TELEHEALTH, WHAT ABOUT THE
PATIENTS THAT LIVE FAR AWAY AND
WE HAVE TO GET BLOOD WORK DONE,
WILL WE BE ABLE TO GET OUR BLOOD
WORK DONE AT ONE OF OUR LOCAL
FACILITIES, AND THEN THEY
WILL -- LIKE THEY DO LIKE --
>>SO ANTOINETTE, LET ME -- THAT
IS A -- THAT WAS A CONTRACTING
ISSUE AND IT WAS AN INITIATIVE
THAT WE WORKED ON IN THE
CLINICAL CENTER FOR A LONG
PERIOD OF TIME, AND I HAVEN'T
HEARD ANYTHING ABOUT IT IN A
WHILE.
BUT I CAN CHECK ON THAT AND
WE'LL GET YOU AN ANSWER.
>>THANKS.
>>OKAY, THANK YOU VERY MUCH,
JIM.
REALLY APPRECIATE IT.
WE LOOK FORWARD TO HEARING
UPDATES ON THE PLAN, MAYBE AT
THE NEXT BOARD MEETING.
CERTAINLY I DON'T KNOW HOW MANY
ORGANIZATIONS CAN HAVE LEAD THE
WORLD AS THEIR NUMBER ONE GOAL
WITHOUT IT BEING CONSIDERED HIGH
HYPERBOLE OR -- SO NEXT UP,
DR. GWEN WALLEN, CHIEF OF THE
TRANSLATIONAL BIOBEHAVIORAL AND
HEALTH DISPARITIES BRANCH.
THIS IS A TREAT TO HAVE
DR. WALLEN PRESENTING AS SHE HAS
SPENT RECENT YEARS INTERACTING
FREQUENTLY WITH THE BOARD IN HER
PRIOR POSITION AS THE CHIEF
NURSING OFFICER HERE AT THE
CLINICAL CENTER.
SO GWEN IS NOW PE PURSUING HER
PASSION FOR NURSING RESEARCH AND
WE LOOK FORWARD TO HEARING OF
HER CURRENT EFFORTS.
SO GWEN, I'LL TURN IT OVER TO
YOU.
>>THANK YOU, GOOD MORNING.
FIRST OF ALL, THANK YOU FOR
HAVING ME HERE IN THIS NEW ROLE,
AND I'M REALLY EXCITED TO TALK
TO YOU ABOUT OUR NEW BRANCH AND
I KNOW IT'S A MOUTHFUL, BUT
WE'RE KNOWN AS TBHD NOW AROUND
THE BUILDING, AND NEXT MONTH
WILL BE OUR TWO-YEAR
ANNIVERSARY.
THIS WAS THE BRAIN CHILD OF BOTH
DR. GALLIN AND WITH THE SUPPORT
OF DR. GILMAN OF DEVELOPING THIS
STANDALONE BRANCH AT THE
CLINICAL CENTER THAT WOULD FOCUS
ON INTERDISCIPLINARY RESEARCH AS
WELL AS FOCUS ON HEALTH
DISPARITIES AND BIOBEHAVIORAL
RESEARCH.
CAN I ADVANCE THEM MYSELF OR
WILL YOU?
OKAY.
SO I APOLOGIZE FOR THE SMALL
LETTERING.
I TOOK A DEEP GULP BECAUSE I
HEARD DAVID THIS MORNING GO, I
REALLY HATE WHEN PEOPLE HAVE
TINY, TINY WORDS ON THE SLIDES.
BUT THIS IS A SCHEMA OF THE
MISSION AND VISION AND GOALS WE
DEVELOPED FOR OUR BRANCH DURING
THE PAST YEAR, WORKING WITH THE
OFFICE OF STRATEGIC PLANNING AND
MANAGEMENT OPERATIONS IN THE
OFFICE OF THE DIRECTOR.
AND I'M EXCITED ABOUT IT BECAUSE
IT REALLY WAS AN EFFORT FROM
EACH OF OUR INVESTIGATORS.
WE CAME TOGETHER OVER A
SIX-MONTH PERIOD WHICH I THOUGHT
THAT'S SUCH A LONG AMOUNT OF
TIME TO DO THIS BUT IT REALLY
CAME TOGETHER WELL.
SO OUR MISSION IS TO ADVANCE
INTERDISCIPLINARY TRANSLATIONAL
SCIENCE FOCUSED ON
BIOBEHAVIORAL, CLINICAL AND
COMMUNITY STUDIES TO IMPROVE
WHOLE PERSON HEALTH.
AND I'LL TALK AS WE GO ALONG
ABOUT WHERE THAT FITS IN WITH
OUR PORTFOLIO.
I'M JUST GOING TO TOUCH ON SOME
OF THE THINGS WE'RE DOING JUST
BECAUSE I HAVE THE HALF AN HOUR
OF TIME.
AND THEN OUR VISION IS A BIG
VISION, BUT IT'S WORLD WHERE
SUSTAINABLE HEALTH PROMOTING
BEHAVIORS IMPROVE THE HEALTH OF
ALL LOCAL AND GLOBAL COMMUNITIES
THROUGH A NETWORK OF
INSTITUTIONAL, SCIENTIFIC, AND
COMMUNITY-ENGAGED PARTNERSHIPS
LEADING BIOBEHAVIORAL RESEARCH.
AND FOR OUR GROUP, THE COMMUNITY
ENGAGED PARTNERSHIPS IS A BIG
PART OF EVERYTHING THAT WE DO.
AND OUR FIRST GOAL IS TO ADVANCE
KEY BIOBEHAVIORAL RESEARCH.
ABOUT EIGHT YEARS AGO, WHEN WE
HAD OUR FIRST BOARD OF
SCIENTIFIC COUNSELORS, WHICH IS
WHEN EXTRAMURAL SCIENTISTS COME
IN TO EVALUATE OUR PROGRAM
BEFORE WE WERE ACTUALLY THIS
BRANCH AND WE WERE PART OF THE
NURSING DEPARTMENT, ONE OF THE
THINGS THAT THEY SAID WAS YOU DO
A LOT OF REALLY GOOD WORK IN
HEALTH DISPARITIES AND BEHAVIOR,
BUT WHERE'S THE BIO SIDE OF THE
BEHAVIOR?
SO THAT'S HOW WE STARTED
FOCUSING ON THE BIOBEHAVIORAL
SIDE OF THINGS.
AND THEN AT FIRST IT REALLY WAS
FOCUSED INWARD, SO TRYING TO GET
OUR INVESTIGATORS TO TARGET
FIRST DOING SIX PAPERS A YEAR,
AND THEN 10 PAPERS A YEAR, AND
ALSO PUTTING DOWN STANDARD
OPERATING PROCEDURES IN A NEW
LABORATORY WE HAVE THAT'S PART
OF THE NATIONAL INSTITUTE OF
NURSING RESEARCH.
THROUGH A MEMORANDUM OF
UNDERSTANDING, THEY'VE GIVEN US
BENCH SPACE WITHIN THEIR
INTRAMURAL PROGRAM.
AND THEN STANDARDIZING OUR
WORKFLOW SINCE THE BENCH AREA
WAS NEW FOR US.
WE'RE REALLY EXCITED AND IT'S
BEEN ACCELERATING QUITE QUICKLY.
THE SECOND GOAL, DEVELOPING
INNOVATIVE TRAINING APPROACHES.
WE'RE GETTING READY TO -- PART
OF THIS IS TO RECRUIT AND
IDENTIFY DIVERSE PEOPLE AND IT
GOES ALONG WITH THE FOURTH GOAL,
WHICH IS DEIA AT THE NIH LEVEL.
BUT REALLY DOING THIS THROUGH
DEVELOPING PARTNERSHIPS BOTH
INTERNALLY, NATIONALLY, AND
GLOBALLY, AND BEGINNING NEXT
MONTH, WE WILL HAVE THE FIRST
COHORT OF STUDENTS FOR THE
PATHWAY TO PH.D. FOR UNDERSERVED
STUDENTS IN THE SCHOOL OF
NURSING AT JOHNS HOPKINS
UNIVERSITY.
THEY'LL BE COMING HERE FOR AN
EXPERIENCE WITH US OVER SEVERAL
DAYS AND THEY'LL BE DOING THAT
OVER -- THEY'LL HAVE DIFFERENT
COHORT OVER FIVE YEARS.
SO POSTBACCALAUREATE STUDENTS
WHO ARE ABLE TO SEE THE
POTENTIAL FOR GOING INTO
PH.D.s, SO REALLY STARTING
EARLY ON.
ALSO STARTING WITH HIGH SCHOOL
STUDENTS IN BIOINFORMATICS, AND
THEN WE'RE DOING -- WE'RE
GETTING READY IN SEPTEMBER TO
WELCOME TWO STUDENTS IN THE
BIOSCIENCES FROM THE UNIVERSITY
OF CALEDONIA IN SCOTLAND.
AND THEN BUILDING THESE
COLLABORATIONS FROM BOTH
INTERNAL BRANCHES AND EXTERNAL
AND THEN GOING AND SPEAKING IN
CONFERENCES, WE'RE DOING A LOT
OF WORK CURRENTLY WITH THE
NATIONAL INSTITUTE OF ALCOHOL
ABUSE AND ALCOHOLISM, AS WELL AS
THE NATIONAL INSTITUTE OF DENTAL
AND CRANIOFACIAL RESEARCH, AND
NATIONAL HEART, LUNG AND BLOOD
INSTITUTE.
WE'VE ALSO RECEIVED SOME
INTRAMURAL FUNDING SUPPORT FROM
DR. SMITH, WHO YOU SAW IN ONE OF
THE EARLIER SLIDES, THE ACTING
DIRECTOR FOR OBSSR, WHICH IS
HELPING US A LOT AS WE'RE
GROWING.
SO THIS IS HOW WE DO OUR
TRANSLATION PIECE.
IT REALLY ISN'T ABOUT BENCH TO
BEDSIDE, IT REALLY IS ABOUT
GOING INTO THE COMMUNITY AND
THEN COMING BACK TO THE BENCH,
BEDSIDE, OUTPATIENT, AND NOT
JUST STARTING IN THE LAB AND
GOING OUT BUT REALLY BRINGING
THINGS BACK.
SO THESE ARE SOME OF OUR
INVESTIGATORS, AND I'LL TALK
ABOUT EACH OF THEM IN A BIT MORE
DETAIL.
SO OUR PROGRAM FOCUSES AROUND
WHAT WE CALL THREE PILLARS OF
HEALTH, AND THE THREE BEHAVIORS
THAT OUR PROGRAM IS FOCUSING
AROUND, WHICH IS EXERCISE, SLEEP
AND NUTRITION.
AND WE USE THE HEALTHY PEOPLE
2030 SOCIAL DETERMINANTS OF
HEALTH.
SO LOOKING AT HEALTHCARE ACCESS,
NEIGHBORHOOD AND BUILT
ENVIRONMENT, SOCIAL AND
COMMUNITY CONTEXT, ECONOMIC
STABILITY, AND THEN EDUCATION
ACCESS AND QUALITY.
AND WITHIN THOSE, WE HAVE
SPECIFIC VARIABLES THAT WE'RE
LOOKING AND FOCUSING ON.
THIS IS ONE OF OUR FIRST
INVESTIGATORS THAT I'M GOING TO
TALK ABOUT.
DR. LENA LE IS TRAINE -- LEE ISD
CLINICALLY AS A NURSE.
SHE RUNS OUR BIOBEHAVIORAL
OUTCOMES IN CANCER AND
CAREGIVING UNIT.
HER LAY TEST STUDY JUST GOT
APPROVED BY THE IRB, WORKING
WITH CAREGIVERS OF PATIENTS
RECEIVING STEM CELL TRANSPLANT.
BASED ON A PREVIOUS STUDY DONE
BY HER GROUP THAT USED
YOGA-BASED INTERVENTIONS, WE'VE
DEVELOPED THIS VIRTUAL REALITY
TECHNOLOGY FOR OUR PATIENTS.
SO THEY'LL BE RECEIVING VIRTUAL
REALITY BASED ON SOME OF THE
INPUTS THAT THEY GAVE US FROM
PREVIOUS WORK THAT WE WERE
DOING.
SUCH AS IT'S HARD TO GET A PLACE
TO DO IT, IT'S HARD TO GET
IMMERSED IN A PRACTICE OF YOGA
AND MINDFULNESS, AND WITH THIS
ONE, WE ARE ADDING A BIO SIDE OF
THE BIOBEHAVIORAL AND DOING SOME
SALIVARY MARKERS.
ONE OF THE REASONS WE'RE DOING
THAT IS TO TRY TO DECREASE THE
BURDEN ON OUR CAREGIVER
PARTICIPANTS WHO ARE HAVING
BLOOD DRAWN BUT ACTUALLY BE ABLE
TO DO SOME SALIVARY MARKERS BY
TEACHING THEM HOW TO COLLECT THE
ISALIVA AT HOME, STORE IT AND
BRING IT IN FOR US, THAT WAY
NEGATING HAVING TO HAVE THEIR
BLOOD DRAWN.
THIS IS ONE OF OUR PHYSICIAN
INVESTIGATORS WHO'S CURRENTLY A
STAFF SCIENTIST, DR. NICOLE
FARMER.
SHE HEADS UP THE SECTION ON DIET
AND BIOPSYCHOSOCIAL HEALTH.
AND HER AREA OF EXPERTISE HAS
BEEN WORKING WITH SICKLE CELL
PATIENTS AND NUTRITION, AND RUNS
A STUDY RIGHT NOW AND THIS GETS
A LITTLE BIT TO YOUR COMMENT,
ANTOINETTE, IN THAT IN THE STUDY
THAT THEY'RE DOING CURRENTLY
OUTPATIENT, WE'RE ALSO DOING --
GETTING PATIENTS OFF SITE AND IN
RURAL AREAS, LARGE NUMBERS OF
PATIENTS CALLING AND WANTING TO
PARTICIPATE, AND SO WE'VE BEEN
ABLE, THROUGH SOME FUNDING FROM
THE NATIONAL HUMAN GENOME
RESEARCH INSTITUTE, WE'VE BEEN
ABLE TO PAY A CONTRACT FOR
HAVING THEM HAVE THEIR BLOOD
DRAWN OUTSIDE AND THEN COME IN
OR HAVE TELEHEALTH VISIT.
SO IT'S BEEN A WAY FOR THEM TO
CONNECT WITH US WITHOUT HAVING
TO NECESSARILY COME IN, AND WE
REALIZE THE INTEREST IS BIG,
BECAUSE WE ORIGINALLY THOUGHT
THAT IT WOULD BE ONLY A SMALL
PERCENTAGE THAT WOULD TAKE US UP
AND NOW WE HAVE A LARGER
PERCENTAGE OF PEOPLE THAT ARE
ACTUALLY USING THE ABILITY TO DO
IT OFF SITE AND THEN GET THE
RESULTS SENT IN TO US.
BUT DR. FARMER IS HOPING TO GO
INTO A TENURE TRACK POSITION IN
THE NEAR FUTURE.
I KNOW THAT SHE HAS APPLIED FOR
ONE OF THE TENURE TRACK
POSITIONS THAT WE HAVE POSTED
AND DR. GRADY HAS RECEIVED NINE
APPLICATIONS FOR THAT POSITION.
SHE'S RUNNING THE SEARCH FOR
THAT.
SO WE SHOULD KNOW ABOUT THAT IN
A FEW MONTHS FROM NOW.
DR. FARMER IS ALSO DOING A
COMMUNITY STUDY.
WE'RE GETTING READY.
IT'S CHALLENGING TO DO COMMUNITY
STUDIES TOO AS AN INTRAMURAL
PROGRAM, WE ARE TRYING TO
FINALIZE A CONTRACT WITH
MARTHA'S KITCHEN IN D.C. ,
BECAUSE THAT IS WHERE WE WANT
OUR PARTICIPANTS TO BE ABLE TO
DO THE INTERVENTION, THEY'LL BE
DOING A COOKING STUDY LOOKING AT
COOKING THE MEDITERRANEAN DIET
AND WHETHER LEARNING HOW TO COOK
AND BE A PART OF THAT INCREASES
THEIR SELF-EFFICACY FOR BEING
ABLE TO COVER AND ADHERE TO A
DIET.
THIS IS KATHERINE MAKI, SHE RUNS
THE BIOBEHAVIORAL AND INTEGRATED
META GENOMICS OR OUR BIOM UNIT.
KATHERINE IS CURRENTLY ON LEAVE.
THE NEWEST PERSON IN OUR GROUP
HAS A BRAND NEW BABY GIRL SO
WE'RE EXCITED ABOUT THAT, BUT
KATHERINE HAS BROUGHT A LOT OF
ENERGY AROUND OUR ALCOHOL USE
DISORDER WORK, LOOKING AT THE
GUT-BRAIN ACCESS, AND HOW THAT
PLAYS OUT IN THESE PATIENTS,
THESE REALLY COMPLEX PATIENTS
WITH ALCOHOL USE DISORDER THAT
WE ADMIT TO OUR 1 SOUTHEAST UNIT
INPATIENT.
I'VE DONE YEARS OF WORK IN SLEEP
IN THIS AREA, BUT WE REALLY
NEEDED TO DEVELOP FURTHER OUR
MICROBIOME SECTION, AND WE HAVE
BEEN SEEING SOME INTERESTING
RESULTS AND WE'LL SOON BE
PUBLISHING SOME PAPERS ON A
COLLABORATION WITH NIAA LOOKING
AT MRIs AS WELL AS FECAL
MICROBIOME IN ORDER TO SEE THE
BRAIN-GUT ACCESS.
THIS IS JENNIFER BARB, DATA
ANALYST IN THE TRANSLATIONAL
SCIENCE UNIT.
AND JEN CAME TO US FROM THE
COMPUTER INFORMATION TECHNOLOGY
GROUP, AND HAS BEEN AT THE NIH
ABOUT 20 YEARS, AND IS A
FABULOUS BIOINFORMATACIST WHO
STARTED OFF IN GENETICS BUT HAS
NOW MOVED VERY QUICKLY INTO THE
MICROBIOME AND HAS BROUGHT A LOT
OF ENERGY TO OUR GROUP AND
TEACHING ALSO STUDENTS COMING IN
ABOUT BIOINFORMATICS AND HOW WE
CAN LEVERAGE LARGE DATASETS THAT
ARE AVAILABLE TO ALL OF US.
I BROUGHT THIS ONE JUST BECAUSE
I THINK IT'S AN INTERESTING PART
OF OUR WORK.
AND THIS WAS INTERDISCIPLINARY
AND ALSO INTRAINSTITUTE, AND
IT'S THE GEOGRAPHIC SOCIAL
VULNERABILITY AND HUMAN
MICROBIOME DIVERSITY PROJECT
THAT WE DID WITH MEMBERS OF OUR
TEAM AS WELL AS FOLKS FROM NHLBI
AND NATIONAL INSTITUTE OF
MINORITY AND HEALTH DISPARITIES.
AND WHAT WE DID WAS, WE TOOK THE
PHASE 1 OF THE HUMAN MICROBIOME
PROJECT DATA AND LOOKED AT THE
SOCIAL VULNERABILITY INDEX
THAT'S CALCULATED, THAT'S ONE
THAT HAD ORIGINALLY BEEN
DEVELOPED BY THE CDC TO SEE IF
THERE WAS ANY RELATION BETWEEN
THOSE WHO SCORED HIGH ON THE
SOCIAL VULNERABILITY INDEX AND
THE ALPHA DIVERSITY OF ORAL SKIN
AIRWAYS AND UROGENITAL SITES,
AND WE DID FIND THAT THERE WAS A
SIGNIFICANT RELATIONSHIP BETWEEN
THE GEOGRAPHIC SOCIAL
VULNERABILITY AND THE DIVERSITY
OF THE ORAL SKIN AIRWAY AND
UROGENITAL.
AND YOU CAN SEE AT THE BOTTOM
RIGHT OF THIS SLIDE THAT WE ALSO
FOUND THAT IT WAS A SIGNIFICANT
MEDIATOR FOR RACIAL AND ETHNIC
DIFFERENCES IN UROGENITAL
MICROBIOME DIVERSITY FOR
PARTICULARLY HISPANIC, LATINX
AND WOMEN WHO IDENTIFIED
THEMSELVES AS OTHER.
AND THIS TO ME WAS THE PERFECT
EXAMPLE OF RESEARCHERS COMING
TOGETHER FROM DIFFERENT
DISCIPLINES AND THEN USING WHAT
IS ALREADY AVAILABLE TO US IN
ORDER TO GENERATE NEW HYPOTHESES
THAT WE CAN DO AT THE CLINICAL
CENTER WITH OUR PATIENT.
AND SO WE'RE GOING TO BE MOVING
FORWARD WITH A COUPLE OF NEW
BIOMARKER STUDIES IN THE
COMMUNITY AS WELL AS A STUDY IN
ORAL HEALTH THAT WI WE'LL BE DOG
WITH SEVERAL OF OUR COLLEAGUES
FROM VARIOUS INSTITUTES.
SO ANOTHER EXCITING PART ABOUT
OUR BRANCH IS THAT WE ARE ABLE,
THROUGH SOME OF OUR
INFRASTRUCTURE LIKE HAVING A
BIOINFORMATACIST AND A
STATISTICIAN, TO BE ABLE TO HAVE
INTERDISCIPLINARY TEAM SCIENCE
STRATEGIES WITH OUR CLINICAL
DEPARTMENT, SO WE ARE WORKING
WITH DR. FRANK, THE DIRECTOR OF
LABORATORY MEDICINE, ON HER
CLEAN MED STUDY BECAUSE SHE
NEEDED SOME SPECIALTY IN THE
MICROBIOME AREA WITH HER GROUP,
AND THEN IN RADIOLOGY AND
IMAGING SCIENCES, WE'RE WORKING
WITH ONE OF THEIR STAFF
SCIENTISTS WHO'S HELPING US WITH
OUR MRI WORK ON THE GUT-BRAIN --
OR THE -- EXCUSE ME -- YES, THE
GUT-BRAIN MICROBIOME STUDY.
IN REHAB MEDICINE, WE ARE
WORKING WITH THE OCCUPATIONAL
HEALTH GROUP, REHAB HEALTH
GROUP, IN ORDER TO LOOK AT HOW
PEOPLE COGNITIVE -- WHAT THE
COGNITIVE LOAD IS ON THOSE WHO
ARE DOING COOKING AND HOW THAT
AFFECTS THEIR OUTCOMES AND I'LL
SHOW YOU A SLIDE IN A MINUTE.
AND THEN STILL CONTINUE VERY
CLOSELY ALIGNED WITH THE
CLINICAL CENTER NURSING
DEPARTMENT AS THEY ARE ON THEIR
MAGNET JOURNEY, SO WORKING
DIRECTLY WITH THEIR NURSES WHO
ARE DOING EVIDENCE-BASED
PRACTICE INITIATIVES ON THEIR
UNITS.
AND LAST, WHAT ARE WE UP TO NE
NEXT?
OUR DREAM IS TO BUILD THIS
MICROBIOME SALIVARY SCIENCE
CAPABILITY THAT WE WOULD ALSO BE
ABLE TO OFFER TO OUR COLLEAGUES
AT NINR AND OTHERS, AND OUR
STAFF WERE TRAINED AT UNIVERSITY
OF CALIFORNIA IRVINE IN THEIR
SALIVARY SCIENCE PROGRAM, SO
DEVELOPING THAT AND THROUGH SOME
OF THE FUNDING THAT WE'RE
RECEIVING FROM OBSSR, BEING ABLE
TO BRING IN ANOTHER LAB TECH AND
THEN HIRE SOMEONE TO ASSIST US
IN LEADING SOME OF THESE
PROJECTS AND GETTING SOME
POSTDOCS IN HERE THAT ARE MORE
ON THE MICROBIOLOGY SIDE.
AND THEN THIS NEW CONTRAPTION ON
THE RIGHT OF THE SLIDE IS A
MOBILE EEG, AND THIS IS ONE OF
OUR STUDENTS WHO VOLUNTEERED TO
USE IT, SO IT'S REALLY MEASURING
THE COGNITIVE WORKLOAD BUT IT'S
ALSO MEASURING HEART RATE
VARIABILITY AND MANY OTHER
THINGS WHILE SHE WAS DOING HER
COOKING ASSIGNMENT, AND WE WILL
BE USING THAT IN OUR PATIENTS,
EVENTUALLY OUR PARTICIPANTS THAT
WILL BE OUT IN THE COMMUNITY TO
SEE HOW THEY ARE REACTING TO
WHAT THEY'RE DOING WHILE THEY'RE
COOKING.
WE HAD AN INTERESTING FEEDBACK
FROM DAVID EISENBERG AT HARVARD
WHEN HE SAID WILL YOU BE ABLE TO
CAPTURE JOY WHEN YOU'RE DOING
IT.
SO THAT'S THE TEASE FOR US IS,
AS WE'RE LOOKING AT COGNITIVE
WORKLOAD, WILL WE BE ABLE TO SEE
WHETHER THEY'RE STRESSED OR
WHETHER THEY HAVE JOY, AND WE'LL
BE DOING SALIVARY SCIENCE WITH
THAT PIECE TOO.
THIS IS JUST A THANK YOU FROM
OUR TEAM.
WE'RE JUST REALLY HAPPY TO BE
HERE AND TALK TO YOU ALL ABOUT
OUR NEW ENDEAVORS, AND JUST
REALLY THANK ALL OF THE NIH
COMMUNITY AND OUTSIDE FOR
SUPPORTING US AS WE ARE THIS NEW
BRANCH.
SO THANK YOU.
>>THIS IS ABSOLUTELY FABULOUS,
GREAT PRESENTATION.
ANY QUESTIONS OR ANY COMMENTS
FOR GWEN?
I HAVE ONE.
AND ACTUALLY AS I WAS LISTENING
AND LOCKING LOOKING AT DR. LEE'N
V.R. AND WHAT YOU JUST SHOWED
ABOUT COGNITIVE WORKLOAD, IS
THERE A FIREWALL BETWEEN THE NIH
AND THE V.A. ON SOME OF THIS?
BECAUSE I SIT ON THE VETERANS'
ADMINISTRATION'S EXECUTIVE
ROUNDTABLE ON A.R. AND V.R., SO
BIG MULTICENTER TRIALS ACROSS
THE V.A. RIGHT NOW USING VIRTUAL
REALITY FOR A NUMBER OF
DIFFERENT THINGS, NOT ONLY
DISEASES BUT -- IN STRESS
MANAGEMENT, BUT ALSO ISOLATION.
I DON'T KNOW THAT WE HAVE REALLY
LOOKED AT THE CAREGIVER PIECE OF
IT THAT YOU'RE LOOKING AT.
AND THEN THERE'S A SUBGROUP OF
THIS LOOKING AT THE INTERFACE
BETWEEN VIRTUAL REALITY,
AUGMENTED REALITY AND COGNITIVE
LOAD.
SO I SEE -- I MEAN, SO THERE ARE
CROSSOVERS HERE, AND I THINK IT
WOULD BE GREAT IF YOUR TEAM
ACTUALLY INTERFACED WITH THE
ROUNDTABLE, THE WORKING GROUP
THAT WE'VE GOT IN THE V.A. AS
WELL.
>>WE WOULD LOVE TO, AND I DON'T
KNOW, SOMETIMES IT'S NOT EVEN
ABOUT A FIREWALL, IT'S ABOUT
CONNECTING THE PEOPLE, BECAUSE
WE'RE WORKING CLOSELY NOW WITH
WALTER REED'S RESEARCH GROUP,
AND ABLE TO DO THAT.
SO I DO THINK -- AND EVEN WHEN
WE WERE DOING A PREVIOUS WORK,
SOME OF MY WORK WITH SHUT EYE
WITH COGNITIVE BEHAVIORAL
THERAPY FOR INSOMNIA, WE GOT A
LOT OF FEEDBACK FROM PEOPLE AT
THE V.A., BUT IT WAS MORE AN
INFORMAL KIND OF WE CALL YOU AND
YOU CALL US, SO I THINK THERE'S
A LOT THAT COULD BE DONE THAT
WAY TOO.
>>IF YOU'D LIKE ME TO MAKE THE
FORMAL INTRODUCTIONS, I WOULD BE
HAPPY TO DO IT.
>>I WOULD LOVE IT.
I KNOW OUR TEAM WOULD LOVE IT
TOO.
>>I THINK THIS IS REALLY
SYMBIOTIC HERE SO I THINK THIS
WOULD BE GREAT.
>>IT WOULD BE OUR PLEASURE.
>>THANK YOU.
DAVID.
>>A QUESTION THAT I WAS CURIOUS
ABOUT, HAVE WE LOOKED AT THE
V.R. AND THE AUGMENTED REALITY
IN THE PARKINSON'S CLINIC AT A
ALL?
>>I DON'T KNOW IF THE
PARKINSON'S GROUP HAS DONE THAT.
I KNOW THAT OUR DIRECTOR OF THE
NATIONAL LIBRARY OF MEDICINE,
PATRICIA BRENNAN, DOES A LOT OF
WORK IN VIRTUAL REALITY AND WE
HAVE SOME OTHER COLLEAGUES, BUT
I'M NOT SURE ABOUT THE
PARKINSON'S ONE.
BUT I CAN LOOK INTO THAT.
>>WE HAVE PARKINSON'S -- I
MEAN, I'M ON THE BOARD OF A
PARKINSON'S CHARITY AND WE HAD
THE HIV C NIH COME IN, MEMBERS M
SEVERAL DIFFERENT ORGANIZATIONS
COME IN AND TALK TO US ABOUT NOT
ONLY THE PARKINSONIANS, PEOPLE
WITH PARKINSONS, BUT THE
CAREGIVERS AND THE NEED TO
ADDRESS STRESS AND COGNITIVE
CHANGES DURING THE COURSE OF THE
DAILY INTERACTION.
>>AND I THINK THAT'S WHAT WE'RE
LOOKING FOR, IS TO TRY TO FIGURE
OUT OTHER PATIENT POPULATIONS
TOO, BECAUSE WE ARE SEEING THAT
WITH MORE AND MORE CAREGIVERS,
AND PEOPLE STAYING AT HOME AS
THEY'RE BEING CARED FOR, WE ARE
SEEING ESPECIALLY HIGH RISK
ARE -- WELL, THE HIGHEST RISK
ARE WOMEN OVER 65, TAKING CARE
OF A FAMILY MEMBER THAT'S NOT
THEIR SPOUSE.
SO LIKE THEIR MOTHER OR, YOU
KNOW, OR A FATHER, BUT WITH THE
SPOUSE, IT'S A LITTLE LESS --
AND I GUESS THAT'S THE
RELATIONSHIP, I'M NOT GOING TO
SPECULATE ABOUT THAT, BUT I
THINK TRYING DIFFERENT -- I
THINK TRYING DIFFERENT
POPULATIONS IS A GOOD -- AND I
CAN IMAGINE THE CAREGIVERS IN
THAT POPULATION WOULD BE AN
IMPORTANT PIECE.
>>THAT'S A FAIRLY LARGE
POPULATION.
>>YEAH, YEAH.
THANK YOU.
>>OKAY, THANK YOU VERY MUCH.
APPRECIATE THAT.
SO WE ARE PERFECTLY -- I'M
SORRY, TONY, DID YOU HAVE A
QUESTION?
>>JUST VERY QUICKLY, THE
PORTABLE EKG MACHINE, ARE THEY
VERY EFFECTIVE.
>>SO THE TECHNOLOGY IS STILL
NEW, AND ONE OF THE THINGS THAT
WE'RE DOING IS THERE'S A NEW
COMPANY THAT HAS A -- IT'S LIKE
64 LEADS, SO THAT'S WHAT WE'RE
GOING TO BE TESTING, ARE THEY
REALLY -- ARE THEY ACCURATE OR
NOT, AND LIKE WHAT PARTS OF THE
BODY, LIKE, ARE WE ABLE TO MOVE
THEM, SO WE'RE GOING TO ACTUALLY
DO A PILOT FIRST TO SEE THAT.
BUT IT'S BEEN SHOWN IN OTHER
STUDIES THAT YOU CAN ACTUALLY
CAPTURE A LOT THIS WAY.
WHY WE'RE DOING THIS CAP THE WAY
WE ARE TOO IS THAT SOME OF THE
PATIENTS THAT WE'LL BE WORKING
WITH INTO THE COMMUNITY AND SOME
MEMBERS OF OUR TEAM SAID, WE
DON'T WANT A BUNCH OF GLUE ON
OUR HAIR AND, YOU KNOW, ALL
THAT, SO WE WANT SOMETHING
THAT'S REALLY EASY TO PUT ON
THAT DOESN'T TAKE FOREVER AND
ISN'T GOING TO RUIN EVERYTHING
WHEN WE PULL IT OFF.
BUT MORE TO COME ON HOW ACCURATE
IT IS.
>>THANK YOU.
>>OKAY, AND WE ARE RIGHT ON
TIME AND ON SCHEDULE, SO BEFORE
WE GO ON BREAK, BECAUSE OF THE
SPECIAL NATURE OF THIS BOARD, WE
ARE SOMEWHAT OF A FAMILY AND SO
IN THE SPIRIT OF FAMILY, TODAY
IS DR. CHIN'S BIRTHDAY.
AND SO WE WOULD JUST LIKE TO
WISH YOU A VERY HAPPY BIRTHDAY
BEFORE WE GO TO BREAK.
HAPPY BIRTHDAY.
>>THANK YOU.
>>NO SECRETS IN THE FAMILY
HERE.
ALL RIGHT.
THANK YOU, EVERYONE.
WE WILL GO AHEAD AND WE'LL TAKE
A 10-MINUTE BREAK.
AND RESUME.
THANK YOU.
OUR NEXT PRESENTER IS MS
MS. CHARLOTTE PAK, SHE'LL GIVE
US AN OVERVIEW OF TRAINING
OPPORTUNITIES FOR CLINICAL
CENTER LEADERS.
CHARLOTTE, TAKE IT AWAY.
>>THANK YOU SO MUCH.
GOOD MORNING, EVERYONE.
THANK YOU FOR HAVING ME.
I'M EXCITED TO BE HERE AND
PRESENT A LITTLE ABOUT
LEADERSHIP DEVELOPMENT PROGRAMS
AND COURSES AT THE CLINICAL
CENTER.
AGAIN MY NAME IS CHARLOTTE PAK,
I'M THE CHIEF OF THE OFFICE OF
WORKFORCE MANAGEMENT DEVELOPMENT
AND I'VE BEEN AT THE CLINICAL
CENTER SINCE 2010.
I BECAME FIRST ACTING AS WE LIKE
TO DO AT THE NIH, ACTING CHIEF
AND THEN CHIEF STARTING IN 2019.
A LITTLE BIT OF OUR OFFICE FOR
THOSE WHO MIGHT NOT BE FAMILIAR
WITH US, I'D LIKE TO SAY WE'RE
SMALL BUT MIGHTY BUT WE ARE
ACTUALLY EXPANDING AND
RECRUITING A COUPLE MORE MEMBERS
SO THAT IS VERY EXCITING.
WE'VE RESTRUCTURED INTO TWO
BRANCHES.
THE WORKFORCE MANAGEMENT SIDE
HANDLES THINGS LIKE PERFORMANCE
MANAGEMENT, EMPLOYEE ENGAGEMENT,
RETENTION, AWARDS, I BELIEVE
YOU'VE HEARD SOME ABOUT OUR FEVS
SURVEY OR THE AWARDS THAT COME
OUT OF OUR OFFICE AND THEN THE
OTHER BRANCH IS AROUND LEARNING
AND DEVELOPMENT WHICH IS WHAT I
WILL FOCUS ON TODAY.
THANK YOU.
OKAY.
SO MY GOAL TODAY IS TO SHARE A
LITTLE BIT ABOUT HOW LEADERSHIP
DEVELOPMENT HAS EVOLVED OVER THE
YEARS.
A LITTLE BIT ABOUT HISTORY OF
OUR PROGRAMS, WHERE WE ARE TODAY
AND WHERE WE'RE HOPING TO GO.
I WOULD LIKE TO THANK
DR. CUNNINGHAM FOR HER QUESTION
LAST SESSION OR ELSE I WOULD NOT
BE HERE TODAY BUT THE QUESTION
AGAIN WAS AROUND EXISTING
PROGRAMS WE HAVE TO HELP DEVELOP
TALENT INTERNALLY FOR SOME OF
THOSE LEADERSHIP VACANCIES WE'VE
HAD.
SO I'M GOING TO TELL YOU A BIT
ABOUT THOSE PROGRAMS WE HAVE
INTERNALLY AND EXTERNALLY AND
HOW THAT PARTICIPATION HAS
REALLY GROWN IN THE LAST FEW
YEARS.
I BELIEVE THAT THAT GROWTH IN
PARTICIPATION IS NOT JUST OUT OF
INCREASED INTEREST BUT WE'VE
REALLY DONE A DELIBERATE JOB
TRYING TO COMMUNICATE AND BUILD
MORE AWARENESS AROUND THOSE
PROGRAMS.
SINCE I'VE BECOME CHIEF MY GOAL
IS TO OFFER AS MANY
OPPORTUNITIES FOR LEADERSHIP
DEVELOPMENT FOR ALL OUR STAFF,
NOT JUST LEADERS, AND WE'RE
REALLY THANKFUL TO HAVE THAT
SUPPORT FROM OUR CLINICAL CENTER
LEADERSHIP, NOT JUST DR. GILMAN
BUT THE WHOLE TEAM, AS IT REALLY
IS PART OF OUR CULTURE.
DR. GILMAN MENTIONED THE SEVEN
GUIDING PRINCIPLES AS PART OF
HIS STRATEGIC PLAN THAT ONE IS
AROUND COMMITMENT TO
PROFESSIONAL GROWTH AND
DEVELOPMENT AND THAT'S REALLY
OUTLINED TO OUR EMPLOYEES AS
SOON AS THEY COME ON BOARD.
NEW MORE EE ORIENTATION, WE
ALREADY MENTIONED THAT WE HAVE
INDIVIDUAL DEVELOPMENT PLANS
WHICH I'LL GO OVER, AND AGAIN
IT'S REALLY PART OF OUR CULTURE
AT THE CLINICAL CENTER.
SO I'LL GO OVER SOME INTERNAL
PROGRAMS MANAGED AT OUR OFFICE
AS WELL AS NIH, A LITTLE ABOUT
EXTERNAL PROGRAMS AND THAT
CULTURE OF LEARNING AND
INVESTMENT IN OUR STAFF.
I'LL START OFF WITH OUR
FUNDAMENTALS OF SUPERVISION
PROGRAM
WE'VE HAD SUPERVISORY OR
LEADERSHIP TRAINING AT THE
CLINICAL CENTER SINCE EVEN
BEFORE MY TIME, I'D SAY AROUND
2005, AND IN 2011, WE
ESTABLISHED THE FUNDAMENTALS OF
SUPERVISION PROGRAM.
IT STARTED OUT AS A FULL YEAR
PROGRAM AND I DON'T KNOW HOW
MANY OF YOU ARE FAMILIAR WITH
OPM SUPERVISORY MANDATE, OFFICE
OF PERSONNEL MANAGEMENT, WHO HAS
A NUMBER OF TOPICS AND HOURS
REQUIRED FOR SUPERVISORS TO
COMPLETE, BOTH WITHIN THEIR
FIRST YEAR AND A REFRESHER EVERY
THREE YEARS, AND THIS PROGRAM
MORE THAN EXCEEDS ALL THOSE
REQUIREMENTS.
WHEN IT WAS A FULL YEAR BUT EVEN
WHEN WE REDUCED IT A LITTLE BIT
IN TIME IN 2019, IT'S STILL WELL
BEYOND ALL THOSE REQUIREMENTS.
SO IN 2019, IT WAS SHORTENED A
LITTLE BIT WITH THE CREATION OF
OUR FUNDAMENTALS IN LEADERSHIP
PROGRAM, WHICH I WILL GO OVER
NEXT.
AND THAT KIND OF TOOK OUT SOME
OF THE LEADERSHIP DEVELOPMENT
OUT OF THIS PROGRAM, ALTHOUGH OF
COURSE YOU CAN'T HAVE
SUPERVISION WITHOUT LEADERSHIP
SO THERE IS SOME OVERLAP, BUT
THIS PROGRAM IS REALLY FOCUSED
ON THE KNOWLEDGE AND SKILLS THAT
SUPERVISORS NEED TO BE A
SUPERVISOR IN THE FEDERAL
WORKFORCE.
WE'VE HAD 242 SUPERVISORS
COMPLETE THIS PROGRAM.
WE ARE ABOUT TO FINISH THE 15TH
COHORT NEXT THURSDAY ACTUALLY,
SO 20 MORE WILL GRADUATE VERY
SOON, AND WE LIKE TO KEEP IT
AROUND 20 TO 25 SUPERVISORS,
LITERATURE SHOWS THAT'S A GOOD
NUMBER TO KEEP IT INTERACTIVE
AND REALLY BUILD THAT COHORT IN
THE TRAINING.
THIS TRAINING IS NOW FULLY
ONLINE.
SINCE THE PANDEMIC WE MOVED ALL
OUR TECHNICAL TRAININGS AND NEW
EMPLOYEE ORIENTATION TO AN
ONLINE PLATFORM BUT EVALUATIONS
HAVE BEEN JUST AS POSITIVE POST
GOING ONLANE AS IT WAS WHEN IT
WAS IN PERSON.
AND AGAIN EVERY YEAR, WE TWEAK
TO EVOLVE ACCORDING TO THE
CHANGING NEEDS AND GUIDANCE
AROUND SUPERVISION.
I WON'T GO OVER THIS IN DETAIL
BUT I JUST WANTED TO OFFER YOU
AN OVERVIEW.
THIS IS OUR LATEST COHORT THAT'S
ENDING NEXT THURSDAY.
YOU WILL SEE PERFORMANCE
MANAGEMENT HIRING AND IT STILL
HAS SOME OF THOSE SOFT SKILLS
LIKE BUILDING AND LEADING
COLLABORATIVE TEAMS, AND THAT
COLOR CODING IS AROUND SOME OF
THE COMPETENCIES FOR FEDERAL
MANAGEMENT AND LEADERSHIP IN THE
GOVERNMENT.
SO NOW ON TO OUR FUNDAMENTALS IN
LEADERSHIP PROGRAM.
SO AS MENTIONED THAT WAS
ESTABLISHED IN 2019.
THIS WAS REALLY A VISION FROM
DR. GILMAN, WHO WORKED CLOSELY
WITH MAUREEN MCDONALD FROM OUR
OFFICE.
AND WE DID A LOT OF RESEARCH
GOING INTO ESTABLISHING THIS
PROGRAM.
WE LOOKED AT OTHER HOSPITALS,
UNIVERSITIES, INDUSTRY,
MILITARY, REALLY LOOKING AT WHAT
WE WANT PARTICIPANTS TO GET OUT
OF THIS PROGRAM AND WE DID SOME
FOCUS GROUPS AS WELL WITH
INTERNAL LEADERS WITHIN THE
CLINICAL CENTER TO GET THEIR
PERSPECTIVE ON WHAT THEY THOUGHT
A LEADERSHIP DEVELOPMENT PROGRAM
SHOULD HAVE AT THE CLINICAL
CENTER.
OUR ENVIRONMENT IS VERY COMPLEX,
IT'S A HOSPITAL, IT'S ALSO
RESEARCH AND IT'S ALSO THE
FEDERAL GOVERNMENT SO WE REALLY
WANTED TO INCLUDE THAT, AND OUR
GOAL IS FOR SUPERVISORS TO
REALLY DEEPEN THE CONNECTION AS
TO WHO THEY ARE.
SELF-AWARENESS IS A REALLY BIG
PART OF THIS PROGRAM, AS IT'S
ESSENTIAL FOR ANY LEADERSHIP
PROGRAM, AND IT'S WOVEN
THROUGHOUT THE ENTIRE PROGRAM.
SO WE WANT TO LOOK AT -- WE HOPE
THAT THEY GET OUT OF IT HOW THEY
LEAD THEMSELVES, HOW THEY LEAD
OTHERS IN THIS COMPLEX
ENVIRONMENT, AND COLLABORATE
WITH EACH OTHER IN THIS COHORT.
SO I WON'T GO THROUGH ALL THE
DETAILS BUT THERE'S A LOT OF
SELF-ASSESSMENTS, THERE'S A LOT
OF ASSIGNMENTS, READING.
IT'S PRETTY INTENSE.
IT'S THREE MONTHS, BUT IT'S
EVERY TWO WEEKS WITH SIX
SESSIONS, SO YOU CAN IMAGINE
THEY'RE SPENDING A WHOLE DAY
ONCE EVERY TWO WEEKS OUT OF THE
OFFICE AND STILL DOING
ASSIGNMENTS AND READINGS BETWEEN
EACH SESSION.
AGAIN AROUND 20 TO KEEP THAT
COHORT, AND THIS ONE IS NOT --
YOU DO NOT HAVE TO BE AN
OFFICIAL SUPERVISOR TO BE IN
THIS COHORT.
SO THESE ARE ALSO FOR INFORMAL
LEADERS WHO MIGHT BE TEAM LEADS
OR LEAD A SPECIAL INITIATIVE IN
THEIR DEPARTMENT, LEAD FROM
WHERE THEY ARE.
ACTUALLY MANY HAVE BEEN PROMOTED
SINCE THEY'VE BEEN IN THIS
PROGRAM, WHICH IS GREAT.
LAST, I DO WANT TO MENTION
SOMETHING VERY UNIQUE ABOUT THIS
PROGRAM IS, ALTHOUGH MAUREEN
FROM OUR OFFICE FACILITATES THE
ENTIRE PROGRAM, EACH DAY WE HAVE
AN EXECUTIVE LEADER COME IN AND
SHARE A BIT ABOUT THEIR STORY.
AND DR. WALLEN ACTUALLY AS THE
CHIEF NURSING OFFICER, SHE CAME
IN ONE DAY.
THESE LEADERS, STARTING WITH DR,
SHARE A BIT ABOUT THEIR JOURNEY
IN LEADERSHIP, AND THEY PICK A
TOPIC THAT'S ALIGNED WITH WHAT
THEY WANT TO DISCUSSED AND GET
KIND OF VULNERABLE AND SHARE
THEIR LEADERSHIP PHILOSOPHY AND
THAT IS REALLY AN INTEGRAL PART
OF THE VALUE OF THIS PROGRAM.
SO AGAIN HERE'S THE OVERVIEW.
I JUST WANT TO SHOW YOU HOW
THOSE FIRST TWO DAYS ARE FULLY
FOCUSED ON SELF-AWARENESS,
LEADING SELF.
WE HAVE DR. GILMAN COMING IN THE
FIRST DAY, AGAIN, AN EXECUTIVE
LEADER COMES TO VISIT, AND WE GO
OVER A NUMBER OF TOPICS.
NOT ONLY SELF-AWARENESS BUT A
LOT AROUND RESILIENCY THROUGHOUT
THIS PROGRAM.
OH, I MEANT TO MENTION, THIS WAS
NOT PUSHED ONLINE BECAUSE BOTH
PARTICIPANTS AND LEADERS ALL
AGREED THAT THE DISCUSSION, THE
CONNECTIONS, THE BRAINSTORMING,
REALLY WOULDN'T BE AS VALUABLE
ONLINE, AND IT WAS WORTH WAITING
UNTIL IT WAS SAFE TO DO SO
AGAIN.
SO WE'RE REALLY EXCITED TO BE
BRINGING IT BACK THIS FALL,
AGAIN WITH AN IN-PERSON COHORT.
SO WITH THIS BEING ONE OF OUR
NEWER PROGRAMS, WE'VE DONE A LOT
OF EVALUATION, MANY, MANY
SURVEYS, AND FOCUS GROUPS, AND
AGAIN, WE'VE SHOWN THE
EVALUATIONS HAVE BEEN EXTREMELY
POSITIVE.
THE PARTICIPANTS REALLY FELT
THAT THEIR INDIVIDUAL
DEVELOPMENT HAS GROWN FROM BEING
IN THIS COURSE, BUT ALSO FELT AN
INCREASED ENGAGEMENT WITH THE
INTERACTION WITH THE EXECUTIVES
AND ALSO JUST FEELING MORE
ENGAGED WITH THE MISSION OF THE
CLINICAL CENTER.
ONE OF THE BIGGEST FEEDBACK WE
RECEIVED WAS THAT THEY DID NOT
WANT THIS TO END, SO IT'S THREE
MONTHS AND EVERY TWO WEEKS, AND
YOU'D THINK THAT'S A LOT, BUT IT
REALLY CREATED A BOND FROM BEING
WITH EACH OTHER THAT OFTEN, AND
THE LAST DAY WAS ACTUALLY KIND
OF A SAD DAY, BECAUSE NO ONE
WANTED TO END.
I KNOW THIS BECAUSE I WAS
ACTUALLY IN THE FIRST COHORT.
THIS WAS BEFORE I BECAME CHIEF
OF THE OFFICE, AND I REALLY
BENEFITED FROM ONE OF THE MOST
REWARDING EXPERIENCES FROM BEING
IN THIS COHORT.
AGAIN, NOT JUST THE INTERACTION
AND HEARING FROM THE LEADERS,
BUT BUILDING THAT NETWORK.
YOU CAN SEE HERE, THIS IS A
PICTURE FROM OUR FIRST COHORT,
AND I'M THE LITTLE FACE WITH THE
GREEN SHIRT IN THE BACK THERE.
WE WERE ALL SMILES BECAUSE IT
WAS A BITTERSWEET BUT HAPPY DAY
ON THAT LAST DAY.
PART OF WHAT WE WANT TO KEEP
DOING IS BUILDING THAT NETWORK,
SO ALTHOUGH WE'VE ONLY HAD TWO
COHORTS, WE'VE INVITED BOTH
COHORTS BACK FOR ADDITIONAL
DEVELOPMENT OPPORTUNITIES, AND
WE'RE LOOKING FORWARD TO DOING
THAT WITH FUTURE COHORTS AS
WELL.
SO THOSE ARE OUR TWO MAIN
PROGRAM, BUT I ALSO WANT TO
MENTION THAT WE DO, I THINK, A
GOOD JOB IN TRYING TO DO MORE
AND MORE -- OFFER MORE AND MORE
LEADERSHIP COURSES TO NOT JUST
LEADERS BUT ALL OF OUR STAFF.
SO THESE ARE JUST SOME EXAMPLES
OF SOME OF THE TRAININGS WE'VE
BROUGHT IN HOUSE, AND THIS IS
SOMETHING WE PAY FOR FROM OUR
OFFICE SO THAT STAFF CAN COME IN
WITHOUT THE BURDEN OF THE COST
TO THEIR DEPARTMENT.
WE JUST DO COURAGEOUS
CONVERSATIONS, WEDNESDAY,
ACTUALLY, AND COR TRAINING, WE
SOMETIMES HELP SOME OF THE DEIA
TRAININGS AND AGAIN WE'VE SEEN
POSITIVE FEEDBACK FROM FRONT
LINE STAFF WHO DOESN'T ALWAYS
HAVE THE OPPORTUNITY TO ATTEND
THIS KIND OF TRAINING AND
REALLY -- THEY ALWAYS FILL UP
REALLY FAST WHEN THEY COME UP.
I ALSO WANTED TO MENTION THIS
NEW SUPERVISORS' ADMINISTRATIVE
FORUM.
A FEW OF US ADMINISTRATIVE
LEADERS HAVE STARTED THIS IN
JANUARY.
IT'S ONCE A MONTH FOR AN HOUR
AND WE HAVE DIFFERENT SUBJECT
MATTER EXPERTS COME IN AND
PRESENT SOME OF THE MATERIALS
THAT YOU MIGHT SEE IN FOS
ACTUALLY, TO HELP SUPERVISORS
LEARN MORE OR ASK QUESTIONS
ABOUT ANY GUIDANCE OR MO POLICI.
AND AGAIN NETWORK, WE HAVE 250
SUPERVISORS, AND THERE'S A LOT
OF GUIDELINES OUT THERE IN THE
FEDERAL GOVERNMENT, SO IT'S
HELPFUL FOR THEM TO HAVE A FORUM
TO ASK QUESTIONS AND SHARE BEST
PRACTICES WITH EACH OTHER.
SO THOSE ARE CLINICAL CENTER,
NOW THE NIH.
IN THE INTEREST OF TIME I WON'T
GO THROUGH ALL OF THESE BUT
THEY'RE PRETTY SELF EXPLANATORY.
WE HAVE THE MID LEVEL, SENIOR
AND EXECUTIVE LEADERSHIP
PROGRAM.
THESE DO HAVE A COST THAT COMES
WITH ATTENDING, SO WE SEND OUR
LEADERS TO THESE TRAININGS
ENTHUSIASTICALLY AND THEY ARE
VERY WELL RECEIVED AS WELL.
DEPENDING ON THE LEVEL OBVIOUSLY
WE HAVE THE GS12, 13, 14 FOR MID
LEVEL, MORE OF OUR DEPARTMENT
HEAD TYPES GO TO SENIOR LEVEL
AND THEN EXECUTIVE IS MORE TOP
FIVE, TOP SIX LEADERS.
AND THE PARTICIPATION IN THESE
PROGRAMS HAS REALLY GROWN THE
LAST COUPLE YEARS.
WHICH I WILL SHOW YOU NOW WITH
SOME DATA.
SO THIS IS OUR PARTICIPATION FOR
BOTH MLP AND SLP.
THE BLUE ARE THOSE WHO
PARTICIPATE IN THE PROGRAM AND
THE ORANGE WERE WAIT LISTED.
USUALLY WHEN YOU'RE WAIT LISTED
YOU GO THE NEXT YEAR, SO IT'S
NOT THAT THEY DON'T GET TO GO
BUT THEY JUST HAVE TO WAIT A
LITTLE BIT.
YOU CAN SEE IN AGAIN 2020, STAA
BIG JUMP FOR MLP.
TRAINING CENTER HAS WORKED TO
ADD MORE AND MORE COHORTS WITH
INCREASED DEMAND, SO THIS YEAR
WE HAD THE LUXURY OF HAVING 35
GO TO THE MLP, WHICH IS GREAT.
FOR SLP, YOU CAN SEE THE
INCREASE THERE.
IT'S A SMALLER COHORT BECAUSE
IT'S A SMALLER POOL OF LEADERS
WHO ARE ELIGIBLE, BUT THERE IS
DEFINITELY AN INCREASE IN
INTEREST THERE AS WELL.
FOR SLP, WE'VE HAD DR. HADIGA N
JUST PARTICIPATED IN THAT THIS
YEAR, OUR CHIEF MEDICAL OFFICER,
AND DAN LONNERDALE WAS IN 2020.
ONE THING WE'RE LOOKING AT IS
LOOKING AT WHO WE'RE SENDING TO
THESE TRAININGS AND WORKING WITH
THE OFFICE OF EDI TO GET SOME
MORE DEMOGRAPHICS AROUND THOSE
WHO ARE GOING AND MAKING SURE IT
REPRESENTS THE DIVERSITY OF OUR
WORKFORCE.
THERE'S A NUMBER OF OTHER
PROGRAMS THAT THE NIH TRAINING
CENTER OFFERS.
MSS, THE MANAGEMENT SEMINAR
SERIES, IS MORE FOR THE
NON-SUPERVISORY STAFF.
WE SEND ABOUT 30 OR 40 OF OUR
EMPLOYEES TO THAT EACH YEAR, AND
ALSO VERY WELL RECEIVED.
DDM SERIES IS A GREAT QUARTERLY
PRESENTATIONS FROM SPEAKERS FROM
ALL OVER THE COUNTRY THAT COME
IN AND THOSE ARE FREE, OPEN TO
ALL STAFF, AND WE JUST HAD ONE
LAST WEEK, ON ZOOM FATIGUE,
WHICH WAS GREAT.
AND THEN THESE ARE SOME EXAMPLES
OF OTHER CLASSES THAT ARE
OFFERED AT THE TRAINING CENTER
THAT, AGAIN, COME WITH A COST,
BUT A LOT OF TIMES OUR OFFICE
TRIES TO TAKE ONE AND BRING IT
IN HOUSE SUCH AS THAT MANAGING
CONFLICT AND CHALLENGING
CONVERSATIONS, WE WILL PAY FOR,
AND HAVE A COUPLE SERIES THAT
CLINICAL CENTER STAFF CAN ATT
ATTEND.
SO THAT WAS CLINICAL CENTER AND
NIH PROGRAMS.
WE DO OFFER IN SOME CASES EITHER
FUNDING OR PARTIAL FUNDING FOR
SOME GRADUATE OR
POSTGRADUATE DEGREES.
WE DO REFUND -- REIMBURSE,
SORRY, LICENSES FOR SOME
PROFESSIONAL SOCIETIES AND
FELLOWSHIPS, WE HAVE A LOT OF
STAFF THAT ARE IN THE AMERICAN
COLLEGE OF HEALTHCARE EXECUTIVES
AND WE'VE HAD A FEW LEADERS GET
MBAs OR OTHER MASTERS.
DR. FRANK PARTICIPATED IN THE
EXECUTIVE LEADERSHIP IN ACADEMIC
MEDICINE AT DREXEL.
WE'VE HAD A FEW IN AU'S KEY
EXECUTIVE LEADERSHIP PROGRAM.
THESE ARE FOR LEADERS WHO MAY
HAVE ALREADY GONE THROUGH THOSE
OTHER PROGRAMS I MENTIONED AND
ARE LOOKING FOR ADDITIONAL
OPPORTUNITIES.
I ALSO WANTED TO MENTION MAUREEN
MCDONALD WHO IS ONE PERSON BUT
WEARS MANY HATS.
SHE NOT ONLY DOES OUR PROGRAMS
IN IN-HOUSE BUT SHE IS ALSO AN
ORGANIZATIONAL DEVELOPMENT
CONSULTANT AND A STRENGTHS COACH
AND SHE HAS BEEN AT THE CLINICAL
CENTER FOR LONGER THAN I HAVE.
OVER 15 YEARS.
AND IS VERY WELL-KNOWN
THROUGHOUT THE ORGANIZATION.
AND LEADERS OFTEN REACH OUT TO
HER FOR REQUESTS OR
CONSULTATIONS, WHETHER IT'S A
TEAM BUILDING WITH THEIR TEAM OR
SOME ASSESSMENTS, CUSTOMIZED
TRAINING, AND SHE MAY DO A
DIRECT INTERVENTION BUT SHE IS
ONLY ONE PERSON SO OFTENTIMES
SHE ALSO WORKS WITH EXTERNAL
RESOURCES, MIGHT COLLABORATE
WITH SOME NIH RESOURCES SUCH AS
OUR OFFICE OF OMBUDSMAN, OR
EXTERNAL CONSULTS WHENEVER
APPROPRIATE.
WE DO HAVE ALSO SOME LEADERSHIP
COACHING, BOTH THE MLP AND THE
SLP HAVE LEADERSHIP COACHING AS
PART OF THE PROGRAM, A CERTAIN
NUMBER OF HOURS WHERE THEY GET
TO WORK WITH A COACH, BUT WE
ALSO HAVE A FEW EMPLOYEES WHO
HAVE ONE ON ONE LEADERSHIP
COACHING THAT IS EITHER FUNDED
BY THEIR DEPARTMENT OR THE
CLINICAL CENTER AS A WHOLE.
LASTLY MORE ABOUT THAT CULTURE
OF LEARNING THAT WE HAVE SO AS
PART OF THE 2019 STRATEGIC PLAN,
OUR OFFICE REALLY WORKED HARD TO
GATHER AND LAUNCH INDIVIDUAL
DEVELOPMENT PLANS THROUGHOUT THE
CLINICAL CENTER.
SO THESE ARE REQUIRED FOR
FEDERAL EMPLOYEES, AND WE
BELIEVE THAT THEY ARE A GREAT
TOOL TO SUPPORT AND PLAN
EMPLOYEES' PROFESSIONAL GROWTH.
THE MAIN FOCUS, THOUGH, THAT WE
HAVE, IT'S NOT JUST ON FILLING
OUT JUST ANOTHER EXERCISE, IT'S
AROUND THE CONVERSATION BETWEEN
THE SUPERVISOR AND THE EMPLOYEE,
AND WE REALLY BELIEVE THAT IT'S
PART OF -- IT FOSTERS EMPLOYEE
ENGAGEMENT AND IT ANOTHER
OPPORTUNITY FOR SUPERVISORS TO
GET TO KNOW THEIR STAFF, TO GET
TO KNOW THEIR GOALS.
THIS IS LED BY THE EMPLOYEE, NOT
BY THE SUPERVISOR, BUT THE
SUPERVISOR IS THERE TO SHOW
SUPPORT.
SO WE LIKE TO JOKE THAT IT COULD
BE WRITTEN ON A POST-IT, FOR ALL
WE CARE, WE JUST REALLY WANT
THAT CONVERSATION TO HAPPEN AND
THE ENGAGEMENT HA HAPPEN BETWEEN
THE EMPLOYEE AND THE SUPERVISOR,
AND AGAIN TO SHOW SUPPORT FOR
THEIR CAREER GOALS, WHETHER IT'S
WITHIN THAT SAME POSITION OR
OUTSIDE, AND OFFER ADVICE ON
SOME GROWTH OPPORTUNITIES.
WE USUALLY TEND TO WAIT UNTIL --
OR WE RECOMMEND WAITING UNTIL
AFTER SIX MONTHS ON BOARD TO
GIVE THEM TIME TO GET SETTLED
INTO THEIR POSITION, AND OUR BIG
EMPHASIS IS THIS IS OUTSIDE OF
PERFORMANCE MANAGEMENT.
THIS SHOULD NOT BE IN THE SAME
MEETINGS WITH PERFORMANCE
MANAGEMENT.
WE TYPICALLY DO IT MORE IN THE
SPRING, BETWEEN PERFORMANCE
MANAGEMENT CYCLES, TO REALLY
EMPHASIZE GROWTH AND NOT
PERFORMANCE.
AND WE HAVE A TON OF TRAININGS
WORKSHOPS AND TEMPLATES AND
GUIDES ON OUR WEBSITE FOR STAFF.
SO JUST TO SUMMARIZE, THE
CLINICAL CENTER REALLY IS COMMIT
TODAY A CULTURE OF LEARNING AND
INVESTMENT NOT JUST FOR LEADERS,
FOR EMPLOYEES IN ALL LEVELS OF
OUR ORGANIZATION.
WE HAVE A LOT OF LEADERS THAT
ARE NOT YOUR TYPICAL GS14s,
15s, AS WE SAY IN THE
GOVERNMENT, BUT WHO MAY NOT EVEN
BE SUPERVISORS BUT WHO LEAD FROM
WHERE THEY ARE AND/OR LEAD
INITIATIVES IN THEIR
DEPARTMENTS.
AND WE AT THE CLINICAL CENTER,
WITH THE GREAT SUPPORT FROM
DR. GILMAN AND CC LEADERSHIP, WE
TRY AS MUCH AS WE CAN IN OUR
OFFICE TO SUPPORT BUT WE REALLY
EMPHASIZE A CULTURE WHERE WE
SUPPORT THE EMPLOYEES' GROWTH,
LISTEN TO THEIR GOALS, AND
SUPPORT THEIR LEADERSHIP
DEVELOPMENT.
SO THAT'S ALL I HAVE.
I'VE INCLUDED MY EMAIL AND PHONE
NUMBER.
PLEASE FEEL FREE TO REACH OUT.
THIS IS MAUREEN, WHO'S OUR GURU
IN LEADERSHIP DEVELOPMENT IN OUR
OFFICE, AND WE HAVE A NUMBER OF
RESOURCES ON OUR WEBSITE TOO.
I'M HAPPY TO SHARE ANYTHING FROM
WHAT I'VE DISCUSSED TODAY OR
ANSWER ANY QUESTIONS.
>>DAVID, PLEASE.
>>FIRST OFF, THANK YOU FOR A
TERRIFIC PRESENTATION.
>>THANK YOU.
>>AND KUDOS TO JIM FOR MAKING
THIS INVESTMENT IN STAFF.
IT'S A SIGNIFICANT INTERNAL
INVESTMENT, SO WONDERFUL.
THE ONLY COMMENT I HAVE, IT MAY
BE EMBEDDED ALREADY IN THE
CURRICULUM, IS THAT PARTICULARLY
FOR CLINICAL STAFF OR LEADERS,
ONE AREA THAT YOU DON'T GET IN
MEDICAL SCHOOL AT ALL IS AROUND
NEGOTIATION.
I'M WONDERING IN THIS VERY
COMPLEX ENVIRONMENT,
ENVIRONMENTS, I SHOULD SAY,
WHETHER OR NOT SOME MORE
TRAINING AND NEGOTIATION MIGHT
BE HELPFUL.
I SEE IT IMPLIED IN SOME OF THE
MODULES SO MAYBE IT'S ALREADY IN
THERE.
>>IT COULD BE ENHANCED MORE.
WE'RE DEFINITELY -- LIKE I SAID,
WE'RE TWEAKING IT FOR THE NEXT
ITERATION.
I FORGOT TO MENTION, YOU KNOW,
THE LAST TWO WERE IN 2019-2020,
SO A LOT HAS CHANGED SINCE THEN,
SO WE'RE WORKING ON KIND OF
REDESIGNING AND ADDING AROUND --
LESSONS WE'VE LEARNED THROUGH
THE PANDEMIC, A LOT MORE FOCUS
ON DEIA, BUT WE WILL CERTAINLY
KEEP THAT IN MIND AND I THINK
THAT'S A GREAT IDEA TO KEEP IN
OUR PROGRAM.
SO THANK YOU.
>>GREAT PRESENTATION AND
WONDERFUL ACTIVITIES.
THE ONE THING I'VE BEEN PART PA
TRI IN ELAM FOR -- I WAS LIKE IN
THE SECOND YEAR CLASS MANY YEARS
AGO.
THEY TAKE THOSE COHORT NOW AND
ACTUALLY THEY CONTINUE TO MEET
WITH EACH OTHER VIRTUALLY OR I
GUESS HERE, THEY CAN EVEN SEE
EACH OTHER.
THE WOMEN I'VE SENT TO THIS
PROGRAM HAS FOUND THE PROGRAM TO
BE AMAZING, BUT THEY REALLY LIKE
THE COHORT BECAUSE WE DIDN'T
HAVE THAT BACK WHEN I HAD THAT,
WHERE YOU HAVE THIS GROUP THAT
YOU CAN CALL TO TALK ABOUT
NEGOTIATION, TO TALK ABOUT
WHATEVER.
SO HAVE YOU THOUGHT ABOUT
KEEPING THOSE COHORTS, TELLING
THEM THEY SHOULD STAY CONNECTED
OR JUST LETTING THAT BE
SOMETHING THAT HAPPENS NATURALLY
WITH THEM?
>>DO YOU MEAN THE ELAN
SPECIFICALLY OR --
>>ALL THE COHORTS.
>>YES, WE DO DO THAT.
WE'VE ONLY HAD TWO FOR
FUNDAMENTALS IN LEADERSHIP, BUT
WE'VE HAD A COUPLE ACTIVITIES
WHERE ONLY ALUMNI WERE IB
VITALLED SO IT WAS A GREAT
CHANCE TO SEE EACH OTHER.
OF COURSE THE PANDEMIC KIND OF
PUT A PAUSE ON THESE THINGS BUT
THAT IS OUR GOAL AS WE ADD MORE
AND MORE COHORTS.
I HAVE TO SAY THAT WAS THE MOST
REWARDING PART OF ME BEING IN
THERE, IS I STILL KEEP IN TOUCH
WITH AT LEAST HALF OF THAT
CLASS, AND IT INVALUABLE.
>>BECAUSE US LEADERS THINK
WE'RE REALLY IMPORTANT BUT
REALLY THE BEST PERSON THEY MET
ARE THOSE IN THEIR CLASS.
>>YES, YES, YES.
TO BE ABLE TO REACH OUT AND
SHARE.
>>I HAVE A QUESTION OR TWO.
NUMBER ONE, THIS PARTICULAR --
YOUR PARTICULAR OFFICE'S
RESPONSIBILITY IS FOCUSED ON
FULL TIME EMPLOYEES.
>>YES.
>>DOES ANYBODY DO ANYTHING WITH
SGEs OR WITH FELLOWS, LIKE
SKILLS OF COMMUNICATION AND
INTERACTIONTION AND CONFLICT
RESOLUTION?
>>I BELIEVE THEY HAVE THE --
WHY AM I BLANKING ON THE NAME?
OITE, THERE YOU GO.
SO THEY HAVE A LOT OF TRAINING
THROUGH THEM FOR THE FELLOWS IN
PARTICULAR.
>>AND WHAT ABOUT VOLUNTEERS?
>>VOLUNTEERS?
>>WE HAVE A LOT OF THEM.
>>WE DO HAVE A LOT OF THEM.
AND I MEAN, I'D BE FINE WITH
THEM COMING TO SOME OF THESE
CLASSES, SO WE COULD CERTAINLY
LOOK INTO THAT.
>>BUT THERE'S NO PROGRAM TO --
>>THERE'S NO PROGRAM SPECIFIC
FOR VOLUNTEERS.
>>THAT YOU KNOW ABOUT.
>>YEAH.
I MEAN, I DON'T KNOW IF THEY'RE
ON -- WE SEND A LOT OF
COMMUNICATION OUT TO C.C. STAFF,
WHICH -- AND WE CAN LOOK INTO
WHO'S ON THAT --
>>I'M AWARE OF SOME OF THEM,
BUT LIKE THE OFFICE OF VOLUNTEER
COORDINATION, IF IT STILL
EXISTS, I DON'T KNOW IF THEY
TELL PEOPLE ABOUT THESE PROGRAMS
OR IF IT WOULD CREATE AN UNDUE
FINANCIAL BURDEN ON YOUR OFFICE.
IF ALL OF A SUDDEN YOU STARTED
GETTING --
>>RIGHT, RIGHT.
WE COULD CERTAINLY LOOK INTO
THAT.
THE BEAUTY OF SOME OF THESE
ONLINE TRAININGS, YOU KNOW, IF
YOU HAVE FIVE MORE OR NOT -- IT
DEPENDS ON HOW INTERACTIVE THE
TRAINING IS, BUT WE COULD
CERTAINLY LOOK INTO THAT.
THANK YOU.
>>AND THE OTHER THING WAS, I
FOUND FROM PROFESSIONAL
MANAGEMENT AND TECHNICAL
TRAINING, WHAT I'VE TAKEN
THROUGH THE YEARS, THAT AN
ORGANIZED MESSAGE BOARD, BUT NOW
IT COULD BE ONLINE
COLLABORATION, HELPS TO
FACILITATE THE COHORT MEMBERS
KEEPING IN TOUCH AND BEING ABLE
TO TALK WITH EACH OTHER ABOUT A
PARTICULAR SCENARIO TO SEEK
ADVICE FROM THEIR PEERS.
>>YEAH, THAT'S A GREAT IDEA AS
WELL.
AND THAT'S KIND OF WHAT THAT
FORUM THAT CAME, YOU KNOW, ONCE
A MONTH, THERE'S A LOT OF
INTERACTION WITHIN THAT FORUM AS
WELL, BUT LIKE I SAID, WE ARE
HIRING MORE, AND WITH THAT,
WE'LL HAVE MORE RESOURCES TO DO
MORE --
>>THANK YOU.
IT WAS A VERY USEFUL
PRESENTATION.
>>THANK YOU SO MUCH.
>>THANK YOU VERY MUCH,
CHARLOTTE.
REALLY APPRECIATE THAT.
THANKS.
ALL RIGHT.
NOW WE'RE GOING TO TRANSITION TO
THE LAST PRESENTATION FOR THE
BOARD MEETING TODAY.
WE HAVE WITH US DR. JENNIFER
ROBERTS, WHO'S THE DIRECTOR OF
RESILIENT SYSTEMS AT ARPA HATCH,
THE ADVANCED RESEARCH PROJECTS
AGENCIES FOR HEALTH.
ARPA-H IS A RESEARCH FUNDING
AGENCY THAT SUPPORTS
TRANSFORMATIVE BIOMEDICAL AND
HEALTH BREAKTHROUGHS RANGING
FROM THE MOLECULAR TO THE
SOCIETAL TO PROVIDE HEALTH
SOLUTIONS FOR ALL.
DR. JENNIFER ROBERT JOINED
ARPA-H IN FEBRUARY OF '23 FROM
THE WHITE HOUSE OFFICE OF
SCIENCE AND TECHNOLOGY POLICY
WHERE SHE WAS ASSISTANT DIRECTOR
OF HEALTH TECHNOLOGIES.
SPECIAL THANKS TO YOU,
DR. ROBERTS, FOR BEING WITH US
TODAY, IN PERSON, AND WE ARE
VERY EXCITED TO HEAR MORE ABOUT
ARPA-H AND TO LEARN HOW THE
CLINICAL CENTER CAN SUPPORT THE
WORK THAT YOU'RE DOING AND BE
INVOLVED IN THIS NEW
ORGANIZATION.
SO THANK YOU.
>>GREAT.
VERY HAPPY TO BE HERE.
SO TODAY I WANTED TO PROVIDE AN
OVERVIEW OF ARPA-H AND WHERE
WE'RE GOING, AND I WELCOME
QUESTIONS ALONG THE WAY IF YOU
GUYS WOULD LIKE TO LEARN MORE
ABOUT ANY PARTICULAR PART OF THE
AGENCY.
SO ARPA-H WAS STOOD UP VERY
RECENTLY IN ORDER TO PURSUE
IDEAS THAT BREAK THE MOLD ON HOW
WE NORMALLY SUPPORT FUNDAMENTAL
RESEARCH IN COMMERCIAL PRODUCTS.
THE PARTS I LIKE ABOUT THIS
QUOTE IS THAT IT'S TALKING ABOUT
THE DISTINCTION BETWEEN WHERE
ARPA-H SITS IN THE ECOSYSTEM, SO
IF THERE'S SOMETHING THAT'S
ALREADY REALLY WORKING WELL FROM
THE FUNDAMENTAL RESEARCH SIDE
THROUGH THE VERY IMPORTANT
INSTITUTES AND CENTERS AT NIH,
THAT'S SOMETHING THAT'S
COMPLEMENTARY TO WHAT WE'RE
DOING, AND IF THERE'S SOMETHING
THAT'S WORKING WELL IN THE
VENTURE CAPITAL COMMUNITY OR IN
THE COMMERCIAL SECTOR, ALSO
COMPLEMENTARY TO WHAT WE'RE
DOING.
WHAT WE'RE TRYING TO DO IS
IDENTIFY AREAS WHERE TECHNICAL
BREAKTHROUGHS AND NEW APPROACHES
CAN COMPLEMENT AND ADDRESS GAPS.
IN THE EXISTING SYSTEMS.
SO OUR MISSION IS TO ACCELERATE
THE IMPROVEMENT OF HEALTH
OUTCOMES FOR EVERYONE.
THERE'S A COUPLE IMPORTANT PARTS
OF THAT.
SO THE ACCELERATION THAT SPEAKS
TO THE EMPHASIS ON NEW
BREAKTHROUGHS AND ADVANCED
RESEARCH THAT FALLS UNDERNEATH
OUR MISSION.
THE BETTER HEALTH OUTCOMES
EMPHASIZES THE FACT THAT WE ARE
VERY INTERESTED IN MOVING THINGS
FROM LABS INTO REAL WORLD
CONTEXTS SO AT THE END OF THE
DAY, WE WANT TO KNOW THAT THE
TECHNICAL BREAKTHROUGHS THAT WE
ARE DEVELOPING ARE HELPING THE
PATIENT POPULATIONS.
AND THEN FOR EVERYONE, WE CARE A
LOT ABOUT THINGS LIKE ACCESS AND
AFFORDABILITY AS WELL, SO HOW DO
WE THINK ABOUT MAKING IT SO THAT
THE INTERVENTIONS THAT WE HAVE
TODAY MEET THE PATIENT
POPULATIONS WHO NEED THEM THE
MOST.
SO ARPA-H IS AN INDEPENDENT
AGENCY INSIDE OF NIH.
IT'S KIND OF UNIQUE IN ITS
STRUCTURE IN THAT THE ARPA-H
DIRECTOR REPORTS DIRECTLY TO THE
HHS SECRETARY.
ADMINISTRATIVELY, WE ARE INSIDE
OF NIH, SO WE APPRECIATE A LOT
OF THE COMMUNITY INSIDE OF THE
NIH INSTITUTE AND CENTERS, AND
WE ALSO APPRECIATE SOME OF THE
ADMINISTRATIVE SUPPORT THAT
COMES FROM BEING PART OF THE NIH
COMMUNITY.
SO NONETHELESS, AS AN
INDEPENDENT AGENCY, WE ALSO HAVE
A DIFFERENT SET OF PROVISIONS,
POLICIES, AND DIFFERENT TYPE OF
AUTONOMY AND EMPHASIS, SO FOR
INSTANCE, OUR PROGRAMS TEND TO
HAVE VERY SPECIFIC GOALS
ASSOCIATED WITH THEM.
WE TEND TO EXECUTE IN TERMS OF
CONTRACTS TO MEET THOSE GOALS,
WITH MEASURABLE MILESTONES, AS
OPPOSED TO GRANTS.
SO IN TERMS OF SOME UNIQUE
FEATURES OF ARPA-H, ONE KEY ONE
IS THAT THE DECISION-MAKING IS
VERY BOTTOM-UP.
SO THE WAY THAT WE WORK IS WE
PULL IN A SERIES OF PROGRAM
MANAGERS THAT HAVE A DEEP
UNDERSTANDING OF A PARTICULAR
PROBLEM AREA, AND THEY HAVE AN
IDEA OF A REVOLUTIONARY NEW
APPROACH THAT COULD
FUNDAMENTALLY CHANGE WHAT'S
POSSIBLE IN THAT AREA.
AND WE PULL IN THESE FOLKS IN
ORDER TO GIVE THEM THE RESOURCES
TO TRY OUT THEIR REF LAWTIONARYY
NEW IDEA AND SEE IF IT WORKS.
SO AS OPPOSED TO ORGANIZATIONS
WHERE THE DIRECTOR MIGHT
STIPULATE WHAT THAT RESEARCH
PORTFOLIO LOOKS LIKE, INSTEAD,
WE'RE PULLING IN EXPERTS WHO
HAVE THESE BREAKTHROUGH IDEAS
AND WE ARE EMPOWERING THEM TO
TRY THEM OUT SO A LOT OF THE
IDEA GENERATION COMES FROM THE
BOTTOM UP.
WE ALSO HAVE ACCELERATED
MECHANISMS FOR CONTRACTING SO
THAT WE CAN MOVE QUICKLY.
AND AGAIN, WE'RE VERY INTERESTED
IN THINGS LIKE OTHER
TRANSACTIONS, COOPERATIVE
AGREEMENTS AND CONTRACTS SO
THERE'S A CLEAR GOAL AND
MEASUREMENTS TO US ACHIEVING
THAT GOAL.
OF COURSE IF THINGS AREN'T
WORKING, WE CAN PIVOT.
BUT WE WANT TO KEEP THE WORK
FOCUSED TOWARD THOSE
REVOLUTIONARY ADVANCES THAT ARE
THE MOTIVATION BEHIND OUR
PROGRAMS.
WE HAVE LEAN AND NIMBLE
MANAGEMENT STRUCTURE, SO FOR
INSTANCE, WHEN WE START A
PROGRAM, THERE'S ONLY TWO PEOPLE
THAT NEED TO SIGN OFF ON IT.
IF IT'S ONE OF MY PROGRAM
MANAGERS, THAT WOULD BE MYSELF
AND THE OFFICE DIRECTOR, WHICH
MAKES IT SO THAT WE CAN COLLECT,
AND WE DO COLLECT, A LOT OF
EXPERT OPINIONS ABOUT WHERE TO
EMPHASIZE, BUT AT THE END OF THE
DAY, WE DON'T NECESSARILY NEED
TO MOVE TOWARD A CONSENSUS FOR
WHERE WE'RE GOING.
WE CAN TRY THINGS THAT ARE MAYBE
A LITTLE BIT OUTSIDE THE BOX,
AND THEN COMPLEMENT THAT WITH
SOME VERY ACTIVE MANAGEMENT SO
THAT I IF IT TURNS OUT IT'S NOT
WORKING, WE REGROUP AND WE TRY
AGAIN WITH SOMETHING ELSE.
AND THEN WE ALSO HAVE SOME
FLEXIBILITY IN HIRING.
SO WE HAVE A SPECIAL HIRING
AUTHORITY THAT MAKES US MORE
COMPETITIVE WITH SALARIES IN
INDUSTRY AS OTHER PARTS OF THE
GOVERNMENT.
IN TERMS OF THE ECOSYSTEM, WE
ARE BUILDING PARTNERSHIPS WITH A
GREAT MANY FOLKS.
SO VERY IMPORTANT GROUP IS THE
CUSTOMERS.
SO THE PATIENTS, THE PROVIDER,
THE PUBLIC, THE FOLKS THAT WILL
HOPEFULLY USE THE TECHNOLOGY AND
BENEFIT FROM THE ADVANCES THAT
ARPA-H IS INVESTING IN.
AND THEN WE HAVE OUR PERFORMER
COMMUNITY.
THESE WOULD BE FOLKS FROM
UNIVERSITIES, FROM INDUSTRY,
NGOs, PRIVATE INVESTORS, SMALL
BUSINESSES, LARGE ONES, WHO CAN
WORK WITH US IN ORDER TO PURSUE
THESE VERY LARGE GOALS.
AND THEN WE ALSO PARTNER
REGULARLY WITH OTHER GOVERNMENT
AGENCIES.
THAT INCLUDES THE INSTITUTES AND
CENTERS INSIDE OF NIH AS WELL AS
A VARIETY OF DIFFERENT FEDERAL
PARTNERS IN ORDER TO MAKE IT SO
THAT AS WE'RE DEVELOPING NEW
TYPES OF TECHNOLOGIES, WE'RE
ALSO THINKING ABOUT THE
REGULATORY ASPECTS, THE ASPECTS
OF PAYMENT, SO THAT ONCE A NEW
TECHNOLOGY IS DEVELOPED, WE HAVE
A PATHWAY TO IT SURVIVING IN THE
REAL WORLD.
IN TERMS OF THE KIND OF UNIQUE
ATTRIBUTES OF ARPA-H, THE
PROGRAM MANAGERS ARE REALLY THE
NUCLEUS OF THE ORGANIZATION.
SO THESE ARE FOLKS THAT COME TO
THE AGENCY WITH EXPERTISE IN A
PARTICULAR AREA AND A GREAT
IDEA.
SO THIGHS PROGRAM MANAGERS, AS
THEY CAS -- THESE PROGRAM MANAGS
THEY COME IN.
, THEY ARE THE ONES
DRIVEN TO ACHIEVE THOSE GOALS
AND WE'RE PROVIDING THEM WITH
THE RESOURCES TO BE SUCCESSFUL
SO THEY REALLY ARE DERIVING A
LOT OF THE FORWARD PROGRESS OF
THE ORGANIZATION.
WE ARE VERY INTERESTED IN
RADICAL CHANGE, REVOLUTIONARY,
NOT INCREMENTAL OR EVOLUTIONARY.
SO WE WANT TO SAY, OKAY, IF
THERE IS A GOAL WE'RE TRYING TO
GET TO IN THE NEXT 10 YEARS, HOW
CAN WE DO THAT IN TWO OR THREE
YEARS?
IS THAT POSSIBLE?
IF THERE'S SOMETHING WHERE MAYBE
THERE'S AN EMERGING TECHNOLOGY
WHERE YOU COULD IMAGINE A NEW
APPLICATION, THAT COULD ALLOW US
TO TREAT PATIENTS IN A FUND
MENTALLY DIFFERENT WAY.
CAN WE MAKE THAT LEAP.
AND WHAT DO WE NEED TO DO TO DO
THAT QUICKLY.
THE PROGRAM MANAGERS ARE GIVEN A
LOT OF AUTONOMY TO PURSUE THE
DIRECTIONS THAT THEY THINK ARE
USEFUL.
WITH THE IDEA THAT ALONG THE
WAY, THEY'RE MEASURING PROGRESS,
AND THEY ARE TESTING AND
EVALUATING TO MAKE SURE THAT
THINGS ARE WORKING WELL.
AND THEN THE TERM LIMITS ARE
REALLY A UNIQUE ASPECT OF THE
ORGANIZATION THAT KEEPS US
AGILE.
SO PROGRAM MANAGERS STAY THREE
TO SIX YEARS, AND WHAT THAT
ALLOWS US TO DO IS IT ALLOWS US
TO CONSTANTLY PULL IN PEOPLE
WITH NEW IDEAS WHO ARE EXPERTS
IN EMERGING SCIENTIFIC AREAS.
SO AGAIN, THE ORGANIZATION IS
ORGANIZED AROUND THESE PROGRAMS,
RUN BY PROGRAM MANAGERS.
THE PROGRAMS ARE THESE AREAS
WHERE WE'RE PURSUING A SPECIFIC
REVOLUTIONARY IDEA AND THEY TEND
TO LAST TWO TO FOUR YEARS.
THE PROGRAM MANAGERS WHO COME IN
FOR THREE TO SIX YEARS TEND TO
START A FEW PROGRAMS WHILE
THEY'RE AT ARPA-H, SO THEY'LL
COME IN, THEY'LL START TWO TO
THREE PROGRAMS, AND THEN THEY
WILL LAUNCH THOSE AND WE WILL
CONTINUE PULLING IN EXPERTS IN
DIFFERENT AREAS TO THE PORTFOLIO
OF THE AGENCY FORWARD.
IN TERMS OF THE TYPES OF FOLKS
THAT WE LOOK FOR, WE LOOK FOR
FOLKS THAT HAVE A DRIVE TO
PURSUE A PARTICULAR CHALLENGE.
THIS IS OFTEN THE TYPE OF
INDIVIDUAL WHO SEES A DIFFERENT
TYPE OF APPROACH THAN WHAT'S
CONVENTIONAL AND IS JUST REALLY
DRIVEN TO TURN THAT INTO
FRUITION.
SO WE'RE LOOKING FOR FOLKS WITH
THAT DRIVE AS WELL AS A
CURIOSITY TO UNDERSTAND WHY SOME
THINGS ARE WORKING, WHY OTHER
THINGS AREN'T, AND NO FEAR OF
FAILURE.
SO THEY'RE TRYING THINGS BUT
THERE'S ALSO SOME TECHNICAL
HONESTY SO THAT IF THINGS FAIL,
THEY CAN PIVOT APPROPRIATELY AND
TRY SOMETHING ELSE.
AND WE DO GET FOLKS FROM ALL
DIFFERENT STAGES OF THEIR
CAREER, SO WE WILL GET FOLKS
THAT ARE VERY LATE CAREER WHERE
THIS IS A CAPSTONE ACTIVITY.
WE'LL GET FOLKS THAT ARE PERHAPS
RELATIVELY EARLY IN THEIR
CAREER, PERHAPS AN EXPERT IN AN
EMERGING AREA AND EVERYWHERE IN
BETWEEN.
IN TERMS OF THE WAY THAT WE
SHAPE THE PORTFOLIO, RIGHT,
BECAUSE WE WANT TO DO THESE
REVOLUTIONARY NEW IDEAS, WE ALSO
WANT TO HAVE A PRINCIPLED WAY TO
MAKE SURE WE'RE INVESTING IN
THINGS THAT ARE LIKELY TO BE
WORKING AND IF WE FIND THAT AN
IDEA SOUNDED GREAT BUT TURNS OUT
THERE'S A SCIENTIFIC LIMITATION
THAT WE DIDN'T KNOW ABOUT, WE
WANT TO BE ABLE TO CATCH THAT
VERY QUICKLY AND THEN PIVOT TO
INVEST IN SOMETHING ELSE.
SO THE HEILMEIER QUESTIONS ARE
SOMETHING ADOPTED FROM DARPA, SO
THEY CREATED THE INTERNET, GPS,
THEY DID SOME FOUNDATIONAL WORK
BETWEEN ANTIBODIES AND THE
MODERNA VACCINE IN THE PANDEMIC,
AND WE'RE TRYING TO TAKE THAT
MODEL AND APPLY TO HEALTH.
SO THE FIRST THREE ARE REALLY
KEY, FIRST THREE QUESTIONS HERE
ARE REALLY KEY TO DEFINING THE
TECHNICAL ASPECTS OF A
PARTICULAR PROBLEM.
SO WE WANT SOMEBODY WHO CAN
CLEARLY ARTICULATE WHAT PROBLEM
SPACE THEY WANT TO WORK WITH AND
WHY IT'S IMPORTANT.
NOT JUST LIKE, IT WOULD BE
USEFUL TO CURE CANCER, BUT
INSTEAD WHAT PART OF CANCER, HOW
MANY PATIENTS IS IT AFFECTING
AND HOW MUCH OF THAT OVERARCHING
PROBLEM DO YOU THINK YOU MIGHT
BE ABLE TO CARVE OFF AND HAVE AN
IMPACT ON VERY QUICKLY?
WE WANT SOMEBODY WHO CAN CLEARLY
ARTICULATE WHAT THE LIMITATIONS
ARE IN THE CURRENT STATE OF
PRACTICE, AND THEN EXPLAIN HOW
THEIR NEW REVOLUTIONARY APPROACH
MIGHT BRING SOME NEW CAPABILITY
OR NEW REVOLUTIONARY IDEA THAT
MIGHT HELP US OVERCOME BARRIERS
THAT WE'VE HAD IN THE PAST.
SO THOSE ARE THE THREE THAT HELP
DEFINE THE SCOPE OF THE PROGRAM,
AND THEN OTHER QUESTIONS HERE
HELP US EVALUATE PROGRESS.
AND ALSO THINK ABOUT THINGS LIKE
EQUITY TO MAKE SURE THAT, SAY
WE'RE HAVING CLINICAL TRIALS,
WE'RE REACHING THE PATIENT
POPULATIONS THAT ARE
REPRESENTATIVE, AND WE ARE ALSO
CONSIDERING THINGS LIKE THE WAY
IN WHICH THE TECHNOLOGY
DEVELOPMENT COULD BE
MISPERCEIVED SO THAT WE'RE
DEVELOPING A STRATEGY SO THAT
THERE'S CLEAR COMMUNICATION
ABOUT THE GOALS TO INCREASE THE
LIKELIHOOD OF ACCEPTANCE.
IN TERMS OF THE PROGRAM
FORMULATION, THE PROGRAM
MONITORS COME IN, AND THEY
DEVELOP THESE PROGRAM CONCEPTS
AS OUTLINED IN THE HALMEIER
QUESTIONS IN THE LAST SLIDE, AND
THEY'RE TRYING TO ADVANCE THESE
CHALLENGES.
THEY WILL PUT TOGETHER A BRIEF
AND DEVELOP BROAD AGENCY
ANNOUNCEMENT AND THEN SELECT
PERFORMERS AND LAUNCH THE TWO TO
FOUR-YEAR EFFORT IN ORDER TO
MAKE PROGRESS ON THAT PROBLEM
USING A DIVERSE SET OF
PERFORMERS.
SO OFTEN WHAT THIS ENTAILS IS
WE'RE DEFINING THESE CHALLENGES
SO THAT THERE MIGHT BE THREE OR
FOUR DIFFERENT APPROACHES THAT
COULD WORK.
WE DON'T KNOW WHICH ONES WILL,
SO WE'RE PULLING IN A NUMBER OF
DIFFERENT PERFORMER TEAMS IN
PARALLEL TO TRY OUT DIFFERENT
IDEAS OF HOW TO ACHIEVE THAT
GOAL IN PARALLEL.
SO WE CAN LEARN WHICH OF THOSE
APPROACHES WORK IN WHAT CONTE
CONTEXTS.
THEN THROUGHOUT THE WAY, WE ARE
DEVELOPING METRICS AND WE ARE
DOING EVALUATIONS TO SEE WHICH
OF THESE APPROACHES ARE REALLY
WORKING IN THE REAL WORLD.
AND SOMETIMES YOU END UP WITH A
CLEAR WINNER AND SOMETIMES YOU
END UP WITH SOMETHING THAT'S
MORE COMPLEX, WHERE SOME
APPROACHES WORK WELL IN CERTAIN
PARTS OF THE SPACE, MAYBE
CERTAIN SUBPOPULATIONS.
I TEND TO DO SOFTWARE.
MAYBE FOR CERTAIN TYPES OF LIKE
DATA CONDITIONS OR WHAT HAVE
YOU.
AND SOME THINGS WORK BETTER IN
OTHERS.
SO THEN YOU CAN USE THAT
SYSTEMICALLY TO DRIVE FORWARD
PROGRESS.
SO NONETHELESS, AS YOU GO
THROUGH THE PROGRAM, YOU'RE
IDENTIFYING WHICH OF THESE
APPROACHES ARE MOST PROMISING,
AND THEN ULTIMATELY, BECAUSE OUR
PROGRAMS LAST TWO TO FOUR YEARS,
WE'RE LOOKING FOR TRANSITION
PATHS.
SO THIS IS A PATH TO EAR HAVING
THE TECHNOLOGY GO TO A COMPANY
OR PERHAPS TO ANOTHER GOVERNMENT
ORGANIZATION IN ORDER TO MAKE IT
SO THAT IT USED IN THE REAL
WORLD.
WE ALSO HAVE AN OFFICE
SPECIFICALLY FOCUSED ON
TRANSITION THAT WILL WORK WITH
THE PROGRAM MANAGER AND THE
PERFORMER TEAM THROUGH THROUGHON
ORDER TO IDENTIFY PLACES WHERE
MAYBE WE CAN THINK ABOUT
ENTREPRENEURS IN RESIDENCE,
MAYBE WE CAN THINK ABOUT FOLKS
THAT CAN COACH THE NEW
TECHNOLOGY DEVELOPERS THROUGH
REGULATORY ASPECTS.
PERHAPS WE'RE PARTNERING WITH
THE FDA TO CREATE A NEW
REGULATORY PATHWAY FOR SOME TYPE
OF NEW TECHNOLOGY.
SO THEN ULTIMATELY, THERE'S A
PATH AGAIN TOWARD THAT
TECHNOLOGY SURVIVING IN THE
WILD.
AND THEN OUR OVERALL MISSION TO
ACCELERATE IMPROVEMENT IN HEALTH
OUTCOMES FOR EVERYONE IS REALLY
QUITE BROAD.
SO WE'VE BROKEN THAT DOWN INTO A
COUPLE DIFFERENT TECHNICAL
AREAS.
THE FIRST IS HEALTH SCIENCE
FUTURES.
AND THIS IS ABOUT CORE ADVANCES
IN THE BIOMEDICAL SCIENCES THAT
WILL FUNDAMENTALLY CHANGE OUR
PERCEPTION OF WHAT'S POSSIBLE.
THEN SCALABLE SOLUTIONS IS ABOUT
ACCESS AND AFFORDABILITY.
PERHAPS WE HAVE AN INTERVENTION
THAT'S AVAILABLE TODAY BUT IT'S
NOT REACHING THE POPULATION THAT
NEEDS IT.
MAYBE IT'S LIMITED TO JUST USE
IN AN ACADEMIC MEDICAL CENTER,
AND WE WOULD LIKE TO MINIATURIZE
DEVICES TO USE IT IN A HOME
HEALTHCARE SETTING, OR MAYBE WE
HAVE A THERAPY THAT COSTS A
MILLION DOLLARS PER DOSE AND WE
WANT TO FIGURE OUT A
MANUFACTURING INNOVATION THAT
COULD BRING THAT COST DOWN.
PROACTIVE HEALTH, SO LOOKING AT
HOW WE PROLONG PERIODS OF HEALTH
AND WELL-BEING.
SO THIS CAN GET INTO PREVENTIVE
APPROACHES, THIS CAN ALSO GET
INTO THINGS LIKE REGENERATIVE
APPROACHES, BUT EFFECTIVELY
TRYING TO CATCH EITHER THE RISK
OF OR THE EARLY ONSET OF DISEASE
EARLIER SO THAT PERHAPS WE CAN
REVERSE THINGS OR AT LEAST STALL
THE PROGRESSION.
AND THEN FILIALLY RESILIENT
HEALTH SYSTEMS.
SO HOW DO WE MAKE OUR HEALTH
SYSTEMS MORE RELIABLE, MORE
ROBUST, AND THIS CAN INCLUDE
ANYTHING FROM A BIOPHYSICAL
SYSTEM TO AN ELECTRONIC HEALTH
RECORD OR PUBLIC HEALTH DATA
SYSTEM SUPPLY CHAINS, OR SOME OF
THE TECHNOLOGIES THAT ASSIST
BETWEEN PATIENT AND CLINICIAN
COMMUNICATION TO MAKE THAT MORE
RESILIENT AS WELL.
SO GETTING INTO SOME OF THE
PEOPLE ASPECTS.
IN TERMS OF WAYS TO WORK WITH
US, WE CURRENTLY HAVE A BROAD
AGENCY ANNOUNCEMENT, AN OPEN
BROAD AGENCY ANNOUNCEMENT, SO
I'VE BEEN TALKING A BIT ABOUT
THE PROGRAMS THAT WE START.
THE OPEN BROAD AGENCY
ANNOUNCEMENT IS AN OPPORTUNITY
FOR INVESTIGATORS TO BRING IDEAS
TO US, THAT THEY THINK WOULD BE
REVOLUTIONARY AND FOLKS CAN
SUBMIT A PROPOSAL AND FOR A
SUBSET, WE'LL FUND THEM AND MOVE
FORWARD WITH THAT IDEA.
SO THAT'S REALLY TO CATCH
ANYTHING REVOLUTIONARY AND
EXCITING THAT MIGHT NOT HAVE AN
ACTIVE PROGRAM AROUND IT.
WE ALSO HAVE OUR FIRST PROGRAM
BROAD AGENCY ANNOUNCEMENT OUT,
NITRO.
THAT'S ON OSTEOARTHRITIS.
SO WE WANT TO MAKE IT SO THAT WE
ARE REDUCING THE NEED FOR KNEE
OR HIP SURGERY THROUGH
REGENERATIVE APPROACHES,
APPROACHS THAT REGENERATE BOTH
BONE AND CARTILAGE.
THEN WE ALSO HAVE AN RFI, SO AN
INTERESTING CONGRESSIONAL
SITUATION IS THAT WE ARE
REQUIRED BY STATUTE -- SORRY, I
SKIPPED ON TO THE SITE SELECTION
ON THERE.
WE'RE REQUIRED BY STATUTE TO
HAVE THREE DIFFERENT LOCATIONS.
THAT'S UNIQUE, I THINK, TO US,
SO WE HAVE ONE IN THE D.C.
AREA, BECAUSE IT'S NICE TO BE
CLOSE TO NIH AND FDA AND
CONGRESS AND CMS.
BUT WE WANT TO TAKE THIS MANDATE
TO HAVE THREE GEOGRAPHIC
LOCATIONS TO TAKE AN OPPORTUNITY
TO CREATE NETWORKS, REALLY, TO
BE ABLE TO REACH PATIENTS AND
CLINICIANS AND FOLKS THAT WILL
ALSO ULTIMATELY BENEFIT FROM
ARPA-H ADVANCES INTO THE
ECOSYSTEM.
SO WE ARE DOING THAT THROUGH A
HUB AND SPOKE STRATEGY, WE'RE
DEVELOPING TWO DIFFERENT
NETWORKS.
ONE IS OF HOSPITAL SYSTEMS AND
COMMUNITY HEALTH CENTERS, WHO
CAN ASSIST WITH TESTING OUT
TECHNOLOGIES AND RUNNING
CLINICAL TRIALS IN
REPRESENTATIVE POPULATIONS.
AND THEN ANOTHER ONE, CALL IT AN
INVESTOR CATALYST NETWORK, IN
ORDER TO ASSIST FOLKS WITH THE
COMMERCIALIZATION, THE
REGULATORY PROCESSES THAT ARE
NEEDED TO BRING A TECHNOLOGY
INTO USE.
AND THEN WE ALSO HAVE RFIs IN
ORDER TO COLLECT MORE
INFORMATION ABOUT WHAT FOLKS
WOULD LIKE TO SEE IN TERMS OF
ARPA-H AND FDA COLLABORATION.
SO A LITTLE BIT MORE ABOUT OUR
FIRST PROGRAM.
THIS IS THE ONE ON TISSUE
REGENERATION FOR OSTEOARTHRITIS.
WE JUST HAD THE PROPOSERS DAY
YESTERDAY, SO LOTS OF INTEREST
THERE, AND IF YOU OR ANY
COLLEAGUES ARE INTERESTED IN
APPLYING FOR THAT, THERE'S A
LINK TO THE BROAD AGENCY
ANNOUNCEMENT AND WE ARE LOOKING
FOR SOME REVOLUTIONARY IDEAS ON
HOW TO EXECUTE ON THE GOALS OF
THIS PROGRAM.
AND THEN FINALLY, I'D LIKE TO
END WITH THIS SLIDE.
IT'S AN ART INSTALLATION AT THE
RENWICK GALLERY ABOUT HOW THIS
PRESENT MOMENT USED TO BE THE
UNIMAGINABLE FUTURE, AND THAT'S
REALLY AS AN AGENCY THE CRUX OF
WHERE WE'RE TRYING TO GO, HOW DO
WE ACCELERATE PROGRESS TOWARDS
AN UNIMAGINABLE FUTURE.
WITH THAT, I'LL OPEN TO
QUESTIONS.
>>THANK YOU SO VERY MUCH.
FIRST QUESTION, DAVID.
>>ACTUALLY IT'S NOT AS MUCH A
QUESTION AS A COMMENT.
THANK YOU FOR A VERY INFORMATIVE
PRESENTATION THAT LAYS OUT
ARPA-H BETTER THAN ANY WAY I'VE
SEEN ANYBODY ELSE TRY TO EXPLAIN
IT.
IT SOUNDS TO ME LIKE IT'S A
CROSS BETWEEN AN AGILE PROGRAM
MANAGEMENT ORGANIZATION AND A
VENTURE CAPITAL ORGANIZATION
BECAUSE YOU'RE FOCUSED ON --
WAYS OF GETTING TO SOLUTIONS AND
THE V.C.'S OBJECTIVE OF GETTING
OUT OF IT AND PASSING IT ON FOR
THE FUTURE TO GO.
I THINK IT'S A VERY INTERE
INTERESTING -- VERY INTERESTING
APPROACH.
>>YES, THANK YOU.
AND IT'S A YES WITH CAVEATS TO
THAT.
SO YES, YES AND.
AND I THINK THAT IN OTHER PLACE,
WE MIGHT HAVE A VENTURE CAPITAL
APPROACH SOMETIMES, BUT AT THE
END OF THE DAY, THE VENTURE
CAPITAL WORLD IS INTERESTED IN A
BUSINESS MODEL THAT WILL MAKE
THEM MONEY.
AND THERE ARE CERTAIN THINGS
THAT ARE VERY IMPORTANT TO
HAPPEN FOR PATIENTS THAT MIGHT
NOT MAKE ANYBODY MONEY FROM THE
OUTSET.
SO THAT'S REALLY A PLACE WHERE
WE TRY AND FOCUS TOO.
AND IN SOME CASE, WE MIGHT BE
DE-RISKING THE TECHNOLOGY ENOUGH
SO THAT THEN AT THE END, THERE'S
A BUSINESS MODEL.
IN OTHERS, WE MIGHT BE LOOKING
FOR DIFFERENT TYPES OF
NON-PROFIT WAYS FOR THESE
TECHNOLOGIES TO SURVIVE IN THE
WILD.
>>I USE THE TERM VENTURE
CAPITAL TO REFER TO THE EXIT
STRATEGY OBJECTIVE.
THESE PROGRAMS HAVE TO HAVE AN
EXIT STRATEGY OBJECTIVE TO BE
PICKED UP BY SOMEBODY ELSE,
WHETHER IT'S COMMERCIALLY,
WHETHER IT'S HOSPITAL, WHETHER
IT'S ANOTHER ORGANIZATION WITHIN
THE GOVERNMENT OR EXTERNAL --
IT'S AN INTERESTING MIX.
>>THANK YOU.
>>ARE THERE ANY OTHER QUESTIONS
OR COMMENTS?
>>I'VE GOT ONE.
CRAIG SAMITT HERE ON THE SCREEN.
THANKS, DR. ROBERTS.
THIS WAS AN EXCEPTIONAL
PRESENTATION AND VERY EXCITING
WORK.
I ESPECIALLY LIKE THE NOTION
THAT EVOLUTIONARY PROPOSERS NEED
NOT APPLY.
I DON'T THINK WE HEAR ENOUGH OF
THAT POINT OF VIEW IN HEALTHCARE
TODAY, SO THANK YOU FOR DRIVING
THIS WONDERFUL WORK.
MY QUESTION RELATES TO THE
METHOD BY WHICH YOU AND YOUR
TEAM WILL DECIDE WHICH PROBLEMS
TO SOLVE FOR.
I WOULD IMAGINE THERE'S GOING TO
BE A LARGE UNIVERSE OF
POSSIBILITIES THAT YOU COULD
HEAR ABOUT, AND HOW ARE YOU
GOING TO DECIDE, IS THERE AN
ASSESSMENT PROCESS OR EVALUATION
CRITERIA TO DETERMINE WHICH ONES
WILL BE MOST IMPACTFUL OR
ATTRACTIVE?
>>THAT'S A GREAT QUESTION, AND
THAT GOES BACK TO THE HALMEIER
QUESTIONS THAT LOOK AT THE
ABILITY FOR SOMEONE TO
ARTICULATE BOTH THE POTENTIAL
IMPACT, THE LIMITATIONS OF THE
STATE OF THE ART, SO WHY WE'RE
NOT GOING TO GET THERE, AND ALSO
WITH THAT REVOLUTIONARY NEW
IDEAS, AND ALSO NOTE THAT WE'RE
TRYING TO -- WE ARE
ACCOMPLISHING THIS SO FAR, WE'RE
HIRING ONE TO TWO PROGRAM
MANAGERS PER MONTH FOR THE
INDEFINITE FUTURE.
SO AT THIS STAGE IN OUR
DEVELOPMENT, THERE'S A LOT OF
POTENTIAL TO PULL IN SOME GREAT
IDEAS.
AND THEN OVER TIME, WE'LL BE
LOOKING FOR RISK BALANCE
PORTFOLIO AND WE'LL BE BALANCING
THAT ACROSS A NUMBER OF
DIFFERENT DIMENSIONS, SO SOME
ASPECTS WILL BE ON THE
TECHNOLOGY SIDE TO MAKE SURE
THAT WE'RE BALANCING ACROSS
TECHNOLOGY AREAS, WE'LL ALSO BE
LOOKING FOR A BALANCE ACROSS
DISEASE AREAS, AND A MIX OF BOTH
DISEASES THAT AFFECT A LARGE
NUMBER OF PEOPLE, SO CANCER,
DIABETES, ET CETERA, AND ALSO
AREAS WHERE MAYBE WE DON'T HAVE
AN EXISTING INTERVENTION.
GETTING INTO RARE DISEASE OR
OTHER DISEASES THAT HAVE
TRADITIONALLY BEEN UNDERFUNDED.
>>SO DO YOU BELIEVE THAT YOU
WILL HAVE A LARGE VOLUME OF
RESPON DES TRESPONDEES TO THE RE
GOING TO NEED TO DO A
SIGNIFICANT SCREENING PROCESS OR
WILL THERE BE A GOOD SET OF
FIRST MORPHS AND YOU'LL BE ABLE
TO TAKE MANY AT THE OUTSET AND
THEN SORT OF NARROW THE FUNNEL
LATER?
>>GREAT QUESTION.
SO FOR RIGHT NOW, TWO PER MONTH
IS KIND OF FAST RAMP-UP.
AND THE INTERVIEW PROCESS
INVOLVES US WORKING ONE ON ONE
WITH CANDIDATES IN ORDER TO
REFINE THEIR IDEAS.
SO IT'S NOT UNUSUAL FOR US TO
INTERACT WITH A CANDIDATE FOR A
COUPLE MONTHS IN ADVANCE OF AN
IN-PERSON INTERVIEW IN ORDER TO
ENSURE THAT THERE'S SOME -- BOTH
RESPONSIVENESS TO THE TECHNICAL
FEEDBACK, SO NOT EVERYBODY COMES
IN WITH, SAY, CLEAR METRICS,
RIGHT?
SO WE WORK WITH THEM TO REFINE
AND THEN BY THE TIME WE'RE AT AN
INTERVIEW STAGE, WE HAVE A
PRETTY GOOD SENSE OF WHETHER
THERE'S A PROGRAM FORMULATION
THAT IS GOING TO BE LIKELY TO
SUCCEED IN THIS MODEL.
AND RIGHT NOW, WE TEND TO BE
INTERACTING AT SOME LEVEL WITH
ABOUT 50 POTENTIAL CANDIDATES AT
A TIME.
>>GREAT.
THANK YOU VERY MUCH.
>>DR. CUNNINGHAM?
>>THANK YOU.
THAT WAS AN EXCELLENT
PRESENTATION.
I'M SO APPRECIATIVE BECAUSE I
WAS NOT CLEAR ON THE ARPA-H AND,
YOU KNOW, AS WE HAD DISCUSSED IN
PREVIOUS MEETINGS.
MY QUESTION TO YOU IS ABOUT ONE
OF THE LATER COMMENTS THAT YOU
MADE ABOUT THE DEVELOPMENT OF A
NETWORK, AND I WANTED TO KNOW
HOW OR SORT OF ARE YOU TARGETING
PARTICULAR AREAS, GEOGRAPHIC, IS
IT AROUND TYPES OF INSTITUTIONS,
IS IT AROUND INDUSTRY, HOW ARE
YOU THINKING ABOUT DEVELOPING
THAT, IF YOU COULD GIVE A LITTLE
IP SITE INTO TINSIGHT INTO THATD
APPRECIATE IT.
>>YES, SO THAT'S AN ONGOING
SOURCE SELECTION RIGHT NOW, SO
IF YOU WANT MORE INFORMATION, IS
AN RCA, SO THERE'S A SITE
SELECTION SOLICITATION ON OUR
WEBSITE THAT GIVES A GOOD AMOUNT
OF CRITERIA.
>>OKAY.
>>AND YES, WE'RE LOOKING FOR
THAT GEOGRAPHIC DISTRIBUTION,
AND WE'RE ALSO LOOKING FOR
CONTRIBUDISTRIBUTION TO MEET PAT
POPULATIONS WHERE THEY ARE
ACROSS MANY DIFFERENT
DEMOGRAPHICS.
AND ULTIMATELY WHAT'S IMPORTANT
TO NOTE ABOUT THAT SOLICITATION
APPROACH IS, WE ARE SELECTING
TWO CONSORTIUM MAN MANAGEMENT
FIRMS TO SERVE AS THE NEXUS FOR
THOSE HUB AND SPOKE NETWORKS BUT
AT THE END OF THE DAY, ALL KINDS
OF ORGANIZATIONS CAN CONTINUE TO
ENTER THOSE AND TAKE PART IN
THOSE CONSORTIA, SO THAT AS WE
MOVE FORWARD, WE CAN CONTINUE TO
PULL IN THE TYPES OF
ORGANIZATIONS THAT WE NEED TO BE
EFFECTIVE.
>>GREAT.
THANK YOU SO MUCH.
>>MS. REEL?
>>THANK YOU.
MY QUESTION HAS BEEN ANSWERED
BUT I WANTED TO KEEP MY HAND UP
JUST TO SAY THANK YOU.
I THOUGHT THE PRESENTATION WAS
SO IMPRESSIVE, AND YOU JUST GIVE
ME ALL THIS SENSE OF OPTIMISM.
SO THANK YOU.
>>DR. DEVASKAR?
>>THANK YOU.
ME TOO.
I JUST WANTED TO SAY THAT THAT
WAS WONDERFUL, THANK YOU,
MS. ROBERTS.
MY QUESTION IS, YOU SAID THAT
YOU WOULD BE TARGETING AREAS
WHICH AFFECT LARGE POPULATIONS
AND YET RARE DISORDERS WAS ALSO
MENTIONED.
I GUESS MY QUESTION IS, THERE
ARE MANY DISORDERS WHERE
THERAPIES COULD BE VERY IMPA
IMPACTFUL, AND PARTICULARLY IN
THE CHILD OR CHILDREN
POPULATION.
AND I JUST WONDERED IF THERE IS
A FOCUS WITHIN YOUR ORGANIZATION
ON THAT WITH A PARTICULAR
PROGRAM MANAGER, OR IS IT JUST
EMBEDDED ACROSS THE WHOLE
ORGANIZATION?
THANK YOU.
>>YES, I THINK IT'S AN
IMPORTANT AREA, AND WE ARE
ACTIVELY HIRING IN THAT AREA, SO
IF YOU HAVE FOLKS THAT YOU CAN
RECOMMEND, WE OF COURSE WOULD
LIKE TO TALK MORE.
IT AN INTERESTING AREA BECAUSE
AS I UNDERSTAND IT, THERE ARE
SOME ISSUES RELATED TO
INCENTIVES AS WELL AS TECHNOLOGY
DEVELOPMENT.
SO WE ARE LOOKING AT THE
PEDIATRIC SPACE, BOTH IN TERMS
OF WHAT TYPES OF PERHAPS
NON-PROFIT ORGANIZATIONS OR
OTHER TYPES OF STRUCTURES NEED
TO BE SET UP ON THE TRANSITION
SIDE.
AND ALSO WHETHER THERE ARE
TECHNICAL ADVANCES, SAY, ONE
THING IS TO MAKE IT EASIER TO
COLLECT REAL WORLD EVIDENCE, OR
SOMETHING, TO ACCELERATE OUR
ABILITY TO MOVE THINGS INTO
PEDIATRIC POPULATIONS.
>>THANK YOU.
>>DR. GILMAN?
>>FIRST OF ALL, I WANT TO THANK
DR. ROBERTS FOR THE
PRESENTATION.
IN SOME WAY, SHAPE OR FORM, THE
OTHER PRESENTERS TODAY ALL WORK
FOR ME, SHE DOES NOT, AND I
APPRECIATE HER WILLINGNESS TO DO
THIS AND TO COME TO IT IN
PERSON.
AND SO I WANT TO THANK HER.
THE SECOND THING IS, DR. COOTS
SORT OF KICKED THIS THING OFF BY
SAYING HOW WOULD IT -- HOW WILL
ARPA-H INTERACT WITH THE
CLINICAL CENTER, AND I THINK
SOME OF THAT IS TO BE DETERM
DETERMINED.
BUT I CAN TELL YOU WHAT WE'RE
ALREADY DOING.
EACH ONE OF THE INSTITUTES AND
CENTERS, INCLUDING THE CLINICAL
CENTER AT THE NIH, IDENTIFIED
SORT OF A POINT OF CONTACT FOR
ARPA-H, AND SO WHEN THEY NEEDED
EXPERTISE FROM AN INSTITUTE BUT
THEY DIDN'T NECESSARILY KNOW WHO
TO GO ASK, THEY WOULD BE ABLE TO
REACH OUT TO THE POINT OF
CONTACT AND SAY, HEY, NATIONAL
HEART, LUNG AND BLOOD INSTITUTE,
WE THINK -- WE THINK YOU HAVE
SOMEBODY THAT KNOWS SOMETHING
ABOUT THIS, AND WE COULD REALLY
USE THEIR HELP IN TERMS OF
EVALUATING SOMEBODY'S BIG IDEA.
AND WE -- FOR THE CLINICAL
CENTER CURRENTLY, I SERVE THAT
FUNCTION, THEY'VE REACHED OUT TO
ME A COUPLE OF TIMES WITH
RESPECT TO THE STAFF AT THE
CLINICAL CENTER WHO THEY THINK
MAY HAVE EXPERTISE THAT'S
RELEVANT TO ONE OF THEIR IDEAS.
IT MAY NOT FIT INTO A NICE
CLINICAL BUCKET.
THE PARTICULAR PERSON INSIDE THE
CLINICAL CENTER, THEY WANTED TO
TALK ABOUT, REALLY HAS MUCH MORE
TO DO WITH SORT OF THIS USE OF
GPS LOCATION AND IMAGING IN
TERMS OF LOCATION, AND IT
WOULDN'T BE SOMEBODY THAT YOU
WOULD THINK THAT KNEW VERY MUCH
ABOUT OSTEOARTHRITIS, BUT THEY
KNOW A LOT ABOUT SOMETHING ELSE
THAT MAY BE RELEVANT TO THE
PROGRAM.
AND SO OF COURSE WE WILL PROVIDE
THEM ACCESS OR WE'LL AUTHORIZE
THEIR ACCESS TO THAT KIND OF
SUBJECT MATTER EXPERTISE.
AND OCCASIONALLY, THERE MAY BE
SOMETHING ABOUT THE NIH THAT THE
FOLKS AT ARPA-H DON'T KNOW YET.
FOR INSTANCE, ONE OF THE THINGS
THAT MANY PEOPLE MAY NOT KNOW IS
THAT IN TERMS OF BONE AND
CARTILAGE, BASIC SCIENCE AND
BIOLOGY, THAT WHILE THE NATIONAL
INSTITUTE OF MUSCULOSKELETAL
DISEASES AND SKIN UNDOUBTEDLY
HAS SOME EXPERTS IN THAT AREA,
THE NATIONAL INSTITUTE OF DENTAL
AND CRANIOFACIAL RESEARCH ALSO
HAS A TREMENDOUS AMOUNT OF
EXPERTISE IN THAT AREA.
AND SO IN ADDITION TO PROVIDING
THEM ACCESS TO THE EXPERTISE OF
THE CLINICAL CENTER, I HAVE THE
OPPORTUNITY TO MAKE SUGGESTIONS
ABOUT OTHER PLACES WHERE THEY
MIGHT WANT TO LOOK FOR THE KIND
OF SUBJECT MATTER EXPERTISE
THEY'RE INTERESTED IN.
THAT'S THE WAY -- THAT'S THE
ONLY PARTICULAR INTERACTION THAT
WE'VE HAD THUS FAR.
I BELIEVE THAT THERE WILL BE
MUCH MORE THAT TAKES PLACE OVER
TIME, BUT THAT'S WHAT WE'RE
TRYING TO DO TO HELP THEM TAKE
OFF AND FLY VERY QUICKLY.
THANKS.
>>THANK YOU.
AND WE CAN ALREADY ATTEST TO THE
FACT THAT THOSE POINTS OF
CONTACT ARE VERY VALUABLE.
WE'VE BEEN USING A NUMBER OF
THEM ALREADY, AND WE REALLY
APPRECIATE THE GREAT CONNECTIONS
THAT WE'RE MAKING ACROSS NIH.
>>IF THERE ARE NO OTHER
QUESTIONS, DR. ROBERTS, THANK
YOU VERY MUCH FOR THE
PRESENTATION TODAY.
WE REALLY APPRECIATE IT.
IT'S ABSOLUTELY FASCINATING.
AND I WOULD HOPE THAT AS THIS
CONTINUES TO MASUR, MATURE, WE T
PERIODIC UPDATES ON SOME OF THE
FASCINATING WORK THAT'S GOING ON
AND SOME OF THE FUTURISTIC
THINGS THAT ARE HAPPENING,
ESPECIALLY IN INTERFACING WITH
THE DIFFERENT INSTITUTES HERE AT
NIH AND WITH THE CLINICAL
CENTER, SO THANK YOU VERY MUCH.
FOR BEING WITH US TODAY.
THANKS.
AND SO THIS BRINGS US TO THE END
OF THE MEETING.
WE HAVE A FEW MINUTES IF THERE'S
ANYTHING THAT ANY MEMBER OF THE
BOARD WOULD LIKE TO BRING UP IN
DISCUSSION, BASED ON ANY OF THE
PRESENTATIONS THAT WE HAD TODAY,
ANY AFTERTHOUGHTS OR SECOND
THOUGHTS?
DAVID.
>>I KNOW THIS MIGHT BE OUTSIDE
OF THE REALM OF THIS BOARD, BUT
IN THE COURSE OF THE
PRESENTATIONS TODAY AND
PREVIOUSLY, THERE'S BEEN A LOT
OF REFERENCE TO DEIA AND THE
VARIOUS PROGRAMS AND GOALS AND
SO FORTH.
AND I JUST WANTED TO SHARE THE
THOUGHT THAT COMES FROM YEARS IN
WORKING IN INDUSTRIES WHERE ALL
OF A SUDDEN, SUDDEN CHANGES HAD
TO BE MADE AND IMPLEMENTED, BUT
WE FOUND THAT THE BEST WAY TO DO
THIS WAS TO BAKE IT IN AND NOT
BOLT IT ON.
THE FOCUS ON INSTANTANEOUS
COMPLIANCE OR REPORTING HAS TO
BE DONE, NOT WITHSTANDING BASED
ON LEGISLATION.
OR REGULATION.
BUT THERE HAS TO BE AN EQUAL
EFFORT THAT'S PUT IN ON CULTURAL
CHANGE AND PROCESS -- IN
PARTICULAR, PROCESS CHANGE WHEN
ACTIVITIES ARE GOING ON THROUGH
THE NORMAL COURSE OF BUSINESS.
DEIA SHOULD BE A PART OF THE
NORMAL COURSE OF BUSINESS, NOT
AN END TO ITSELF.
JUST MY 2 CENTS.
>>LET ME RESPOND.
I THINK THAT AS WE PRESENT THE
INITIATIVES IN OUR RACIAL AND
ETHNIC EQUITY PLAN, I THINK THAT
WE ARE STARTING THE PROCESS OF
WHAT DAVID REFERS TO AS BAKING
IT IN, AND NOT BOLTING IT ON.
YOU HAVE TO START SOMEWHERE, AND
CERTAINLY SOME OF THAT LOOKS
LIKE IT'S BOLTED ON.
BUT I THINK WE ALSO CHOSE
INITIATIVES THAT REALLY GO
PRETTY DEEPLY INTO THE
ORGANIZATION, AND WILL RESULT IN
CHANGE.
IT WILL NOT BE FAST.
IT WILL NOT BE NEXT WEEK OR THE
WEEK AFTER.
AND WE UNDERSTOOD THAT WHEN WE
PUT THE PLAN TOGETHER.
BUT I THINK WE DO HAVE
INITIATIVES THAT WILL RESULT IN
SOME LASTING CHANGE.
>>THANK YOU VERY MUCH, JIM.
APPRECIATE THE ANSWER, AND
THANKS, DAVID, FOR THAT
QUESTION.
AND KIND OF LIKE DAVID CHIN
MENTIONED EARLIER, THERE ARE A
LOT OF THINGS THAT AREN'T TAUGHT
IN MEDICAL SCHOOL AND NURSING
SCHOOL, PROFESSIONAL SCHOOLS.
DEIA IS EARN ISLY NOT ONE OF
THEM.
MAYBE IT'S STARTING TO BE TAUGHT
NOW BUT ALL THOSE PIECES AND
PARTS OF IT FROM ANTI-RACISM,
ANTIBUY A CULTURAL HUMILITY AND
ULTIMATELY THOSE THINGS ALL LEAD
TO HEALTH EQUITY.
SO IT IS VERY IMPORTANT.
WE ARE AT A STARTING POINT, IT'S
A JOURNEY, SO WE LOOK FORWARD TO
CONTINUING TO SEE HOW THE DEIA
PROCESS DEVELOPS THROUGHOUT THE
CLINICAL CENTER, AT LEAST UNTIL
THERE'S ANOTHER ADMINISTRATION.
SO AT WHICH POINT, WE MAY BE
TURNING BACKWARDS, WHO KNOWS.
BUT AT ANY RATE, I'M TRYING TO
STAY APOLITICAL ON THIS ONE.
>>[INAUDIBLE]
>>THAT'S RIGHT.
SO IF THERE ARE NO OTHER ISSUES
OR ITEMS TO BE BROUGHT BEFORE
THE BOARD, I THINK WE HAVE RUN
ALL OF THE BUSINESS OF THE BOARD
TODAY.
I'D LIKE TO THANK YOU ALL FOR A
GREAT MEETING.
OUR NEXT MEETING IS OCTOBER THE
20TH, AND THAT WILL BE THE LAST
MEETING FOR 2023.
WE SHOULD BE GETTING THE MEETING
DATES FOR 2024 BEING SENT OUT AS
SOON AS THOSE ARE CONFIRMED, AND
SO WITH THAT, HAPPY FATHER'S
DAY, HAPPY JUNETEENTH, HAPPY
FOURTH OF JULY, HAPPY LABOR DAY.
I'D LIKE TO WISH EVERYONE A
SAFE, HEALTHY AND HAPPY SUMMER,
AND I LOOK FORWARD TO ALL OF US
GATHERING TOGETHER AGAIN AND
HOPEFULLY MORE OF US IN PERSON
THIS NEXT TIME, INCREASINGLY
OVER TIME TOO, WHEN WE SEE EACH
OTHER IN OCTOBER.
SO WITH THAT, THIS MEETING
STANDS ADJOURNED.